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SCIENTIFIC OPINION
Scientific Opinion on Flavouring Group Evaluation 21, Revision 5
(FGE.21Rev5): Thiazoles, thiophenes, thiazoline and thienyl derivatives
from chemical groups 29 and 301
EFSA Panel on Food Contact Materials, Enzymes,
Flavourings and Processing Aids (CEF)2, 3
European Food Safety Authority (EFSA), Parma, Italy
ABSTRACT
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety
Authority was requested to evaluate 41 flavouring substances in Flavouring Group Evaluation 21, Revision 5,
using the Procedure in Commission Regulation (EC) No 1565/2000. This revision was carried out because of the
inclusion of the assessment of new toxicity data on the candidate substances, 5-ethylthiophene-2-carbaldehyde
[FL-no: 15.074] and 2-pentylthiophene [FL-no: 15.096]. These data on 5-ethylthiophene-2-carbaldehyde [FL-no:
15.074] should cover 2-acetylthiophene [FL-no: 15.040] and 2-propionylthiophene [FL-no: 15.097]. These data
on 2-pentylthiophene [FL-no: 15.096] should cover 2-butylthiophene [FL-no: 15.045], 2-hexylthiophene [FL-no:
15.076] and 2-octylthiophene [FL-no: 15.093]. For two of the substances [FL-no: 15.060 and 15.119] the Panel
concluded that additional genotoxicity data are required. The remaining 39 substances were evaluated through a
stepwise approach (the Procedure) that integrates information on structure–activity relationships, intake from
current uses, toxicological threshold of concern and available data on metabolism and toxicity. The Panel
concluded that the 39 flavouring substances [FL-no: 15.038, 15.039, 15.040, 15.044, 15.045, 15.050, 15.051,
15.052, 15.054, 15.055, 15.057, 15.058, 15.061, 15.062, 15.063, 15.067, 15.068, 15.069, 15.071, 15.074, 15.076,
15.078, 15.079, 15.080, 15.082, 15.084, 15.085, 15.086, 15.087, 15.089, 15.093, 15.096, 15.097, 15.098, 15.108,
15.115, 15.116, 15.118 and 15.135] do not give rise to safety concerns at their levels of dietary intake, estimated
on the basis of the Maximised Survey-derived Daily Intake (MSDI) approach. Besides the safety assessment of
these flavouring substances, the specifications for the materials of commerce have also been considered.
Adequate specifications, including complete purity criteria and identity for the materials of commerce, have been
provided for all 41 candidate substances.
© European Food Safety Authority, 2015
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SUMMARY
Following a request from the European Commission (EC), the European Food Safety Authority
(EFSA) Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF Panel)
was asked to deliver scientific opinion on the implications for human health of chemically defined
flavouring substances used in or on foodstuffs in the Member States. In particular, the Panel was
requested to evaluate 41 flavouring substances in the Flavouring Group Evaluation 21, Revision 5
(FGE.21Rev5), using the Procedure as referred to in the Commission Regulation (EC) No 1565/2000.
These 41 flavouring substances belong to chemical group 29 and 30, Annex I of the Commission
Regulation (EC) No 1565/2000.
The present revision of FGE.21, FGE.21Rev5, includes the assessment of additional toxicity data for
2-pentylthiophene [FL-no (Flavour Information System number): 15.096] supporting 2-butylthiophene
[FL-no: 15.045], 2-hexylthiophene [FL-no: 15.076] and 2-octylthiophene [FL-no: 15.093] and also
additional toxicity data for 5-ethylthiophene-2-carbaldehyde [FL-no: 15.074] supporting 2-
acetylthiophene [FL-no: 15.040] and 2-propionylthiophene [FL-no: 15.097]. Updated information on
European production figures has been provided by the European Flavour and Fragrance Association
(EFFA) for these seven substances [FL-no: 15.040, 15.045, 15.074, 15.076, 15.093, 15.096 and
15.097] and the information has been included in the evaluation.
All candidate substances are five- or six-member sulphur-containing heterocyclic compounds, some of
which also contain nitrogen. They have been divided into two main groups: (A) those with an aromatic
ring (33 candidate substances) and (B) those with a non-aromatic ring structure (8 candidate
substances). All are ring-substituted with one or more of the substituents alkyl, alkenyl, aryl, alcohol,
keto and thio. For assessment purposes, the following further subdivision of groups (A) and (B) has
been made:
• Group (A): Aromatic:
– (Subgroup A-Ia: Thiophene. The substance previously allocated to the group is no longer
supported for use as a flavouring substance in Europe by Industry.)
– Subgroup A-Ib: Thiophene derivatives with non-thiol-containing ring substituents.
– Subgroup A-Ic: Thiophene derivatives with thiol-containing ring substituents.
– Subgroup A-II: Thiazole derivatives.
– (Subgroup A-III: Benzothiazoles. The substance previously allocated to the group is no
longer supported for use as flavouring substance in Europe by Industry.)
• Group (B): Non-aromatic:
– (Subgroup B-I: Dihydrothiophenes. The substance previously allocated to the group is no
longer supported for use as a flavouring substance in Europe by Industry.)
– Subgroup B-II: Thiazolines.
– (Subgroup B-III: Thiazolidines. The substances previously allocated to the group are no
longer supported for use as flavouring substances in Europe by Industry.)
– Subgroup B-IV: Dithiazine derivatives.
– (Subgroup B-V: Dihydrothiazines. The substances previously allocated to the group are
no longer supported for use as flavouring substances in Europe by Industry.)
– (Subgroup B-VI: Thiadiazine derivatives. The substance previously allocated to the group
is no longer supported for use as a flavouring substance in Europe by Industry.)
Flavouring Group Evaluation 21 Revision 5
EFSA Journal 2015;13(4):4066 4
Two of the 41 flavouring substances possess one chiral centre [FL-no: 15.060 and 15.119], three
substances possess two chiral centres [FL-no: 15.054, 15.057 and 15.135] and two possess three chiral
centres [FL-no: 15.055 and 15.079]. The stereoisomeric composition has been specified for all
substances.
Thirty-three of the candidate substances belong to structural class (SC) II and eight belong to SC III.
Thirty-one of the candidate substances have been reported to occur naturally in a wide range of foods.
In its evaluation, the Panel used as a default the “Maximised Survey-derived Daily Intake” (MSDI)
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when the
Panel examined the information provided by the European Flavour Industry on the use levels in
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly
underestimate the intake by regular consumers of products flavoured at the use level reported by the
Industry, especially in those cases where the annual production values were reported to be small. In
consequence, the Panel had reservations about data on use and use levels provided and the intake
estimates obtained by the MSDI approach.
In the absence of more precise information that would enable the Panel to make a more realistic
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake”
(mTAMDI) approach based on the normal use levels reported by Industry. In those cases where the
mTAMDI approach indicated that the intake of a flavouring substance might exceed its corresponding
threshold of concern, the Panel decided not to carry out a formal safety assessment using the
Procedure. In these cases, the Panel requires more precise data on use and use levels.
According to the default MSDI approach, the flavouring substances in this FGE.21Rev5 have intakes,
in Europe, ranging from 0.0012 to 5.7 µg/capita per day, which are below the thresholds of concern
values for SC II (540 µg/person per day) and SC III (90 µg/person per day) substances.
On the basis of the reported annual production volumes of the candidate substances as flavourings in
Europe, the combined estimated daily per capita intakes per subgroup and SC range from 0.14 to
8.0 µg. For all subgroups the total combined intakes are below the thresholds of concern of
540 µg/person per day and 90 µg/person per day for SCs II and III, respectively.
The candidate substances are structurally related to 28 supporting substances evaluated by the Joint
Food and Agriculture Organization of the United Nations (FAO)/World Health Organization (WHO)
Expert Committee on Food Additives (JECFA) at its 59th and 68th JECFA meetings. The total
combined daily per capita intakes (in Europe) of candidate and supporting substances evaluated
through the Procedure in each of the five subgroups for which supporting substances were available in
the same SC are: subgroup A-Ib (8 substances from SC II) 2.9 µg; subgroup A-Ic (5 substances from
SC III) 0.15 µg; subgroup A-II (37 substances from SC II) 500 µg; subgroup B-II (2 substances from
SC II) 0.52 µg; subgroup B-IV (4 substances from SC II) 3.6 µg.
For all subgroups, the total combined intakes are below the thresholds of concern of 540 µg/person per
day and 90 µg/person per day for SCs II and III, respectively.
It is concluded that genotoxicity data are limited and that genotoxicity could not be assessed
adequately for the flavouring substances in FGE.21Rev5. However, except for the two 3-thiazolines,
2,4-dimethyl-3-thiazoline [FL-no: 15.060] and 2-isobutyl-3-thiazoline [FL-no: 15.119], the available
genotoxicity data do not preclude the evaluation of the remaining 39 candidate substances using the
Procedure.
The available metabolism data were insufficient to allow conclusions about the metabolic fate of the
candidate substances and, accordingly, the 39 candidate substances evaluated through the Procedure
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could not be anticipated to be metabolised to innocuous products. However, the Panel concluded that
the evidence of binding to macromolecules from possible formation of electrophilic metabolites, (e.g.
by either ring scission or S-oxidation) was not sufficiently strong to preclude the application of the
Procedure.
Valid toxicological data were available for candidate substances from subgroup A-Ib (thiophenes with
non-thiol-containing ring substituents), subgroup A-Ic (thiophenes with thiol-containing ring
substituents), subgroup A-II (thiazoles), subgroup B-II (only 2-thiazolines) and subgroup B-IV
(dithiazines). Based on these data, the margin of safety compared with the intakes from use as
flavouring substances was considered adequate, based on the MSDI approach.
In order to determine whether the conclusion for the 39 candidate substances, which have been
evaluated using the Procedure, can be applied to the materials of commerce, it is necessary to consider
the available specifications. Adequate specifications, including purity and identity for the materials of
commerce, have been provided for all 39 flavouring substances evaluated through the Procedure.
For the 39 flavouring substances [FL-no: 15.038, 15.039, 15.040, 15.044, 15.045, 15.050, 15.051,
15.052, 15.054, 15.055, 15.057, 15.058, 15.061, 15.062, 15.063, 15.067, 15.068, 15.069, 15.071,
15.074, 15.076, 15.078, 15.079, 15.080, 15.082, 15.084, 15.085, 15.086, 15.087, 15.089, 15.093,
15.096, 15.097, 15.098, 15.108, 15.115, 15.116, 15.118 and 15.135], evaluated using the Procedure,
the Panel concluded that they would present no safety concerns at their estimated levels of intake
based on the MSDI approach.
The estimated intakes, based on the mTAMDI, for the 34 candidate substances assigned to SC II and
evaluated using the Procedure, range from 78 to 220 µg/person per day, which is below the threshold
of concern for SC II of 540 µg/person per day. The estimated intakes based on the mTAMDI of the
seven candidate substances assigned to SC III and evaluated through the Procedure ranged from 78 to
250 µg/person per day. For the candidate substances [FL-no: 15.055 and 15.135] the estimated intakes
are above the threshold of concern for SC III of 90 µg/person per day. For two candidate substances
[FL-no: 15.057 and 15.079], assigned to SC III, no use levels were provided.
In conclusion, more reliable exposure data are required for [FL-no: 15.055, 15.057, 15.079 and
15.135]. On the basis of such additional data, these flavouring substances should be re-evaluated using
the Procedure.
For two substances [FL-no: 15.060 and 15.119] the Panel concluded that additional genotoxicity data
are required.
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION
The use of flavourings in food is regulated under Regulation (EC) No 1334/2008 of the European
Parliament and of the Council of 16 December 20084 on flavourings and certain food ingredients with
flavouring properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an
evaluation and approval are required for flavouring substances.
The Union List of flavourings and source materials was established by Commission Implementing
Regulation (EC) No 872/20125. The list includes flavouring substances for which the scientific
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/20006.
On 24 November 2011, the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and
Processing Aids (CEF) adopted an opinion on Flavouring Group Evaluation 21, Revision 3
(FGE.21Rev3): thiazoles, thiophenes, thiazoline and thienyl derivatives from chemical groups 29 and
307.
In its opinion, the Panel stated that for the 3 candidate substances [FL-nos: 15.040, 15.074 and 15.097]
evaluated through the Procedure, no appropriate NOAEL was available and that additional toxicity
data are required.
The substances are currently listed in the Union List with a Footnote 2.
On 23 January 2014, the applicant submitted additional data of these 3 flavouring substances
(candidate chemicals) relevant to the Flavouring Group Evaluation of the Chemical Groups 29 and 30
(Annex I of 1565/2000/EC): consideration of thiazoles, thiophenes, thiazoline and thienyl derivatives
as evaluated by EFSA in FGE.21Rev3.
In addition, we would like to draw your attention to the earlier request for re-evaluation of flavouring
substances belonging to the same evaluation group FGE.21Rev2. On 28 November 2013, you
informed us that you agreed to perform the safety assessment of these substances [FL-nos: 15.045,
15.076, 15.093 and 15.096] by 25 July 2014 (your reference KL/cc(2013)out-8076804, our reference
Ares(2013)3602415).
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION
The European Commission requests the European Food Safety Authority (EFSA) to evaluate this new
information and, depending on the outcome, proceed to the full evaluation on these flavouring
substances in accordance with Commission Regulation (EC) No 1565/2000.
If appropriate, EFSA may combine this re-evaluation with the above-mentioned re-evaluation of
flavouring substances from FGE.21Rev2 (EFSA-Q-2013-00861 to 864).
SUPPORTING DOCUMENTS
Submission by the European Flavour Association.
4 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and
certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No
1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34–50.
5 Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of flavouring substances
provided for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to
Regulation (EC) No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation (EC)
No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 1–161.
6 Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8–16.
7 EFSA Journal 2012;10(2)2457
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INTERPRETATION OF THE TERMS OF REFERENCE
The above background and terms of reference include also a previous mandate received from the
European Commission on 25 October 20138. The present scientific opinion FGE.21Rev5 covers the
safety assessment of the following flavouring substances: 2-pentylthiophene [FL-no: 15.096], 2-
butylthiophene [FL-no: 15.045], 2-hexylthiophene [FL-no: 15.076] and 2-octylthiophene [FL-no:
15.093], 5-ethylthiophene-2-carbaldehyde [FL-no: 15.074], 2-acetylthiophene [FL-no: 15.040] and 2-
propionylthiophene [FL-no: 15.097].
8 SANCO.E3/MGR/ave (2013) Ares(2013)3318725
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ASSESSMENT
1. History of the evaluation of the substances in the present Flavouring Group Evaluation
(FGE)
In FGE.21, and the first revision (FGE.21Rev1), the European Food Safety Authority (EFSA) Panel
on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF), hereafter referred to as
the Panel, considered that additional toxicity data were needed for 23 of the substances (subgroups A-
Ia, A-Ib, A-III, B-I, B-IV and B-VI) evaluated through the Procedure, as no adequate toxicity study
from which a no-observed-adverse-effect level (NOAEL) could be established was available, neither
on the candidate substances nor on supporting substances.
In the second revision of FGE.21 (FGE.21Rev2) additional toxicity data and metabolism data became
available (Flavour Industry, 2010a) for two substances, thiophene [FL-no: 15.106] from subgroup A-
Ia and 2-pentylthiophene [FL-no (Flavour Information System number): 15.096] from subgroup A-Ib.
The Panel concluded that these data were not valid for the purposes of establishing a NOAEL. Further,
information on stereoisomeric composition was provided by the European Flavour and Fragrance
Association (EFFA) on nine substances [FL-nos 15.042, 15.054, 15.055, 15.060, 15.077, 15.090,
15.099, 15.119 and 15.129] (EFFA, 2010, 2011b).
The third revision of FGE.21 (FGE.21Rev3) included the assessment of three additional substances,
4,6-dimethyl-2-(1-methylethyl)dihydro-1,3,5-dithiazine [FL-no: 15.057], 2-isobutyldihydro-4,6-
dimethyl-1,3,5-dithiazine [FL-no: 15.079] and ethyl thialdine [FL-no: 15.135]. For these three
candidate substances [FL-no: 15.057, 15.079 and 15.135], a NOAEL could not be derived for the
substance or a structurally related substance. Accordingly, additional data were required for these
three flavouring substances.
Since the publication of FGE.21Rev3, 18 substances [FL-nos: 15.037, 15.042, 15.043, 15.064, 15.070,
15.072, 15.077, 15.088, 15.090, 15.091, 15.092, 15.094, 15.099, 15.106, 15.107, 15.114, 15.129 and
15.133] of the 59 candidate substances are no longer supported for use as flavouring substances in
Europe by Industry (DG SANCO, 2012, 2013) and will therefore not be considered any further. The
18 substances are listed in Table 1.
Table 1: Substances no longer supported for use as flavouring substances
FL-no EU register name
15.037 2-Acetyl-3-methylthiophene
15.042 2-Butyl-4-methyl(4H)pyrrolidino[1,2d]-1,3,5-dithiazine
15.043 2-Butyl-5-ethylthiophene
15.064 2,5-Dimethylthiophene
15.070 2-Ethyl-5-methylthiophene
15.072 2-Ethylthiophene
15.077 4-Hydroxy-2,5-dimethylthiophen-3(2H)-one
15.088 2-Methyl-4,5-benzothiazole
15.090 2-Methylthiazolidine
15.091 2-Methylthiophene
15.092 3-Methylthiophene
15.094 2-Pentanoylthiophene
15.099 2-Propylthiazolidine
15.106 Thiophene
15.107 Thiophene-2-carbaldehyde
15.114 6-Acetyl-2,3-dihydro-1,4-thiazine
15.129 Tetrahydro-2,4,6-trimethyl-1,3,5(2H)-thiadiazine
15.133 5-Acetyl-2,3-dihydro-1,4-thiazine
Flavouring Group Evaluation 21 Revision 5
EFSA Journal 2015;13(4):4066 11
These 18 substances will be excluded in the following text, except in Tables 4 and 10. Information in
the text on these substances will be kept only if relevant for the remaining candidate substances.
As a consequence of this, the following supporting substance (Table 2) has been deleted from this
revision.
Table 2: Supporting substance deleted from this revision
FL-
no/JECFA no
EU register name Structural formula
15.016/1040 Benzothiazole
JECFA, the Joint Food and Agriculture Organization (FAO)/World Health Organization (WHO) Expert Committee on Food
Additives.
The fourth revision of FGE.21 (FGE.21Rev4) included a re-evaluation of six candidate substances,
dihydro-2,4,6-triethyl-1,3,5(4H)-dithiazine [FL-no: 15.054], [2S-(2a,4a,8ab)]2,4-Dimethyl-
(4H)pyrrolidino[1,2e]-1,3,5-dithiazine [FL-no: 15.055], 4,6-dimethyl-2-(1-methylethyl)-dihydro-
1,3,5-dithiazine [FL-no: 15.057], 2-isobutyldihydro-4,6-dimethyl-1,3,5-dithiazine [FL-no: 15.079], 2-
methyl-2-thiazoline [FL-no: 15.086] and ethyl thialdine [FL-no: 15.135]. Additional data (a 14-day
and 90-day dietary study, a bacterial reverse mutation assay and a micronucleus induction assay)
became available for supporting substances and FGE.21Rev4 included the evaluation of these data
submitted by Industry (Bauter, 2012a, 2013a; McGarry, 2012; Watters, 2012). The Panel concluded
that these six candidate substances are not of safety concern at their estimated levels of intake based
on the Maximum Survey-derived Daily Intake (MSDI) approach.
Furthermore, new information on European production figures has been provided for five substances
[FL-no: 15.054, 15.055, 15.057, 15.079 and 15.135] (EFFA, 2013b), and new information on missing
stereoisomeric composition for [FL-no: 15.057, 15.079 and 15.135] was also included (EFFA, 2013b).
Table 3 gives information on publication dates and links to the published versions.
Table 3: Publication dates and links to the published versions of FGE.21
FGE Opinion adopted
by EFSA
Link No of
candidate
substances
FGE.21 8 February 2007 http://www.efsa.europa.eu/EFSA/efsa_locale-
1178620753812_1178694698331.htm
54
FGE.21Rev1 26 March 2009 http://www.efsa.europa.eu/en/scdocs/scdoc/1023.htm 56
FGE.21Rev2 4 February 2011 http://www.efsa.europa.eu/en/efsajournal/doc/1989.pdf 56
FGE.21Rev3 23 November 2011 http://www.efsa.europa.eu/en/efsajournal/pub/2457.htm 59
FGE.21Rev4 24 October 2013 http://www.efsa.europa.eu/en/efsajournal/pub/3451.htm 41
FGE.21Rev5 19 March 2015 41
The present revision of FGE.21, FGE.21 Revision 5, deals with the following additional toxicity data
which have become available:
• A 90-day dietary rat study for 2-pentylthiophene [FL-no: 15.096] (Bauter, 2013b). This
substance has been selected as a representative substance for 2-butylthiophene [FL-no:
15.045], 2-hexylthiophene [FL-no: 15.076] and 2-octylthiophene [FL-no: 15.093]. Further
information on the stability of 2-pentylthiophene [FL-no: 15.096] in feed has been submitted
(EFFA, 2014; Mendes, 2014).
N
S
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• A 14-day dietary study and a 90-day gavage rat study for 5-ethylthiophene-2-carbaldehyde
[FL-no: 15.074] (Bauter, 2012b, 2013c). This substance has been selected as a representative
substance for 2-acetylthiophene [FL-no: 15.040] and 2-propionylthiophene [FL-no: 15.097].
A literature search for toxicity data on [FL-no: 15.074 and 15.096] has been performed, but no
pertinent data have been found.
Since the publication of FGE.21Rev4, updated information on European production figures has been
provided by EFFA for seven substances [FL-no: 15. 040, 15.045, 15.074, 15.076, 15.093, 15.096 and
15.097] (IOFI, 2013a, b) In the Union List, the name of [FL-no: 15.096] has been changed from sec-
pentylthiophene to 2-pentylthiophene. The name of [FL-no: 15.055] has also been changed from 2,4-
Dimethyl(4H)pyrrolidino[1,2e]-1,3,5-dithiazine to [2S-(2a,4a,8ab)] 2,4-Dimethyl(4H)-pyrrolidino-
[1,2e]-1,3,5-dithiazine.
2. Presentation of the substances in Flavouring Group Evaluation 21, Revision 5
2.1. Description
The present FGE.21Rev5, using the Procedure as referred to in the Commission Regulation (EC) No
1565/2000 (the Procedure is shown in schematic form in Appendix A of this FGE), deals with 41
flavouring substances (candidate substances) from chemical groups 29 and 30, Annex I of
Commission Regulation (EC) No 1565/2000. The candidate substances in FGE.21Rev5 fall into the
chemical groups of thiazoles (S- and N-containing) and dithiazines (S- and N-containing) (Table 4, and
Table 8 in Section 5).
The candidate substances, as well as their chemical register names, Flavour Information System
(FLAVIS) (FL-no), Chemical Abstract Service (CAS), Council of Europe (CoE) and Flavor and
Extract Manufacturers Association (FEMA) numbers, structure and specifications, are listed in
Table 4.
A summary of the outcome of the safety evaluation of the candidate substances is listed in Table 10.
The candidate substances are structurally related to 28 flavouring substances (supporting substances)
evaluated at the 59th and 68th JECFA meetings (JECFA, 2002a, 2003, 2007, 2008) in the group of
“sulphur-containing heterocyclic compounds”. Two of these supporting substances (see Table 11) are
mixtures (one of two isomeric isobutyl-substituted and one of two isomeric isopropyl-substituted
dimethyldihydrodithiazine derivatives) and are not included in the register.
Flavouring Group Evaluation 21 Revision 5
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SUMMARY OF SPECIFICATION DATA
Table 4: Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 5
FL-no EU Register name Structural formula FEMA no
CoE no
CAS no
Physical
form
Molecular
formula
Molecular
weight
Solubility
(a)
Solubility
in ethanol
(b)
Boiling point,
(°C) (c)
Melting point,
(°C)
ID test
Assay
minimum
Refractive
Index (d)
Specific
gravity (e)
Specification comments
15.037 2-Acetyl-3-
methylthiophene 11590
13679-72-6
Liquid
C7H8OS
140.20
Practically
insoluble or
insoluble
Freely
soluble
216
MS
95 %
1.558-1.564
1.130-1.136 No longer supported by
Industry (DG SANCO,
2012).
15.038 2-Acetyl-4-
methylthiazole 11589
7533-07-5
Solid
C6H7NOS
141.19
Practically
insoluble or
insoluble
Freely
soluble
95 (16 hPa)
34
MS
95 %
n.a.
n.a.
15.039 2-Acetyl-5-
methylthiazole
59303-17-2
Solid
C6H7NOS
141.19
Practically
insoluble or
insoluble
Freely
soluble
93 (16 hPa)
30
MS
95 %
n.a.
n.a.
15.040 2-Acetylthiophene
11728
88-15-3
Solid
C6H6OS
126.17
Practically
insoluble or
insoluble
Freely
soluble
213
34
MS
98 %
1.563-1.569
1.164-1.171
15.042 2-Butyl-4-
methyl(4H)pyrrolidino[
1,2d]-1,3,5-dithiazine 132344-97-9
Solid
C11H21NS2
231.42
Practically
insoluble or
insoluble
Freely
soluble
304
164
NMR
95 %
n.a.
n.a. No longer supported by
Industry (DG SANCO,
2012).
15.043 2-Butyl-5-
ethylthiophene 11596
54411-06-2
Solid
C10H16S
168.30
Practically
insoluble or
insoluble
Freely
231
54
MS
95 %
n.a.
n.a. No longer supported by
Industry (DG SANCO,
2012).
S
O
N
S
O
N
S
O
S
O
S N
S
S
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Table 4: Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 5
FL-no EU Register name Structural formula FEMA no
CoE no
CAS no
Physical
form
Molecular
formula
Molecular
weight
Solubility
(a)
Solubility
in ethanol
(b)
Boiling point,
(°C) (c)
Melting point,
(°C)
ID test
Assay
minimum
Refractive
Index (d)
Specific
gravity (e)
Specification comments
soluble
15.044 2-Butylthiazole
11597
37645-61-7
Solid
C7H11NS
141.23
Practically
insoluble or
insoluble
Freely
soluble
212
79
NMR
95 %
n.a.
n.a.
15.045 2-Butylthiophene
1455-20-5
Liquid
C8H12S
140.24
Practically
insoluble or
insoluble
Freely
soluble
182
MS
95 %
1.504-1.510
0.951-0.957
15.050 2,5-Diethyl-4-
methylthiazole
41981-71-9
Solid
C8H13NS
155.26
Practically
insoluble or
insoluble
Freely
soluble
85 (20 hPa)
115
MS
95 %
n.a.
n.a.
15.051 2,5-Diethyl-4-
propylthiazole
4276-68-0
Solid
C10H17NS
183.31
Practically
insoluble or
insoluble
Freely
soluble
72 (21 hPa)
139
NMR
95 %
n.a.
n.a.
15.052 2,5-Diethylthiazole
15729-76-7
Solid
C7H11NS
141.23
Practically
insoluble or
insoluble
Freely
soluble
187
92
MS
95 %
n.a.
n.a.
15.054 Dihydro-2,4,6-triethyl-
1,3,5(4H)-dithiazine
54717-17-8
Solid
C9H19NS2
205.38
Practically
insoluble or
insoluble
Freely
soluble
287
188
MS
95 %
n.a.
n.a. Mixture of
diastereoisomers (EFFA,
2010). Mixture of
isomers ((R/R), (R/S),
N
S
S
N
S
N
S
N
S
S NH
S
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Table 4: Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 5
FL-no EU Register name Structural formula FEMA no
CoE no
CAS no
Physical
form
Molecular
formula
Molecular
weight
Solubility
(a)
Solubility
in ethanol
(b)
Boiling point,
(°C) (c)
Melting point,
(°C)
ID test
Assay
minimum
Refractive
Index (d)
Specific
gravity (e)
Specification comments
(S/R) and (S/S) at equal
ratio, i.e. 25 % of each)
(EFFA, 2011b).
15.055
1763
[2S-(2a,4a,8ab)] 2,4-
Dimethyl(4H)pyrrolidin
o[1,2e]-1,3,5-dithiazine
4321
116505-60-3
Solid
C8H15NS2
189.34
Practically
insoluble or
insoluble
Freely
soluble
235
130
MS
95 %
n.a.
n.a.
15.057 4,6-Dimethyl-2-(1-
methylethyl)dihydro-
1,3,5-dithiazine
3782
104691-40-9
Liquid
C8H17NS2
191.36
Slightly
soluble
Soluble
109 (0.23hPa)
MS
71 %
1.496-1.500
0.951-0.959 Mixture of four
diastereoisomers (25 % of
each) (EFFA, 2013b). At
least 44 % 2-Isopropyl-
4,6-dimethyl and 27 % 4-
Isopropyl-2,6-dimethyl;
secondary components at
least 24 %: 2,4,6-
Trimethyldihydro-; 6-
Methyl-2,4-diisopropyl-;
4-Methyl-2,6-
diisopropyl-; 2,4,6-
Triisopropyl-dihydro-
1,3,5-dithiazine (EFFA,
2011c).
15.058 4,5-Dimethyl-2-
ethylthiazole
873-64-3
Solid
C7H11NS
141.23
Practically
insoluble or
insoluble
Freely
soluble
185
104
MS
96 %
n.a.
n.a.
S N
S
HN
S
S
N
S
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Table 4: Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 5
FL-no EU Register name Structural formula FEMA no
CoE no
CAS no
Physical
form
Molecular
formula
Molecular
weight
Solubility
(a)
Solubility
in ethanol
(b)
Boiling point,
(°C) (c)
Melting point,
(°C)
ID test
Assay
minimum
Refractive
Index (d)
Specific
gravity (e)
Specification comments
15.060 2,4-Dimethyl-3-
thiazoline
60755-05-7
Solid
C5H9NS
115.19
Practically
insoluble or
insoluble
Freely
soluble
52 (15 hPa)
102
MS
95 %
n.a.
n.a. Racemate (EFFA, 2010).
15.061 2,5-Dimethyl-4-
ethylthiazole
32272-57-4
Solid
C7H11NS
141.23
Practically
insoluble or
insoluble
Freely
soluble
185
104
MS
95 %
n.a.
n.a.
15.062 2,4-Dimethylthiazole
11605
541-58-2
Solid
C5H7NS
113.18
Practically
insoluble or
insoluble
Freely
soluble
145
69
MS
95 %
n.a.
n.a.
15.063
1758
2,5-Dimethylthiazole
4175-66-0
Solid
C5H7NS
113.18
Practically
insoluble or
insoluble
Freely
soluble
152
69
MS
95 %
n.a.
n.a.
15.064 2,5-Dimethylthiophene
11609
638-02-8
Liquid
C6H8S
112.19
Practically
insoluble or
insoluble
Freely
soluble
135
MS
95 %
1.508-1.514
0.982-0.988 No longer supported by
Industry (DG SANCO,
2013).
15.067 4-Ethyl-2-
methylthiazole
32272-48-3
Solid
C6H9NS
127.20
Practically
insoluble or
insoluble
Freely
soluble
91 (89 hPa)
80
MS
95 %
n.a.
n.a.
N
S
N
S
N
S
N
S
S
N
S
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Table 4: Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 5
FL-no EU Register name Structural formula FEMA no
CoE no
CAS no
Physical
form
Molecular
formula
Molecular
weight
Solubility
(a)
Solubility
in ethanol
(b)
Boiling point,
(°C) (c)
Melting point,
(°C)
ID test
Assay
minimum
Refractive
Index (d)
Specific
gravity (e)
Specification comments
15.068 5-Ethyl-2-
methylthiazole
19961-52-5
Solid
C6H9NS
127.20
Practically
insoluble or
insoluble
Freely
soluble
170
80
MS
95 %
n.a.
n.a.
15.069 4-Ethyl-5-
methylthiazole
52414-91-2
Solid
C6H9NS
127.20
Practically
insoluble or
insoluble
Freely
soluble
174
80
MS
95 %
n.a.
n.a.
15.070 2-Ethyl-5-
methylthiophene
40323-88-4
Liquid
C7H10S
126.22
Practically
insoluble or
insoluble
Freely
soluble
158
MS
97 %
1.503-1.509
0.963-0.970 No longer supported by
Industry (DG SANCO,
2012).
15.071 2-Ethylthiazole
15679-09-1
Liquid
C5H7NS
113.18
Practically
insoluble or
insoluble
Freely
soluble
148
MS
95 %
1.511-1.517
1.058-1.064
15.072 2-Ethylthiophene
11614
872-55-9
Liquid
C6H8S
112.19
Practically
insoluble or
insoluble
Freely
soluble
133
MS
95 %
1.510-1.516
0.989-0.995 No longer supported by
Industry (DG SANCO,
2013).
15.074 5-Ethylthiophene-2-
carbaldehyde
36880-33-8
Solid
C7H8OS
140.20
Practically
insoluble or
insoluble
Freely
soluble
104 (12 hPa)
62
MS
95 %
n.a.
n.a.
N
S
N
S
S
N
S
S
S
O
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Table 4: Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 5
FL-no EU Register name Structural formula FEMA no
CoE no
CAS no
Physical
form
Molecular
formula
Molecular
weight
Solubility
(a)
Solubility
in ethanol
(b)
Boiling point,
(°C) (c)
Melting point,
(°C)
ID test
Assay
minimum
Refractive
Index (d)
Specific
gravity (e)
Specification comments
15.076
1764
2-Hexylthiophene 4137
11616
18794-77-9
Solid
C10H16S
168.30
Practically
insoluble or
insoluble
Freely
soluble
92 (13 hPa)
41
MS
95 %
n.a.
n.a.
15.077 4-Hydroxy-2,5-
dimethylthiophen-
3(2H)-one 26494-10-0
Solid
C6H8O2S
144.19
Practically
insoluble or
insoluble
Freely
soluble
296
133
MS
95 %
n.a.
n.a. No longer supported by
Industry (DG SANCO,
2012).
15.078 2-Isobutyl-4,5-
dimethylthiazole 11617
53498-32-1
Solid
C9H15NS
169.29
Practically
insoluble or
insoluble
Freely
soluble
267
112
MS
97 %
n.a.
n.a.
15.079 2-Isobutyldihydro-4,6-
dimethyl-1,3,5-
dithiazine
3781
101517-87-7
Liquid
C9H19NS2
205.39
Slightly
soluble
Soluble
115 (0.33 hPa)
MS
82 %
1.488-1.492
0.961-0.967 Mixture of
diastereoisomers, each of
them racemic (EFFA,
2013b). At least 64 % 2-
isobutyl-4,6-dimethyl and
18 % 4-Isobutyl-2,6-
dimethyl; secondary
components at least 13
%: 2,4,6-trimethyl-; 2,4-
diisobutyl-6-methyl-; 2,6-
dimethyl-4-butyldihydro-
1,3,5-dithiazine;
substituted 1,3,5-
thiadiazine (EFFA,
2011c).
S
S
HO O
N
S
S
N
H
S
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Table 4: Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 5
FL-no EU Register name Structural formula FEMA no
CoE no
CAS no
Physical
form
Molecular
formula
Molecular
weight
Solubility
(a)
Solubility
in ethanol
(b)
Boiling point,
(°C) (c)
Melting point,
(°C)
ID test
Assay
minimum
Refractive
Index (d)
Specific
gravity (e)
Specification comments
15.080 2-Isopropyl-4,5-
dimethylthiazole
53498-30-9
Solid
C8H13NS
155.26
Practically
insoluble or
insoluble
Freely
soluble
244
101
MS
95 %
n.a.
n.a.
15.082 3-Mercaptothiophene
7774-73-4
Liquid
C4H4S2
116.20
Slightly
soluble
Freely
soluble
171
MS
95 %
1.617-1.623
1.248-1.254
15.084 5-Methyl-2-
pentylthiazole
86290-21-3
Solid
C9H15NS
169.26
Practically
insoluble or
insoluble
Freely
soluble
262
114
NMR
95 %
n.a.
n.a.
15.085 4-Methyl-2-
propionylthiazole 11622
13679-83-9
Solid
C7H9NOS
155.21
Practically
insoluble or
insoluble
Freely
soluble
86 (12 hPa)
142
NMR
95 %
n.a.
n.a.
15.086 2-Methyl-2-thiazoline
2346-00-1
Solid
C4H7NS
101.17
Slightly
soluble
Freely
soluble
144
62
MS
95 %
n.a.
n.a.
15.087 2-Methyl-3-
mercaptothiophene
2527-76-6
Solid
C5H6S2
130.22
Slightly
soluble
Freely
soluble
73 (15 hPa)
27
MS
95 %
n.a.
n.a.
15.088 2-Methyl-4,5-
benzothiazole
120-75-2
Liquid
C8H7NS
149.21
Practically
insoluble or
insoluble
238
MS
1.612-1.618
1.173-1.179 No longer supported by
Industry (DG SANCO,
N
S
S
SH
N
S
N
S
O
N
S
S
SH
N
S
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Table 4: Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 5
FL-no EU Register name Structural formula FEMA no
CoE no
CAS no
Physical
form
Molecular
formula
Molecular
weight
Solubility
(a)
Solubility
in ethanol
(b)
Boiling point,
(°C) (c)
Melting point,
(°C)
ID test
Assay
minimum
Refractive
Index (d)
Specific
gravity (e)
Specification comments
Freely
soluble
95 % 2012).
15.089 2-Methylthiazole
11626
3581-87-1
Liquid
C4H5NS
99.15
Slightly
soluble
Freely
soluble
128
MS
95 %
1.511-1.517
1.109-1.116
15.090 2-Methylthiazolidine
24050-16-6
Liquid
C4H9NS
103.18
Slightly
soluble
Freely
soluble
160
MS
95 %
1.522-1.528
1.519-1.525 No longer supported by
Industry (DG SANCO,
2012).
15.091 2-Methylthiophene
11631
554-14-3
Liquid
C5H6S
98.16
Practically
insoluble or
insoluble
Freely
soluble
112
MS
97 %
1.516-1.523
1.013-1.022 No longer supported by
Industry (DG SANCO,
2013).
15.092 3-Methylthiophene
11632
616-44-4
Liquid
C5H6S
98.16
Practically
insoluble or
insoluble
Freely
soluble
115
MS
95 %
1.514-1.520
1.018-1.024 No longer supported by
Industry (DG SANCO,
2013).
15.093 2-Octylthiophene
880-36-4
Solid
C12H20S
196.35
Practically
insoluble or
insoluble
Freely
soluble
259
64
MS
95 %
n.a.
n.a.
15.094 2-Pentanoylthiophene
53119-25-8
Solid
C9H12OS
168.26
Practically
insoluble or
insoluble
Freely
soluble
257
80
MS
95 %
n.a.
n.a. No longer supported by
Industry (DG SANCO,
2012).
N
S
NH
S
S
S
S
S
O
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Table 4: Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 5
FL-no EU Register name Structural formula FEMA no
CoE no
CAS no
Physical
form
Molecular
formula
Molecular
weight
Solubility
(a)
Solubility
in ethanol
(b)
Boiling point,
(°C) (c)
Melting point,
(°C)
ID test
Assay
minimum
Refractive
Index (d)
Specific
gravity (e)
Specification comments
15.096
2106
2-Pentylthiophene 4387
11634
4861-58-9
Liquid
C9H14S
154.27
Practically
insoluble or
insoluble
Freely
soluble
201
MS
95 %
1.495-1.501
0.940-0.946 The former incorrect
name sec-pentylthiophene
has been changed.
15.097 2-Propionylthiophene
11635
13679-75-9
Solid
C7H8OS
140.20
Practically
insoluble or
insoluble
Freely
soluble
225
57
MS
95 %
n.a.
n.a.
15.098 2-Propylthiazole
17626-75-4
Solid
C6H9NS
127.20
Practically
insoluble or
insoluble
Freely
soluble
172
78
MS
95 %
n.a.
n.a.
15.099 2-Propylthiazolidine
24050-10-0
Solid
C6H13NS
131.24
Practically
insoluble or
insoluble
Freely
soluble
75 (13 hPa)
84
MS
95 %
n.a.
n.a. No longer supported by
Industry (DG SANCO,
2012).
15.106 Thiophene
11647
110-02-1
Liquid
C4H4S
84.14
Practically
insoluble or
insoluble
Freely
soluble
84
MS
95 %
1.525-1.531
1.062-1.068 No longer supported by
Industry (DG SANCO,
2012).
15.107 Thiophene-2-
carbaldehyde 11874
98-03-3
Liquid
C5H4OS
112.15
Slightly
soluble
Freely
soluble
198
MS
95 %
1.585-1.592
1.216-1.225 No longer supported by
Industry (DG SANCO,
2012).
15.108 2-
Thiophenemethanethiol
Liquid
C5H6S2
Slightly
soluble
82 (16 hPa) 1.571-1.578
1.165-1.171
S
S
O
N
S
NH
S
S
S
O
S
SH
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Table 4: Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 5
FL-no EU Register name Structural formula FEMA no
CoE no
CAS no
Physical
form
Molecular
formula
Molecular
weight
Solubility
(a)
Solubility
in ethanol
(b)
Boiling point,
(°C) (c)
Melting point,
(°C)
ID test
Assay
minimum
Refractive
Index (d)
Specific
gravity (e)
Specification comments
6258-63-5 130.22 Freely
soluble
MS
95 %
15.114 6-Acetyl-2,3-dihydro-
1,4-thiazine
4296
101417-25-8
Solid
C6H9NOS
143.2
Sparringly
soluble
Freely
soluble
242
126
NMR
95 %
n.a.
n.a. No longer supported by
Industry (DG SANCO,
2012).
15.115 2-Isobutyl-4-methyl
thiazole
61323-24-8
Solid
C8H13NS
155.26
Slightly
soluble
Freely
soluble
189
88
MS
95 %
n.a.
n.a.
15.116 2-Acetyl-4-
ethylthiazole
233665-91-3
Solid
C7H9NOS
155.22
Slightly
soluble
Freely
soluble
270
142
NMR
95 %
n.a.
n.a.
15.118 4-Butylthiazole
53833-33-3
Solid
C7H11NS
141.23
Practically
insoluble or
insoluble
Freely
soluble
212
79
MS
95 %
n.a.
n.a.
15.119 2-Isobutyl-3-thiazoline
39800-92-5
Solid
C7H13NS
143.25
Very
slightly
soluble
Freely
soluble
197
80
MS
95 %
n.a.
n.a. Racemate (EFFA,
2011b).
N
H
S
O
N
S
N
S
O
N
S
N
S
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Table 4: Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 5
FL-no EU Register name Structural formula FEMA no
CoE no
CAS no
Physical
form
Molecular
formula
Molecular
weight
Solubility
(a)
Solubility
in ethanol
(b)
Boiling point,
(°C) (c)
Melting point,
(°C)
ID test
Assay
minimum
Refractive
Index (d)
Specific
gravity (e)
Specification comments
15.129 Tetrahydro-2,4,6-
trimethyl-1,3,5(2H)-
thiadiazine 53897-63-5
Solid
C6H14N2S
146
Soluble
Soluble
216-266 (1
hPa)
65-70
99 %
n.a.
n.a. No longer supported by
Industry (DG SANCO,
2012).
15.133
1766
5-Acetyl-2,3-dihydro-
1,4-thiazine
164524-93-0
Solid
C6H9NOS
143
Soluble
Soluble
289+/-30
67-69
98 %
n.a.
n.a. No longer supported by
Industry (DG SANCO,
2012).
15.135 Ethyl thialdine 4667
54717-14-5
Liquid
C7H15NS2
177.33
Poorly
soluble
Soluble
75
IR NMR MS
90 %
1.5344-
1.5544
1.0745-1-
0765
Mixture of
diastereoisomers, each of
them racemic (EFFA,
2013b). Minimum assay
value 90 %. Secondary
components: 3,5-diethyl-
1,2,4-trithiolane (< 5 %);
thialdine (< 2 %); others
(< 3 %) (Flavour
Industry, 2011).
(a): Solubility in water, if not otherwise stated.
(b): Solubility in 95 % ethanol, if not otherwise stated.
(c): At 1013.25 hPa, if not otherwise stated.
(d): At 20°C, if not otherwise stated.
(e): At 25°C, if not otherwise stated.
HN NH
S
S
N
H
O
S
N
H
S
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2.2. Stereoisomers
It is recognised that geometrical and optical isomers of substances may have different properties. Their
flavour may be different; they may have different chemical properties resulting in possible variability
in their absorption, distribution, metabolism, elimination and toxicity. Thus, information must be
provided on the configuration of the flavouring substance, i.e. whether it is one of the
geometrical/optical isomers or a defined mixture of stereoisomers. The available specifications of
purity will be considered in order to determine whether the safety evaluation carried out for candidate
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring
substances with different configurations should have individual chemical names and codes (CAS
number, FLAVIS number, etc.)
Two of the 41 candidate substances possess one chiral centre [FL-no: 15.060, and 15.119], three
possess two chiral centres [FL-no: 15.054, 15.057 and 15.135] and two possess three chiral centres
[FL-no: 15.055 and 15.079]. The stereoisomeric composition has been specified for all substances
(EFFA, 2010, 2011b, 2013b) (see Table 4).
2.3. Natural occurrence in food
Thirty-one candidate substances have been reported to occur naturally in one or more of the following
food items: shellfish, shrimps, squid, pork, beef, lamb, chicken, vegetables, peanut, wheaten bread,
butter, cheese, tea, coffee, cocoa and various types of alcoholic beverages. Quantitative data on the
natural occurrence in foods have been reported for nine of these substances (TNO, 2000, 2010, 2011),
see Table 5.
Table 5: Candidate substances reported to occur in food
FL-no Name Quantitative data reported
15.038 2-Acetyl-4-methylthiazole 0.02 mg/kg in kohlrabi
15.040 2-Acetylthiophene Up to 1.25 mg/kg in coffee, 0.02 mg/kg in kohlrabi, up to
0.00002 mg/kg in pork (grilled, roasted)
15.061 2,5-Dimethyl-4-
ethylthiazole
0.00001 mg/kg in pork (grilled, roasted)
15.062 2,4-Dimethylthiazole Up to 0.00004 mg/kg in pork (grilled, roasted)
15.069 4-Ethyl-5-methylthiazole Up to 0.00001 mg/kg in pork (grilled, roasted)
15.076 2-Hexylthiophene Up to 0.002 mg/kg in guinea hen
15.096 2-Pentylthiophene 0.001 mg/kg in chicken (roasted)
15.097 2-Propionylthiophene 0.8 mg/kg in coffee
15.135 Ethyl thialdine 0.02 mg/kg in krill, up to 0.3 mg/kg in shrimps
Ten of the candidate substances have not been reported to occur naturally in any food items according
to the Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek (TNO) (TNO,
2000, 2010, 2011, 2014), see Table 6.
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Table 6: Candidate substances not reported to occur in food
FL-no Name
15.044 2-Butylthiazole
15.055 [2S-(2a,4a,8ab)] 2,4-Dimethyl(4H)pyrrolidino[1,2e]-1,3,5-dithiazine
15.074 5-Ethylthiophene-2-carbaldehyde
15.079 2-Isobutyldihydro-4,6-dimethyl-1,3,5-dithiazine
15.082 3-Mercaptothiophene
15.087 2-Methyl-3-mercaptothiophene
15.108 2-Thiophenemethanethiol
15.115 2-Isobutyl-4-methylthiazole
15.116 2-Acetyl-4-ethylthiazole
15.119 2-Isobutyl-3-thiazoline
3. Specifications
Purity criteria for the candidate substances have been provided by the flavouring industry (EFFA,
2004d, 2011a; Flavour Industry, 2010b).
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000, the
information is adequate for all 41 substances (see Section 2.2 and Table 4).
4. Intake data
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production
figure only represents 60 % of the use in food because of underreporting and that 10 % of the total EU
population are consumers (SCF, 1999).
However, the Panel noted that because of year-to-year variability in production volumes, to
uncertainties in the underreporting correction factor and to uncertainties in the percentage of
consumers, the reliability of intake estimates on the basis of the MSDI approach is difficult to assess.
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In
such cases, the human exposure thresholds below which exposures are not considered to present a
safety concern might be exceeded.
Considering that the MSDI model may underestimate the intake of flavouring substances by certain
groups of consumers, the Scientific Committee on Food (SCF) recommended also taking into account
the results of other intake assessments (SCF, 1999).
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable
beverages and foods in general, with exceptional levels for particular foods. This method is regarded
as a conservative estimate of the actual intake by most consumers because it is based on the
assumption that the consumer regularly eats and drinks several food products containing the same
flavouring substance at the upper use level.
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use
levels of the flavouring substances. This modified approach is less conservative (e.g. it may
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels
reported). However, it is considered as a suitable tool to screen and prioritise the flavouring substances
according to the need for refined intake data (EFSA, 2004).
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4.1. Estimated daily per capita intake (MSDI approach)
The intake estimation is based on the MSDI approach, which involves the acquisition of data on the
quantities used in food as flavourings (SCF, 1999). These data are derived from surveys on annual
production volumes in Europe. These surveys were conducted in 1995 by the International
Organization of the Flavour Industry (IOFI), in which flavour manufacturers reported the total
quantity of each flavouring substance incorporated into food sold in the EU during the previous year
(IOFI, 1995). The intake approach does not consider the possible natural occurrence in food.
Average per capita intake (MSDI) is estimated on the assumption that the quantity added to food is
consumed by 10 % of the population9 (Eurostat, 1998). This is derived for candidate substances from
estimates of annual volume of production provided by Industry and incorporates a correction factor of
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999).
The total annual volume of production of the candidate substances from use as flavouring substances
in Europe has been reported to be approximately 110 kg (EFFA, 2004b, 2011a, 2012a; Flavour
Industry, 2010b; IOFI, 2013a, b). 4,6-Dimethyl-2-(1-methylethyl)dihydro-1,3,5-dithiazine [FL-no:
15.057] and 2-isobutyldihydro-4,6-dimethyl-1,3,5-dithiazine [FL-no: 15.079] accounts for 60 kg. For
27 of the 28 supporting substances the annual volume of production is approximately 4 100 kg in
Europe (JECFA, 2003; EFFA, 2012a, b, 2013a). Thiamine hydrochloride [FL-no: 16.027] accounts for
2 500 kg and 5-(2-hydroxyethyl)-4-methylthiazole [FL-no: 15.014] for 1 200 kg.
On the basis of the annual volumes of production reported for the candidate substances, the daily per
capita intakes for each of these flavourings have been estimated (Tables 9 and 10).
The estimated daily per capita intake of 2-isobutyldihydro-4,6-dimethyl-1,3,5-dithiazine [FL-no:
15.079], from use as a flavouring substance, is 5.7 µg, of 4,6-dimethyl-2-(1-methylethyl)dihydro-
1,3,5-dithiazine [FL-no: 15.057] 1.6 µg and of 4-butylthiazole [FL-no: 15.118] 1.3 µg. For the
remaining 37 substances, the estimated daily per capita intakes are in the range of 0.0012 to 0.85 µg
(Tables 9 and 10).
4.2. Intake estimated on the basis of the modified TAMDI (mTAMDI)
The method for calculation of the modified Theoretical Added Maximum Daily Intake (mTAMDI)
values is based on the approach used by SCF up to 1995 (SCF, 1995).
The assumption is that a person may consume a certain quantity of flavourable foods and beverages
per day.
For the present evaluation of the candidate substances, information on food categories and normal and
maximum use levels10,11,12 were submitted by the Flavour Industry (EFFA, 2004c, d, 2007; Flavour
Industry, 2004–5, 2010b) for 39 substances. No information on use levels have been submitted for
[FL-no: 15.057 and 15.079]. The candidate substances are used in flavoured food products, divided
into the food categories outlined in Annex III of the Commission Regulation (EC) No 1565/2000, as
shown in Table 7. For the present calculation of the mTAMDI, the reported normal use levels were
used. In cases where different use levels were reported for different food categories the highest
reported normal use level was used.
9 EU figure, 375 million. This figure relates to EU population at the time for which production data are available, and is
consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No production data are available
for the enlarged EU.
10 “Normal use” is defined as the average of reported usages and “maximum use” is defined as the 95th percentile of reported
usages (EFFA, 2002).
11 The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from figures derived
from 12 model flavouring substances (EFFA, 2004a).
12 The use levels from food category 5 “Confectionery” have been inserted as default values for food category 14.2
“Alcoholic beverages” for substances for which no data have been given for food category 14.2 (EFFA, 2007).
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Table 7: Use of the 39 candidate substances for which data on use have been provided in
various food categories
Food
category
Description Flavourings used (a)
01.0 Dairy products, excluding products of category 2 All
02.0 Fats and oils, and fat emulsions (type water-in-oil) All
03.0 Edible ices, including sherbet and sorbet All except one [FL-no:
15.135]
04.1 Processed fruits All
04.2 Processed vegetables (including mushrooms and fungi, roots and
tubers, pulses and legumes), and nuts and seeds
[FL-no: 15.062 and
15.135]
05.0 Confectionery All except two [FL-
no: 15.062 and
15.135]
06.0 Cereals and cereal products, including flours and starches from roots
and tubers, pulses and legumes, excluding bakery
All
07.0 Bakery wares All
08.0 Meat and meat products, including poultry and game All
09.0 Fish and fish products, including molluscs, crustaceans and
echinoderms
All except two [FL-
no: 15.039 and
15.135]
10.0 Eggs and egg products None
11.0 Sweeteners, including honey None
12.0 Salts, spices, soups, sauces, salads, protein products, etc. All except one [FL-no:
15.089]
13.0 Foodstuffs intended for particular nutritional uses All except one [FL-no:
15.135]
14.1 Non-alcoholic (“soft”) beverages, excluding dairy products All except one [FL-no:
15.135]
14.2 Alcoholic beverages, including alcohol-free and low-alcoholic
counterparts
All except two [FL-
nos: 15.062 and
15.135]
15.0 Ready-to-eat savouries All except one [FL-no:
15.068]
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat)—foods that
could not be placed in categories 1–15
All except one [FL-no:
15.135]
(a): No use levels have been submitted for [FL-nos: 15.057 and 15.079].
According to the Flavour Industry, the normal use levels range from 0.1 to 2 mg/kg food, and the
maximum use levels range from 0.2 to 12 mg/kg (EFFA, 2004c, d, 2007; Flavour Industry, 2004–5,
2010b) for 39 of the 41 substances for which use levels have been provided (Section 7 and Appendix
B).
The mTAMDI values for the 34 candidate substances from structural class (SC) II (see Section 7)
range from 78 to 220 µg/person per day. For the remaining seven candidate substances from SC III,
for which data have been provided, the mTAMDI range from 78 to 250 µg/person per day.
For detailed information on use levels and intake estimations based on the mTAMDI approach, see
Section 7 and Appendix B.
5. Absorption, distribution, metabolism and elimination
The 41 candidate substances are structurally related to 28 supporting substances evaluated by the
JECFA in “Sulfur-containing heterocyclic compounds” (JECFA, 2003, 2008). The substances are
divided into subgroups based on the nature of the ring; aromatic (clustered in subgroups A-Ib, A-Ic
and A-II) vs. non-aromatic (clustered in subgroups B-II and B-IV)), on type and number of ring
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heteroatoms (sulphur or sulphur with nitrogen) and the degree of saturation in the non-aromatic rings.
The assignment of the individual substances to the different subgroups is presented in Table 8 (the
substances previously allocated to subgroup A-Ia, A-III, BI, B-III, B-V and B-VI are no longer
supported by Industry). The structures of the substances and a description of the characteristic features
of the subgroups are also given in Table C.1 and the accompanying text in Appendix C.
Table 8: Division of candidate substances into structural subgroups
Subgroup and
common ring
structure
Register name FL-no
A Aromatic subgroups
A-Ia: Thiophene The substance previously allocated to the group is no longer supported for use as a
flavouring substance in Europe by Industry
A-Ib: Thiophenes
(with non-thiol-
containing ring
substituents)
S
R
2-Acetylthiophene 15.040
2-Butylthiophene 15.045
5-Ethylthiophene-2-carbaldehyde 15.074
2-Hexylthiophene 15.076
2-Octylthiophene 15.093
2-Pentylthiophene 15.096
2-Propionylthiophene 15.097
A-Ic: Thiophenes
(with thiol-containing
ring substituents)
S
(R)-SH
3-Mercaptothiophene 15.082
2-Thiophenemethanethiol 15.108
2-Methyl-3-mercaptothiophene 15.087
A-II: Thiazoles
S
N
2-Methylthiazole 15.089
2-Ethylthiazole 15.071
2-Propylthiazole 15.098
2-Butylthiazole 15.044
4-Butylthiazole 15.118
2,4-Dimethylthiazole 15.062
2,5-Dimethylthiazole 15.063
5-Ethyl-2-methylthiazole 15.068
4-Ethyl-2-methylthiazole 15.067
4-Ethyl-5-methylthiazole 15.069
2,5-Diethylthiazole 15.052
5-Methyl-2-pentylthiazole 15.084
4,5-Dimethyl-2-ethylthiazole 15.058
2,5-Dimethyl-4-ethylthiazole 15.061
2,5-Diethyl-4-methylthiazole 15.050
2,5-Diethyl-4-propylthiazole 15.051
2-Isobutyl-4-methylthiazole 15.115
2-Isobutyl-4,5-dimethylthiazole 15.078
2-Isopropyl-4,5-dimethylthiazole 15.080
2-Acetyl-4-methylthiazole 15.038
2-Acetyl-5-methylthiazole 15.039
2-Acetyl-4-ethylthiazole 15.116
4-Methyl-2-propionylthiazole 15.085
A-III: Benzothiazoles The substance previously allocated to the group is no longer supported for use as a
flavouring substance in Europe by Industry
B Non-aromatic subgroups
B-I: Dihydrothiophenes The substance previously allocated to the group is no longer supported for use as a
flavouring substance in Europe by Industry
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B-II: Thiazolines
S
N
2-Methyl-2-thiazoline 15.086
2,4-Dimethyl-3-thiazoline 15.060
2-Isobutyl-3-thiazoline 15.119
B-III: Thiazolidines The substances previously allocated to the group are no longer supported for use as
flavouring substances in Europe by Industry
B-IV: Dithiazines
NH
S
S
Dihydro-2,4,6-triethyl-1,3,5(4H)-
dithiazine
15.054
[2S-(2a,4a,8ab)] 2,4-
Dimethyl(4H)pyrrolidino[1,2e]-1,3,5-
dithiazine
15.055
4,6-Dimethyl-2-(1-methylethyl)dihydro-
1,3,5-dithiazine
15.057
2-Isobutyldihydro-4,6-dimethyl-1,3,5-
dithiazine
15.079
Ethyl thialdine 15.135
B-V: Dihydrothiazines The substances previously allocated to the group are no longer supported for use as
flavouring substances in Europe by Industry
B-VI: Thiadiazine The substance previously allocated to the group is no longer supported for use as a
flavouring substance in Europe by Industry
From the limited data available on absorption, distribution and elimination of the aromatic candidate
substances in this FGE, it is anticipated that they may be absorbed and eliminated after
biotransformation. Some volatile substances may also be eliminated unchanged via exhalation. For the
non-aromatic substances there are no data available for the candidate or for the supporting substances.
For the evaluation of the metabolism of the candidate substances, only limited data were available.
These were confined to a few studies on some thiophene and thiazole derivatives (i.e. only directly
relevant for the evaluation of subgroups A (A-Ib, A-Ic and A-II)), the aromatic candidate substances.
Other information was found in several review papers. However, virtually no data were found on the
metabolism of substances from the B subgroups possessing non-aromatic ring structures.
5.1. Metabolism of substances in subgroup A-I
The structurally related thiophene and the ring-substituted thiophenes (A-Ib and A-Ic) may undergo S-
oxidation to give sulphoxides. These primary metabolites may react spontaneously or via glutathione
transferase with glutathione (GSH), and it is likely that they also exhibit reactivity towards protein
thiols. The glutathione conjugates may be further metabolised to the corresponding mercapturic acids
and excreted in the urine. S-oxide intermediates may also be subject to dimerisation via a Diels-Alder
reaction. In addition, 4,5-epoxide formation has been reported for 2-phenylthiophene, followed by
subsequent conjugation of the epoxide with glutathione. This may also be anticipated for other ring-
substituted thiophenes.
Only very limited information was submitted to show whether side chain oxidation of the ring-
substituted thiophenes could also occur. Based on some studies with a substituted thiazole
(chlormethiazole) and one (heavily) substituted thiophene (olanzapine), such side chain reactions may
be anticipated. For the substances in subgroup A-Ib, metabolites of the side chain oxidation pathways
may be expected to be conjugated, e.g. with glucuronic acid. Similar reactions (e.g. omega or omega-1
oxidations) for ring-substituent chains have been discussed for alkylated pyrazines (EFSA CEF Panel,
2011a). The thiophene carbaldehyde candidate substance, 5-ethylthiophene-2-carbaldehyde [FL-no:
15.074] may be expected to be oxidised to the corresponding carboxylic acid. Where applicable,
conjugation with amino acids (e.g. glycine) or glucuronic acid may also be expected to occur (see
FGE.13Rev2 (EFSA CEF Panel, 2011b); FGE.14Rev1 (EFSA, 2009); FGE.17Rev2 (EFSA CEF
Panel, 2011a)). The acyl-substituted thiophenes [FL-no: 15.040 and 15.097] may be subject to keto-
reduction, possibly followed by conjugation, similar to acetyl derivatives of furans (EFSA CEF Panel,
2011b) and of pyrazines (EFSA CEF Panel, 2011a).
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The mercapto group in the ring-substituent of the substances in subgroup A-Ic may undergo S-
methylation to produce the corresponding methyl thioether, with further oxidation to the
corresponding sulphoxide and sulphone. They may also react with glutathione or other endogenous
thiol substances to form mixed disulphides, which may undergo reduction to thiols or oxidative
desulphuration. Alternatively, they may undergo enzymatic oxygenation resulting in the formation of
the corresponding sulphinic or sulphonic acids. These metabolites are all expected to be excreted in
the urine. A more detailed discussion on the metabolism of sulphur compounds can be found in
FGE.13Rev2 (EFSA CEF Panel, 2011b).
5.2. Metabolism of substances in subgroup A-II
Thiazoles may be subject to ring S- and N-oxidation. From the various studies with thiazole
derivatives (A-II), it can be seen that their metabolites may react spontaneously with glutathione, and
it is likely that they also exhibit reactivity towards biomacromolecules. In addition, for some thiazole
derivatives, ring C-oxidation may be accompanied by heterocyclic ring cleavage which can result in
the formation of alpha-diketone and thioamide intermediates. For the latter, a relationship with
nephro- and hepatotoxicity has been established, especially after glutathione depletion, but this is a
high-dose phenomenon. Owing to the compound specificity of these reactions, the extent of formation
cannot be generalised; however, these thioamide intermediates and the S-oxides seem to be
quantitatively minor metabolites.
Similar to the situation with the ring-substituted thiophenes, only very limited information was
available which could demonstrate whether side chain oxidation of the ring-substituted thiazoles could
occur. Based on some studies with a substituted thiazole (chlormethiazole) such side chain reactions
may be anticipated. Metabolites of the side chain oxidation pathways may be expected to be
conjugated, e.g. with glucuronic acid. Similar reactions (e.g. omega or omega-1 oxidations) for ring-
substituent chains have been discussed for alkylated pyrazines (EFSA CEF Panel, 2011a). The acyl-
substituted thiazoles [FL-no: 15.038, 15.039, 15.085 and 15.116] may be subject to keto-reduction,
possibly followed by conjugation, similar to acetyl derivatives of furans (EFSA CEF Panel, 2011b)
and pyrazines (EFSA CEF Panel, 2011a).
5.3. Conclusions for the substances in the subgroups A-I to A-II
From the very limited data available on the aromatic subgroups (A) it is not anticipated that the
thiophenes (A-I) and thiazoles (A-II) utilise similar metabolic pathways. These sulphur-containing
heteroaromatic derivatives can be expected to participate in metabolic pathways principally involving
side chain C-oxidation, epoxidation of double bonds, ring S-oxidation and (for the thiazoles) ring N-
oxidation to yield sulphoxides or sulphones and N-oxides respectively. The reactive intermediates (e.g.
epoxides and S-oxides) may be conjugated with glutathione; the glutathione conjugates may be
excreted directly in the urine or following further biotransformation to the corresponding mercapturic
acids.
In the light of the above considerations, and as a consequence of the expected reactivity of the thiol
groups and the possible reactions of the ring side chains, it cannot be anticipated that the substances in
the aromatic subgroups (A) are metabolised to innocuous substances. The Panel was aware of the
potential bio-activation of candidate substances with heteroaromatic rings to yield intermediates via
ring-scission or S/N-oxidation which could be reactive to proteins or DNA. However, taking into
account available data on structurally related thiazoles and considering the available genotoxicity data
on thiophenes and thiazoles in the present revision of FGE.21 (FGE.21Rev5) (negative Ames tests and
a chromosome aberration test), the Panel concluded that there are not sufficient indications to preclude
the application of the Procedure to the thiophenes and thiazoles (A-I and A-II).
5.4. Metabolism of the substances in subgroups B-II and B-IV
No specific information was available on the metabolism of the thiazoline and dithiazine derivatives
or related substances for any of these non-aromatic substances in the B subgroups. It may be
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speculated that the substances in these groups are metabolised primarily by ring S-oxidation, or, if
applicable, via N-oxidation. In addition, metabolism of the ring substituents is likely to occur.
The substances exhibiting thioacetal structures could be subject to acid hydrolysis in the stomach,
similar to oxygen-containing acetals. However, thioacetals are more resistant to hydrolysis than
oxygen acetals. It is thus to be anticipated that these substances may reach the intestinal lumen intact
and may also be absorbed as such.
5.5. Conclusions for the substances in the subgroups B-II and B-IV
Owing to the lack of metabolism data it cannot be concluded that the candidate substances in the B
subgroups will be metabolised to innocuous products.
A more detailed description of the metabolism is given in Appendix C.
6. Application of the Procedure for the safety evaluation of flavouring substances
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach.
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its
corresponding threshold of concern, a formal safety assessment, using the mTAMDI approach, is not
carried out using the Procedure. In these cases, the Panel requires more precise data on use and use
levels. For comparison of the intake estimations based on the MSDI approach and the mTAMDI
approach see Section 7.
For the three thiazolines in subgroup B-II (2-methyl-2-thiazoline [FL-no: 15.086], 2,4-dimethyl-3-
thiazoline [FL-no: 15.060] and 2-isobutyl-3-thiazoline [FL-no: 15.119]), the Panel concluded in
FGE.21Rev3 that, in the absence of further genotoxicity data, the Procedure could not be applied to
these substances from subgroup B-II. However, new adequate in vitro genotoxicity studies (gene
mutation test in bacteria and micronucleus assay in human peripheral blood lymphocytes) on 2-acetyl-
2-thiazoline [FL-no: 15.010], which is considered as a supporting substance for 2-methyl-2-thiazoline
[FL-no: 15.086] (EFSA CEF Panel, 2012a), have become available. Based on these new data, the
Panel concluded that 2-methyl-2-thiazoline [FL-no: 15.086] was not of concern with respect to
genotoxicity and could be evaluated through the Procedure. For the 3-thiazolines in subgroup B-II,
2,4-dimethyl-3-thiazoline [FL-no: 15.060] and 2-isobutyl-3-thiazoline [FL-no: 15.119], no studies
with respect to genotoxicity have become available, nor on the supporting substance (4,5-dimethyl-2-
isobutyl-3-thiazoline [FL-no: 15.032]). These two compounds were therefore not evaluated through
the Procedure.
Thus, the Panel concluded that, in the absence of further genotoxicity data, the Procedure could not be
applied to 2,4-dimethyl-3-thiazoline [FL-no: 15.060] and 2-isobutyl-3-thiazoline [FL-no: 15.119].
For the safety evaluation of the remaining 39 candidate substances from chemical groups 29 and 30
the Procedure as outlined in Appendix A was applied, based on the MSDI approach. The outcome of
the evaluations of the 41 substances are summarised in Table 10.
6.1. Step 1
According to the decision tree approach, presented by Cramer et al. (1978), 32 of the candidate
substances, evaluated through the Procedure, are classified into SC II and seven into SC III (see
Table 10).
6.2. Step 2
None of the 39 candidate substances can be predicted to be metabolised to innocuous products.
Therefore, the evaluation of all 39 candidate substances, evaluated through the Procedure, proceeds
via the B-side of the Procedure.
Flavouring Group Evaluation 21 Revision 5
EFSA Journal 2015;13(4):4066 32
6.3. Step B3
The 32 candidate substances in SC II have estimated European daily per capita intakes (MSDI)
ranging from 0.0012 to 2.2 µg (Table 9). These intakes are below the threshold of concern of
540 µg/person per day for SC II substances.
Similarly, the estimated daily per capita intakes of the seven candidate substances in SC III, ranging
from 0.0073 to 5.7 µg (Table 9), are below the threshold of concern of 90 µg/person per day for SC III
substances.
Accordingly, the evaluation of all 39 candidate substances proceeds to step B4.
6.4. Step B4
6.4.1. Subgroup A-Ib: Thiophenes with non-thiol-containing ring substituents
For candidate substance 5-ethylthiophene-2-carbaldehyde [FL-no: 15.074] an oral gavage 90-day
study on rats has been made available. From this study, a NOAEL of 7.5 mg/kg body weight (bw) per
day can be derived. This NOAEL covers the acyl-substituted thiophenes in subgroup A-Ib [FL-no:
15.040 and 15.097]. The combined estimated daily per capita intake of 0.10 µg for the acyl- or
carbaldehyde-substituted thiophene candidate substances of subgroup A-1b [FL-no: 15.040, 15.074
and 15.097] corresponds to 0.0017 µg/kg bw per day for 60 kg body weight. Thus, an adequate margin
of safety of 4.4 × 106 can be calculated.
For the candidate substance 2-pentylthiophene [FL-no: 15.096] a 90-day dietary study has been
provided from which the Panel derived a NOAEL of 5.5 mg/kg bw per day. This NOAEL covers the
remaining 2-alkylthiophenes from subgroup A-Ib [FL-no: 15.045, 15.076, 15.093 and 15.096]. The
combined estimated daily per capita intake of 2.07 µg for the candidate substances [FL-no: 15.045,
15.076, 15.093 and 15.096] corresponds to 0.034 µg/kg bw per day for 60 kg body weight. Thus, a
margin of safety of 1.6 × 105 can be calculated.
On the basis of the application of the Procedure [FL-no: 15.040, 15.045, 15.074, 15.076, 15.093,
15.096 and 15.097] are not expected to be of safety concern at their estimated levels of intake.
6.4.2. Subgroup A-Ic: Thiophenes with thiol-containing ring substituents
A NOAEL of 0.29 mg/kg bw per day was reported for the supporting substance 2-thienyl disulphide
[FL-no: 15.008] in a single-dose level 90-day study in rats. The combined estimated daily per capita
intake of 0.14µg for the three candidate substances 3-mercaptothiophene [FL-no: 15.082], 2-methyl-3-
mercaptothiophene [FL-no: 15.087] and 2-thiophenemethanethiol [FL-no: 15.108] in subgroup A-Ic
corresponds to 0.0023µg/kg bw per day for 60 kg body weight. Thus, a margin of safety of 1.3 × 105
can be calculated.
On the basis of the application of the Procedure, 3-mercaptothiophene [FL-no: 15.082], 2-methyl-3-
mercaptothiophene [FL-no: 15.087] and 2-thiophenemethanethiol [FL-no: 15.108] are not expected to
be of safety concern at their estimated levels of intake.
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6.4.3. Subgroup A-II: Thiazoles
A NOAEL of 25 mg/kg bw per day was reported for the supporting substance 5-acetyl-2, 4-
dimethylthiazole [FL-no: 15.011] in a single-dose level 90-day study in rats. The combined estimated
daily per capita intake of 2.3 µg for the 23 candidate substances in subgroup A-II corresponds to
0.038 µg/kg bw per day for 60 kg body weight. Thus, a margin of safety of 6.6 × 105 can be
calculated.
On the basis of the application of the Procedure, the 23 candidate substances [FL-no: 15.038, 15.039,
15.044, 15.050, 15.051, 15.052, 15.058, 15.061, 15.062, 15.063, 15.067, 15.068, 15.069, 15.071,
15.078, 15.080, 15.084, 15.085, 15.089, 15.098, 15.115, 15.116 and 15.118] in subgroup A-II are not
expected to be of safety concern at their estimated levels of intake.
6.4.4. Subgroup B-II: Thiazolines
No toxicological data were available for 2-methyl-2-thiazoline [FL-no: 15.086]. However, for 2-
acetyl-2-thiazoline [FL-no: 15.010], which is considered a supporting substance for 2-methyl-2-
thiazoline [FL-no: 15.086], a NOAEL of 1.8 mg/kg bw per day from a 90-day rat study that examined
a mixture of flavouring substances (including 2-acetyl-2-thiazoline [FL-no: 15.010] (0.9 %)) was
examined (Munday and Kirkby, 1971). The estimated daily per capita intake of 0.012 µg
(0.0002 µg/kg bw per day) for 2-methyl-2-thiazoline [FL-no: 15.086] provides a margin of safety of
9 × 106, in relation to the estimated levels of exposure from the use of 2-methyl-2-thiazoline [FL-no:
15.086] as flavouring substance. The Panel agrees that this provides a sufficient safety margin and that
the flavouring substance 2-acetyl-2-thiazoline [FL-no: 15.010] can be concluded at step B4 in the
Procedure to be of no safety concern.
6.4.5. Subgroup B-IV: Dithiazines
There were no toxicological data available on the candidate substances in this subgroup B-IV.
However, a new adequate 90-day oral toxicity study in rats on the supporting substance 5,6-dihydro-
2,4,6-tris(2-methylpropyl)-4H-1,3,5-dithiazine [FL-no: 15.113] from FGE.76Rev1 (EFSA CEF
Panel, 2013) provides a NOAEL of 9.3 mg/kg bw per day. The combined estimated daily per capita
intake of approximately 8.2 µg for the candidate substances in subgroup B-IV corresponds to
0.136 µg/kg bw per day for 60 kg body weight. Thus, a margin of safety of 7 × 104 can be calculated.
On the basis of the application of the Procedure, 2-butyl-4-methyl(4H)pyrrolidino[1,2d]-1,3,5-
dithiazine [FL-no: 15.042], dihydro-2,4,6-triethyl-1,3,5(4H)-dithiazine [FL-no: 15.054], [2S-
(2a,4a,8ab)] 2,4-Dimethyl(4H)pyrrolidino[1,2e]-1,3,5-dithiazine [FL-no: 15.055], 4,6-dimethyl-2-(1-
methylethyl)dihydro-1,3,5-dithiazine [FL-no: 15.057], 2-isobutyldihydro-4,6-dimethyl-1,3,5-
dithiazine [FL-no: 15.079] and ethyl thialdine [FL-no: 15.135] are not considered to be of safety
concern at their estimated levels of intake. However, 2-butyl-4-methyl(4H)pyrrolidino[1,2d]-1,3,5-
dithiazine [FL-no: 15.042] is no longer supported by the Industry (DG SANCO, 2012).
6.5. Summary of application of the Procedure
None of the 39 candidate substances evaluated through the Procedure is of safety concern at their
estimated levels of intake based on the MSDI approach (see Table 10).
7. Comparison of the intake estimations based on the MSDI approach and the mTAMDI
approach
The estimated intakes, based on the mTAMDI, for the 32 candidate substances assigned to SC II and
evaluated using the Procedure range from 78 to 220 µg/person per day, which is below the threshold
of concern for SC II of 540 µg/person per day.
The estimated intakes, based on the mTAMDI, for five candidate substances assigned to SC III and
evaluated using the Procedure, range from 78 to 250 µg/person per day. For two of these candidate
substances [2S-(2a,4a,8ab)] 2,4-Dimethyl(4H)pyrrolidino[1,2e]-1,3,5-dithiazine [FL-no: 15.055] and
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ethyl thialdine [FL-no: 15.135] the mTAMDI values are above the threshold of concern for SC III
substances of 90 µg/person per day. For comparison of the MSDI and mTAMDI values see Table 9.
For two candidate substances [FL-no: 15.057 and 15.079] assigned to SC III, no information on use
levels has been provided.
Therefore, further information is required for four substances [FL-no: 15.055, 15.057, 15.079 and
15.135]. This would include more reliable intake data. On the basis of such additional data, these
flavouring substances should be reconsidered along the steps of the Procedure. Following this
procedure, additional toxicological data might become necessary.
Table 9: Estimated intakes based on the MSDI approach and the mTAMDI approach
FL-no EU register name MSDI
(µg/capita
per day)
mTAMDI
(µg/person
per day)
Structural
class
Threshold of
concern
(µg/person per
day)
15.038 2-Acetyl-4-methylthiazole 0.0049 160 Class II 540
15.039 2-Acetyl-5-methylthiazole 0.0024 160 Class II 540
15.040 2-Acetylthiophene 0.049 78 Class II 540
15.044 2-Butylthiazole 0.011 160 Class II 540
15.045 2-Butylthiophene 0.012 78 Class II 540
15.050 2,5-Diethyl-4-methylthiazole 0.012 160 Class II 540
15.051 2,5-Diethyl-4-propylthiazole 0.0012 160 Class II 540
15.052 2,5-Diethylthiazole 0.015 160 Class II 540
15.058 4,5-Dimethyl-2-ethylthiazole 0.015 130 Class II 540
15.061 2,5-Dimethyl-4-ethylthiazole 0.011 160 Class II 540
15.062 2,4-Dimethylthiazole 0.61 140 Class II 540
15.063 2,5-Dimethylthiazole 0.0061 160 Class II 540
15.067 4-Ethyl-2-methylthiazole 0.0037 160 Class II 540
15.068 5-Ethyl-2-methylthiazole 0.0061 220 Class II 540
15.069 4-Ethyl-5-methylthiazole 0.012 160 Class II 540
15.071 2-Ethylthiazole 0.028 160 Class II 540
15.074 5-Ethylthiophene-2-
carbaldehyde
0.037 78 Class II 540
15.076 2-Hexylthiophene 0.46 78 Class II 540
15.078 2-Isobutyl-4,5-
dimethylthiazole
0.12 160 Class II 540
15.080 2-Isopropyl-4,5-
dimethylthiazole
0.012 160 Class II 540
15.084 5-Methyl-2-pentylthiazole 0.0037 160 Class II 540
15.085 4-Methyl-2-propionylthiazole 0.0037 160 Class II 540
15.086 2-Methyl-2-thiazoline 0.012 160 Class II 540
15.089 2-Methylthiazole 0.018 150 Class II 540
15.093 2-Octylthiophene 0.012 160 Class II 540
15.096 2-Pentylthiophene 1.6 160 Class II 540
15.097 2-Propionylthiophene 0.012 160 Class II 540
15.098 2-Propylthiazole 0.085 160 Class II 540
15.115 2-Isobutyl-4-methyl thiazole 0.011 160 Class II 540
15.116 2-Acetyl-4-ethylthiazole 0.024 160 Class II 540
15.118 4-Butylthiazole 1.3 160 Class II 540
15.060 2,4-Dimethyl-3-thiazoline 0.012 160 Class II 540
15.119 2-Isobutyl-3-thiazoline 0.011 160 Class II 540
15.054 Dihydro-2,4,6-triethyl-
1,3,5(4H)-dithiazine
0.85 160 Class III 90
15.055 [2S-(2a,4a,8ab)] 2,4-
Dimethyl(4H)pyrrolidino[1,2e
]-1,3,5-dithiazine
0.012 160 Class III 90
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FL-no EU register name MSDI
(µg/capita
per day)
mTAMDI
(µg/person
per day)
Structural
class
Threshold of
concern
(µg/person per
day)
15.057 4,6-Dimethyl-2-(1-
methylethyl)dihydro-1,3,5-
dithiazine
1.6 Class III 90
15.079 2-Isobutyldihydro-4,6-
dimethyl-1,3,5-dithiazine
5.7 Class III 90
15.082 3-Mercaptothiophene 0.011 78 Class III 90
15.087 2-Methyl-3-
mercaptothiophene
0.12 78 Class III 90
15.108 2-Thiophenemethanethiol 0.0073 78 Class III 90
15.135 Ethyl thialdine 0.012 250 Class III 90
8. Considerations of combined intakes from use as flavouring substances
Because of structural similarities of candidate and supporting substances, it can be anticipated that
many of the flavourings are metabolised through the same metabolic pathways and that the
metabolites may affect the same target organs. Further, in cases of combined exposure to structurally
related flavourings, the pathways could be overloaded. Therefore, combined intake should be
considered. As flavourings not included in this FGE may also be metabolised through the same
pathways, the combined intake estimates presented here are only preliminary. Currently, the combined
intake estimates are based on only MSDI exposure estimates, although it is recognised that this may
lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed.
The total estimated combined daily per capita intake of structurally related flavourings is estimated by
summing the MSDI for individual substances.
Two of the candidate substances [FL-no: 15.060, and 15.119] have not been evaluated through the
Procedure (see Section 6) and are therefore not considered together with the other 39 candidate
substances evaluated in FGE.21Rev5 in the combined intake.
On the basis of the reported annual production volumes in Europe (EFFA, 2004b, 2011a, 2012a;
Flavour Industry, 2010b; IOFI, 2013a, b), the combined estimated daily per capita intakes as
flavourings of the candidate substances in subgroups, with more than one substance, evaluated through
the Procedure, from a SC, are: subgroup A-Ib (seven substances from SC II) 2.2 µg; subgroup A-Ic
(three substances from SC III) 0.14 µg; subgroup A-II (23 substances from SC II) 2.3 µg; subgroup B-
IV (four substances from SC III) 8.2 µg.
The 39 candidate substances evaluated through the Procedure, are structurally related to 28 supporting
substances evaluated by JECFA at its 59th and 68th meetings (JECFA, 2002a, 2007). The total
combined daily per capita intakes (in Europe) of candidate and supporting substances in each of the
five subgroups for which supporting substances were available in the same SC are: subgroup A-Ib
(eight substances from SC II) 2.9 µg; subgroup A-Ic (five substances from SC III) 0.15 µg; subgroup
A-II (37 substances from SC II) 500 µg. subgroup B-II (two substances from SC II) 0.52 µg; subgroup
B-IV (four substances from SC II) 3.6 µg.
For all subgroups, the total combined intakes are below the thresholds of concern of 540 µg/person per
day and 90 µg/person per day for SCs II and III, respectively.
9. Toxicity
9.1. Acute toxicity
Data are available for 16 of the 28 supporting substances. The oral median lethal dose (LD50) values in
rats or mice ranged from 400 to 4800 mg/kg bw.
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The acute toxicity data are summarised in Table 12.
9.2. Subacute, subchronic, chronic and carcinogenicity studies
Subacute toxicity data were available for the candidate substances 2-pentylthiophene [FL-no: 15.096]
and the structurally related thiophene former [FL-no: 15.106] and thiophene-2-carbaldehyde former
[FL-no: 15.107] and for 11 supporting substances, of which nine are in the register [FL-no: 15.002,
15.004, 15.005, 15.008, 15.010, 15.011, 15.020, 15.029 and 15.113] and two are mixtures of
structurally related substances (one mixture of 2-isobutyl-4,6-dimethyldihydro-1,3,5-dithiazine and 4-
isobutyl-2,6-dimethyldihydro-1,3,5-dithiazine, and one mixture of 2-isopropyl-4,6-dimethyldihydro-
1,3,5-dithiazine and 4-isopropyl-2,6-dimethyldihydro-1,3,5-dithiazine).
Repeated dose toxicity data are summarised in Table 13.
9.2.1. Subgroup A-Ib: Thiophenes with non-thiol-containing ring substituents
9.2.1.1. 28-Day gavage study on 2-pentylthiophene [FL-no: 15.096]
In a study conducted in accordance with Organisation for Economic Co-operation and Development
(OECD) Guideline 407, 2-pentylthiopene [FL-no: 15.096] was administered by gavage to three groups
each comprising five male and five female Sprague–Dawley Crl:CD® (SD) IGS BR strain rats, for
28 days, at dose levels of 15, 150 or 500 mg/kg bw per day (Dhinsa et al., 2006). A control group of
five males and five females was dosed with vehicle alone (Arachis oil). Clinical signs during treatment
included increased salivation in all animals treated with 500 mg/kg bw per day and the majority of
animals treated with 150 mg/kg bw per day. A slight reduction in body weight gain was observed in
males only treated with 500 mg/kg bw per day, while males and females treated with 500 mg/kg bw
per day showed an increase in water consumption. Haematological examination revealed haemolytic
anaemia in animals treated with 500 or 150 mg/kg bw per day, as evidenced by reductions in
haemoglobin, haematocrit and erythrocyte count and evidence of reticulocytosis. Clinical chemical
determinations on day 28 showed increases in bilirubin and alanine aminotransferase for animals of
both sexes treated with 500 mg/kg bw per day, with increases in bilirubin also noted in both sexes for
animals treated with 150 mg/kg per day, and in females receiving 15 mg/kg bw per day. Absolute and
relative liver, kidney and spleen weights were increased in both sexes treated with 500 mg/kg bw per
day or 150 mg/kg bw per day. At necropsy, animals in these dose groups had dark and enlarged
spleens. Histopathological examination revealed hepatocellular hypertrophy in animals of both sexes
treated with 500 or 150 mg/kg bw per day. Histopathological evidence of extramedullary
haemopoiesis and haemosiderin accumulation in the spleen of animals of both sexes treated with 500
or 150 mg/kg bw per day, together with observations of haemosiderin deposits in the liver and kidney,
were typical of a haemolytic anaemia, as also evidenced by the haematological measurements. There
was also some evidence of renal damage in males and females treated with 500 or 150 mg/kg bw per
day, as evidenced in only a few animals by tubular hypertrophy, tubular dilatation and tubular
basophilia, pyelitis with associated hyperplasia of the renal papillary/pelvic epithelium (females only)
and globular accumulations of eosinophilic material in the renal tubules (males only). Epithelial
hyperplasia of the urinary bladder and associated epithelial and subepithelial inflammatory cell
infiltrates were observed for two females treated with 500 mg/kg bw per day. Hypertrophy of the
thyroid was reported in animals of both sexes treated with 500 mg/kg bw per day, and for males
treated with 150 mg/kg bw per day.
In a follow-up study to evaluate the hepatic effects and the slight increase in bilirubin seen at the
lowest dose of 15 mg/kg bw per day in this study, 2-pentylthiophene was administered by gavage to
one group comprising five male and five female Sprague–Dawley Crl:CD® (SD) IGS BR strain rats,
for 28 consecutive days, at a dose level of 3 mg/kg per day. A control group of five males and five
females was given vehicle alone (Arachis oil BP). Clinical signs, body weight development and food
and water consumption monitored during the study revealed no significant differences between test
and control animals. Haematology and blood chemistry were evaluated for all animals at the end of the
study and showed no significant changes. There were no treatment-related changes in spleen weights
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for treated animals in comparison to controls. No macroscopic abnormalities were detected at
necropsy (Marr and Watson, 2007).
The authors concluded that oral administration of 2-pentylthiophene to rats for a period of up to
28 days at a dose level of 3 mg/kg bw per day resulted in no toxicologically or haematologically
significant effects.
9.2.1.2. 90-Day dietary study on 2-pentylthiophene [FL-no: 15.096]
A 90-day dietary study was performed with 2-pentylthiophene [FL-no: 15.096] (Bauter, 2013b). The
study was performed according to OECD Guideline 408. Four groups of rats (10/sex/dietary intake
level) of male and female Charles River Laboratories (CRL) Sprague–Dawley CD®IGS rats were fed
a diet containing 0 (dietary control), 28, 140 and 700 mg 2-pentylthiophene per kilogram of diet in
order to obtain target approximate intake levels of 2, 10 and 50 mg/kg bw per day. The animal diets
were renewed weekly. To test the stability of the test substance in the dietary matrix, subsamples of
test diets were placed into feeding jars and maintained for up to 10 days unrefrigerated in the animal
holding room were the study was conducted. Samples were taken for analysis at days 4, 7 and 10. In
seven days the amount of test substance in the diet declined to 53, 59 and 54 % of the respective
starting levels. The Panel considered this loss of the candidate substance in the feed and decided that
the intake levels of 2-pentylthiophene for the different age groups will be calculated on the basis of the
dietary level measured on the seventh day of the study. Thus, the intake levels that have been
calculated for the dosage groups are the following: males 1.0, 5.5 and 24.4 mg/kg bw per day, females
1.1, 6.2 and 28.4 mg/kg bw per day.
There were no mortalities and no clinical, ophthalmological, body weight, body weight gain, food
consumption or food efficiency changes attributable to the administration of 2-pentylthiophene.
General decreases in body weight and food consumption were not statistically or biologically
significant. Sporadic changes in body weight gain and food consumption in males were considered
incidental and not of toxicological concern.
There were few clinical pathology, macroscopic, microscopic, or organ weight changes associated
with the administration of 2-pentylthiophene.The only statistically significant (p < 0.05) haematology
finding among females was limited to a decrease in mean cell haemoglobin concentration in the
highest dose group. There were no statistically significant differences in haematology parameters for
males. There were minimal changes in haemoglobin concentration, erythrocyte count and haematocrit
in males of the high-dose group, which did not reach statistical significance. For males in the highest
dosage group there was a statistically significant (p < 0.05) decrease in prothrombin time.
Based on the haematological effects observed in males at the high-dose level, a NOAEL can be
derived from the mid-dose group of 5.5 mg/kg bw per day. This NOAEL is supported by the
observation that no significant toxicological or haematological effects were observed after oral
administration (gavage) of 2-pentylthiophene at a dose level of 3 mg/kg bw per day for a period of
28 days (Dhinsa et al., 2006; Marr and Watson, 2007).
9.2.1.3. 14-Day oral toxicity study with 5-ethylthiophene-2-carbaldehyde [FL-no: 15.074]
A 14-day dietary toxicity study was conducted in Hsd:SD® rats (Bauter, 2012b). Twenty-four healthy
rats (12 males and 12 females) were selected for the test and equally distributed into four groups (three
males and three females per group). Dietary levels of (Group 1, basal diet control) 0, (Group 2, low
dose level) 240, (Group 3, middle dose level) 2400 and (Group 4, high dose level) 12000 mg 5-
ethylthiophene-2-carbaldehyde per kg diet were selected for the test. The mean overall (days 0–14)
daily intake of 5-ethylthiophene-2-carbaldehyde in male rats was 0, 21.9, 193.6 and 675.5 mg/kg bw
per day, respectively. The mean overall daily intake in female rats was 0, 21.5, 195.3, and
686.2 mg/kg bw per day, respectively. The test substance, as received and in the diet, was considered
stable over the course of the study.
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Body weights were recorded twice during the acclimatisation period, including prior to test product
introduction (day 0), and on days 3, 7 and 14 prior to terminal sacrifice. Individual food consumption
was also recorded to coincide with body weight measurements. Gross necropsies were performed on
all animals.
There were no test substance-related or other mortalities during this study. The substance-related
adverse effects observed for the high dose group, included clinical signs of reduced faecal volume and
variations in body weight, feed consumption and feed efficiency. One male of the high dose group,
was severely affected by multiple clinical signs such as red oral/nasal discharge, red facial and
anogenital staining, nose/snout swelling, cuts and eschar, tremors, biting and hyperactivity. Males fed
with middle doses of 5-ethylthiophene-2-carbaldehyde also exhibited reduced body weights after
exposure.
There were no macroscopic findings at scheduled sacrifice for all dose levels in males and females
that were considered attributable to test substance administration.
9.2.1.4. 90-Day oral toxicity study with 5-ethylthiophene-2-carbaldehyde [FL-no: 15.074]
A 90-day gavage study was performed with 5-ethylthiophene-2-carbaldehyde [FL-no: 15.074]
(Bauter, 2013c). The study was performed according to OECD Guideline 408. Four groups of rats
(10/sex/dietary intake level) of male and female CRL Sprague-Dawley CD®IGS rats were
administered 0 (dietary control: maize oil), 2.0, 7.5, 75 mg/kg bw per day.
Urine and blood samples were collected on day 84 from all study animals for urinalysis, haematology
and clinical chemistry determinations. Coagulation assessments were performed on day 92 or 93, prior
to necropsy. Gross necropsies and histological evaluation of selected organs and tissues were
performed on all study animals.
There were no test substance-related mortalities during this study. There were no clinical or
ophthalmological signs in either male or female animals attributed to the administration of 5-
ethylthiophene-2-carbaldehyde.
There were no changes in mean body weight, mean daily body weight gain, food consumption or food
efficiency attributed to the administration of 5-ethylthiophene-2-carbaldehyde. There were no
statistically significant relative organ weight findings except for an increase in liver to total body
weight in male rats in the high dose group (p < 0.05), the same tendency was recorded for female rats
although not statistically significant.
There were no statistically significant changes in haematology parameters, except for a decrease
(p < 0.05) in neutrophil counts between low dose females and control.
Statistically significant findings (p < 0.05) in clinical chemistry were increased inorganic phosphorus
concentration and decreased urea nitrogen in males in the high dose group, the same trend was found
in females of the high dose group but was not significant. Females of the high dose group showed a
statistically significant decrease in total protein.
Statistically significant (p < 0.05) differences in urine parameters were the increase in urine volume
and specific gravity in male rats of low and high dose groups, along with an increased pH and a
decreased urine protein in male rats of the low dose group. The decrease of urine protein in males of
the high dose group was of the same magnitude as for the low dose one, although not recorded as
significant. Female rats in the low dose group showed a significantly decreased urinary pH.
At sacrifice there were no macroscopic observations that were attributed to the test substance.
Microscopic findings that were attributed to the test substance were minimal to moderate
submandibular salivary gland atrophy of animals in the high dose group, which, with regard to
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severity, was more pronounced in males than in females. The changes included moderate atrophy of
the convoluted (granular) glands, which appeared as a decrease in the glands’ epithelial cell height and
was accompanied with a loss of intra-cytoplasmic zymogen granules in all high dose males and in 9
out of 10 high dose females.
The Panel derived a NOAEL for 5-ethylthiophene-2-carbaldehyde [FL-no: 15.074] of 7.5 mg/kg bw
per day, based on histopathological findings of atrophy of submandibular salivary gland and clinical
chemistry parameters observed at the highest dose level of 75 mg/kg bw per day.
9.2.2. Subgroup A-Ic: Thiophenes with thiol-containing ring substituents
No toxicity data were available for the three candidate substances in this subgroup [FL-nos: 15.082,
15.087 and 15.108]. The supporting substance 2-thienyl disulphide (2,2′-dithiodithiophene) [FL-no: 
15.008] was tested in a 90-day dietary feeding study in male and female rats at a single-dose level of
0.29 mg/kg bw per day (Morgareidge and Oser, 1970). Body weight changes, food consumption,
haematological and clinical chemistry parameters were assessed, urinalysis was undertaken and a
comprehensive range of tissues were examined histopathologically. No changes were detected in any
of the parameters assessed, and accordingly a NOAEL of 0.29 mg/kg bw per day could be established.
9.2.3. Subgroup A-II: Thiazoles
There were no subacute, subchronic or chronic toxicity studies on any of the 23 candidate thiazoles in
subgroup A-II.
A 90-day dietary feeding study was carried out on the supporting substance 5-acetyl-2,4-
dimethylthiazole [FL-no: 15.011] in male (23) and female (23) rats, at a single-dose level of
approximately 25 mg/kg bw per day (Shellenberger, 1971). Body weight, food consumption,
haematological and clinical chemistry parameters were assessed, urinalysis was undertaken and a
comprehensive range of tissues were examined histopathologically. No changes were detected in any
of the parameters assessed, and accordingly a NOAEL of 25 mg/kg bw per day could be established.
In a 90-day study on the supporting substance 2-acetylthiazole [FL-no: 15.020], male rats (10/group)
were fed diets containing 0, 100, 1000 or 10 000 mg/kg test substance, reported to be equivalent to an
average daily intake of 0, 5, 50 and 500 mg/kg bw per day (Wheldon et al., 1970). The dose level in
the highest dose group was increased to 20 000 mg/kg at week 6. Test substance-related changes at
10 000–20 000 mg/kg included reduced body weight gain, increased relative liver, adrenal and thyroid
weights and minimal fatty changes in the liver. The authors reported a NOAEL of 50 mg/kg bw per
day. However, because of limitations in the study design and reporting, the Panel concluded that this
NOAEL could not be used in the Procedure.
Two further 90-day studies were carried out at single-dose levels with the supporting substances 2-
methyl-5-methoxythiazole [FL-no: 15.002] and 2,4-dimethyl-5-vinylthiazole [FL-no: 15.005]
(Posternak et al., 1975). Owing to limitations in reporting of experimental details and results, the Panel
concluded that these studies could not be used to derive a NOAEL to be used in the Procedure.
Oral intakes of up to 500 mg thiamine per day (8 mg/kg bw per day for 60 kg body weight) have been
reported to have no adverse effects in humans (SCF, 2001).
9.2.4. Subgroup B-II: Thiazolines
There were no toxicological data available for the three candidate substances in this subgroup. The
supporting substance 2-(sec-butyl)-4,5-dimethyl-3-thiazoline [FL-no: 15.029] was tested in a 90-day
dietary feeding study in male and female rats (15/sex) at one-dose level of approximately 1 mg/kg bw
per day (Babish and Re, 1978). Body weight changes, food consumption, limited haematological and
clinical chemistry parameters were assessed, urinalysis was undertaken and a comprehensive range of
tissues were examined histopathologically. No changes were detected in any of the parameters
assessed and accordingly a NOAEL of 1 mg/kg bw per day could be established.
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The supporting substance 2-acetyl-2-thiazoline [FL-no: 15.010] was tested in a 90-day dietary feeding
study in male and female rats (eight/sex). The diet contained 197, 492, 983, 1966, 2949 and
3932 mg/kg diet of a mixture of flavouring substances (including 2-acetyl-2-thiazoline [FL-no:
15.010] (0.9 %) (Munday and Kirkby, 1971). The parameters assessed during the study were body
weight gain, food intake, food utilisation, water intake, urine analysis (pH, protein, blood, glucose,
refractive index and a transaminase activity), serum chemistry (various enzymes, urea nitrogen,
creatinine, various ions, several proteins), organ weights (only heart, liver, spleen, kidneys, brain,
testes, adrenals, thyroid and pituitary), haematology (packed cell volume, haemoglobin level, white
blood cell count and a differential leucocyte count) and histopathology of lung, liver, spleen and
kidney. Clearly the assessment was much more limited than that of an OECD Guideline 408 study. No
changes were detected in any of the parameters assessed and accordingly a NOAEL of 1.8 mg/kg bw
per day could be established for 2-acetyl-2-thazoline [FL-no: 15.010].
9.2.5. Subgroup B-IV: Dithiazines
There were no toxicological data available on the five candidate substances in subgroup B-IV [FL-
nos: 15.054, 15.055 15.057, 15.079 and 15.135].
Short-term toxicity tests are available on the mixture 2-isobutyl-4,6-dimethyldihydro-1,3,5-dithiazine
and 4-isobutyl-2,6-dimethyldihydro-1,3,5-dithiazine (Rush, 1989a) and the mixture 2-isopropyl-4,6-
dimethyldihydro-1,3,5-dithiazine and 4-isopropyl-2,6-dimethyldihydro-1,3,5-dithiazine (Rush,
1989b). The mixtures were incorporated in the diet of Sprague–Dawley rats (five/sex/group) intake of
approximately 10 mg/kg bw per day over a period of 14 days. No treatment-related effects were seen.
The Panel considered that these studies were inadequate for deriving a NOAEL to be used in the
Procedure because of the short duration of the studies.
New 14-day and 90-day dietary studies in rats were available on the supporting substance 5,6-
dihydro-2,4,6-tris(2-methylpropyl)-4H-1,3,5-dithiazine [FL-no: 15.113].
A 14-day range-finding dietary study was performed with 5,6-dihydro-2,4,6-tris(2-methylpropyl)-4H-
1,3,5-dithiazine [FL-no: 15.113] (Bauter, 2012a). The study was performed according to OECD
Guideline 407. Groups (three/sex/dietary intake level) of male and female Hsd:SD® rats were fed a
diet containing 0 (dietary control), 120, 1200 and 2400 mg 5,6-dihydro-2,4,6-tris(2-methylpropyl)-4H-
1,3,5-dithiazine per kilogram diet. These dietary levels were equal to daily intakes of 0, 11.3, 111.2
and 217.0 mg/kg bw for males and 0, 11.2, 107.2 and 206.1 mg/kg bw for females, respectively.
Clinical observations were recorded daily and body weights and food consumption observations were
made on days 0, 7 and 14. No mortality was observed throughout the course of the study and the
general condition of the rats was unremarkable. No gross pathology was related to the test substance.
A 90-day dietary study was performed with 5,6-dihydro-2,4,6-tris(2-methylpropyl)-4H-1,3,5-
dithiazine [FL-no: 15.113] (Bauter, 2013a). The study was performed according to OECD Guideline
408. Four groups of rats (10/sex/dietary intake level) of male and female CRL Sprague–Dawley
CD®IGS rats were fed a diet containing 0 (dietary control), 140, 1050 and 2100 mg 5,6-dihydro-2,4,6-
tris(2-methylpropyl)-4H-1,3,5-dithiazine per kilogram diet. These dietary levels were equivalent to
daily intakes of 0, 9.3, 67.9 and 131.9 mg/kg bw for males and 0, 11.0, 77.1 and 153.7 mg/kg bw for
females, respectively (Bauter, 2013a). The animals were observed daily for signs of gross toxicity,
viability and behavioural changes. Clinical observations of toxicity were performed on day 0 and
weekly until sacrifice. Animals were weighed on day 0 at the start of the study and weekly
thereafter. Food consumption and efficiency were measured and calculated weekly. Blood chemistry
and haematology were performed on blood drawn via sublingual bleed during week 12 after
overnight fast and coagulation assessment was performed prior to necropsy. Urine was collected
during the 15 hours prior to the blood draw. Prior to initiation of the study and on day 91 the eyes
of all rats were examined by focal illumination and indirect ophthalmoscopy. At termination of the
study all animals were sacrificed and subject to full necropsy. The following tissues were weighed
wet post dissection: adrenals, brain, epididymides, heart, kidneys, liver, ovaries, testes, spleen,
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thymus, uterus with oviducts. Histopathology was performed on a comprehensive number of
tissues and organs in accordance with the guidelines.
No mortality was observed in any group throughout the study. There were no toxicologically
significant or dose-related differences in animals between treatment and control groups in food
consumption or food efficiency, body weight and body weight gain and clinical or
ophthalmological parameters. Only a reduction in food consumption in females at the highest dose
was reported to be statistically significant, which, however, was not accompanied with body weight
changes and was not considered adverse or biologically relevant. No treatment-related differences in
clinical or gross pathology or in organ weights were observed. Treatment-related microscopic
findings were reported in the urinary bladder of males and females of the two highest dose groups
(1050 and 2100 mg/kg diet) and involved a statistically significant increase in the incidence of
minimal to slight simple and diffuse hyperplasia of the mucosal epithelium with increased severity in
the highest dose group. This finding was not correlated to any other clinical or pathological
changes.
The author concluded that under the conditions of the study, the NOAEL for dietary administration of
5,6-dihydro-2,4,6-tri(2-methylpropyl)-4H-1,3,5-dithiazine [FL-no: 15.113] was determined to be
140 mg/kg diet, equivalent to an estimated daily intake of 9.3 mg/kg bw per day for males and
11.0 mg/kg bw per day for females, based on the effects noted on the urinary bladder. The Panel
agreed to this conclusion and used 9.3 mg/kg bw per day in the margin of safety assessment of the
candidate substances in subgroup B-IV using the Procedure.
Repeated dose toxicity data are summarised in Table 13.
9.3. Developmental/reproductive toxicity studies
No reproductive and developmental toxicity studies have been available for the candidate substances
or the supporting substances in this revision of FGE.21 (FGE.21Rev5). One study, a combined repeat
dose/reproductive and developmental toxicity study, in accordance with OECD Guideline 422, has
been carried out with the structurally related thiophene [former FL-no: 15.106], which is no longer
supported for use as flavouring substance in Europe by Industry (DG SANCO, 2012).
In the study, males were dosed for 42 days and females from 14 days before mating until day 3 of
lactation (Nagao, 2006). The full report of this study was in Japanese; however, a summary of the
study design, results and conclusions to be drawn were available to the Panel in English.
Groups of Sprague–Dawley Rats (13/sex/dose) were administered thiophene via gavage at dose levels
of 0, 25, 100 or 400 mg/kg bw per day. No adverse effects on copulation, ovulation or fertility in
treatment groups were observed when compared with the control groups. However, in each group,
abnormal parturition was found. Females in the 100 or 400 mg/kg bw per day group, showing
evidence of histopathological change in the cerebellum, exhibited abnormal lactation. Pups born to the
400 mg/kg bw per day group showed reduced birth weights and viability decreased at postnatal day 4.
No morphological abnormalities associated with the administration of thiophene were found in any
pups. With respect to effects on reproduction, the NOAEL was suggested by the authors to be
400 mg/kg bw per day for males and 25 mg/kg bw per day for females (Nagao, 2006).
It should be noted, however, based on available data on metabolism in the previous versions of
FGE.21, the toxicity of thiophene was considered separately from the substituted thiophenes in
subgroup A-Ib.
The developmental/reproductive toxicity study is summarised in Table 14.
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9.4. Genotoxicity studies
Genotoxicity data were provided for three of the candidate substances, six structurally related
substances (no longer supported) and four supporting substances. These 13 substances belong to the
following subgroups: Subgroup A-Ia: Thiophene (former [FL-no: 15.106]), subgroup A-Ib: 2-
Methylthiophene (former [FL-no: 15.091]), 3-methylthiophene (former [FL-no: 15.092]), 2,5-
dimethylthiophene (former [FL-no: 15.064]), 2-acetylthiophene [FL-no: 15.040], 2-acetyl-3-
methylthiophene (former [FL-no: 15.037]), thiophene-2-carbaldehyde (former [FL-no: 15.107]), 5-
ethylthiophene-2-carbaldehyde [FL-no: 15.074], 5-methylthiophene-2-carbaldehyde [FL-no: 15.004];
subgroup A-II: 2,4-Dimethylthiazole [FL-no: 15.062], 4,5-dimethylthiazole [FL-no: 15.017], 4-
methylthiazole [FL-no: 15.035] and subgroup B-II: 3-Acetyl-2- thiazoline [FL-no: 15.010].
9.4.1. Subgroup A-I
The candidate substance 2-acetylthiophene [FL-no: 15.040] was negative in microbial tests, using
Salmonella typhimurium strains TA98 and TA100, with and without metabolic activation, and in the
SOS chromotest with metabolic activation. 2-Acetylthiophene was reported to be positive without
metabolic activation in the SOS Escherichia coli chromotest (Mosier et al., 2003). In the same study,
the structurally related 2-acetyl-3-methylthiophene former [FL-no: 15.037], thiophene-2-carbaldehyde
former [FL-no: 15.107] and candidate substance 5-ethylthiophene-2-carbaldehyde [FL-no: 15.074]
gave positive results without metabolic activation in the SOS E. coli chromotest. The concentrations
tested were not reported for any of the substances subjected to the SOS E. coli chromotest (Mosier et
al., 2003). The Panel considered the endpoint of this test inappropriate for the estimation of genotoxic
potential. The supporting substance 5-methyl-2-thiophenecarbaldehyde [FL-no: 15.004] was negative
in a microbial mutagenicity assay. The structurally related substances, thiophene former [FL-no:
15.106], 2-methylthiophene former [FL-no: 15.091], 3-methyl-thiophene former [FL-no: 15.092] and
2,5-dimethylthiophene former [FL-no: 15.064] were reported to be negative in microbial mutagenicity
assays.
Thiophene (former [FL-no: 15.106]), i.e. no longer supported, was tested in accordance with OECD
Guidelines in a bacterial reverse mutation test in strains of S. typhimurium and in strain WP2 uvrA of
E. coli. No evidence of mutagenic response was reported when strains TA100, TA1535, TA98 and
TA1537 of S. typhimurium were incubated at concentrations of 0, 78.1, 156, 313, 625, 1250, 2500 and
5000 µg/plate with and without S9 metabolic activation. Toxicity was observed at 1250 µg/plate in
TA1537 and 2500 µg/plate in strains TA100, TA1535 and TA98, with and without metabolic
activation. Toxicity was observed at 5 000 µg/plate in WP2, with and without S9 metabolic activation
(Shibuya, 2006).
In a chromosomal aberration test, thiophene was tested on Chinese hamster lung cells in accordance
with Japanese Guidelines. No chromosomal aberrations or polyploidy was reported when incubated
with concentrations of 0, 210, 420, 840 µg/ml of thiophene, with and without metabolic activity
(Tanaka, 2006).
9.4.2. Subgroup A-II
2,4-Dimethylthiazole [FL-no: 15.062] was reported to be negative in microbial assays, using
S. typhimurium, but only in strain TA100 and only in the absence of metabolic activation (Voogd et
al., 1983). Two supporting substances, 4,5-dimethylthiazole [FL-no: 15.017] and 4-methylthiazole
[FL-no: 15.035] were negative (with and without S9 metabolic activation) in microbial mutagenicity
assays.
9.4.3. Subgroup B-II
No genotoxicity information was available for any candidate or supporting substances in this
subgroup. However, considering the structural similarities between the thiazolines in subgroup B-II
and the thiazolidines in subgroup B-III, the Panel in FGE.21Rev3 concluded that the thiazolines [FL-
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no: 15.060, 15.086 and 15.119] could not be evaluated through the Procedure (see subgroup B-III in
FGE.21Rev3 (EFSA CEF Panel, 2012b).
However, new in vitro genotoxicity studies (gene mutation test in bacteria and micronucleus assay in
human peripheral blood lymphocytes) have become available on 2-acetyl-2-thiazoline [FL-no:
15.010], which is considered to be structurally related to and a supportive substance for the 2-
thiazoline included in this FGE, 2-methyl-2-thiazoline [FL-no: 15.086].
9.4.3.1. Ames test
2-Acetyl-2-thiazoline was tested for the induction of gene mutations in S. typhimurium strains TA98,
TA100, TA1535, TA1537 and TA102, both in the presence and absence of Aroclor 1254-induced rat
liver S9 mix. Two independent experiments were carried out (McGarry, 2012).
In the first experiment, 2-acetyl-2-thiazoline [FL-no: 15.010] was tested in all five strains in the
absence and presence of S9 mix using the plate incorporation methodology at concentrations of 5,
15.8, 50, 158.1, 500, 1581 and 5000 µg/plate. No evidence of toxicity was observed.
In the second experiment, the concentrations of 2-acetyl-2-thiazoline [FL-no: 15.010] used in all
strains in the absence and presence of S9 mix were 156.3, 312.5, 625.0, 1250, 2500 and 5000 µg/plate
of 2-acetyl-2-thiazoline, and the pre-incubation method was used for treatments in the presence of S9.
No evidence of toxicity was observed.
It is concluded that 2-acetyl-2-thiazoline [FL-no: 15.010] did not induce mutations in five histidine-
requiring strains (TA98, TA100, TA1535, TA1537 and TA102) or S. typhimurium when tested under
the conditions of the study (Table 15). The study was conducted using Good Laboratory Practice
(GLP) and the design complied with current recommendations (OECD Guideline 471) and an
acceptable top concentration was achieved.
9.4.3.2. Micronucleus assay
2-Acetyl-2-thiazoline [FL-no: 15.010] was tested for the induction of chromosome damage and
potential aneugenic effects in an in vitro micronucleus assay using duplicate human peripheral blood
lymphocytes prepared from pooled blood from two healthy male volunteers. Treatments were
performed both in the absence and presence of Aroclor 1254-induced rat liver S9 mix (Watters, 2012).
Cells were stimulated for 48 hours with phytohaemagglutinin to produce exponentially growing cells.
A preliminary toxicity range-finding experiment was carried out using a 3-hour treatment with S9 mix
and 3- and 24-hour treatments without S9 mix. Toxicity was evaluated as the effect of treatment on the
Replication Index (RI). Twelve concentrations from 4.6 to 1262 µg/ml were tested. The concentrations
selected for the main experiment were based on toxicity data from this preliminary test.
In the main experiment, cells were treated for 3 hours, followed a 21-hour recovery period, (3 + 21
hours) with 0, 600, 1000 or 1292 µg/ml of 2-acetyl-2-thiazoline in the absence and in the presence of
S9 mix. The levels of toxicity (reduction in RI) at the top concentration were 15 % and 0 % in the
absence and presence of S9 mix, respectively. In a parallel assay, cells were treated for 24 hours
(24 + 0 hours) with 0, 100, 200, 400 or 600 µg/ml of 2-acetyl-2-thiazoline in the absence of S9 mix
with no recovery period. The top concentration induced 55 % toxicity. Relevant positive and negative
controls were included in all experiments. There were two replicate cultures per treatment, and 1000
binucleate cells per replicate (i.e. 2000 cells per dose) were scored for micronuclei. Thus, the study
was conducted under GLP and the design complies with current recommendations (including draft
OECD Guideline 487). No evidence of chromosomal damage or aneuploidy was observed as indicated
by the lack of increased levels of micronucleated binucleate cells (MNBN) in the presence or absence
of rat liver S9 mix metabolic activation (Table 15).
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In conclusion, 2-acetyl-2-thiazoline [FL-no: 15.010] did not induce micronuclei in male human
peripheral blood lymphocyte cultures when tested for 3 + 21 hours in the presence of S9 mix and
24 + 0 hours in the absence of S9 mix.
Based on the new studies on the supporting substance 2-acetyl-2-thiazoline [FL-no: 15.010], the Panel
concluded that 2-methyl-2-thiazoline [FL-no: 15.086] does not give rise to concern with respect to
genotoxicity and can, accordingly, be evaluated using the Procedure.
9.4.4. Subgroup B-IV
No genotoxicity information was available for any candidate or supporting substance in this subgroup.
9.4.4.1. Overall conclusion on genotoxicity
Based on the new studies on the supporting substance 2-acetyl-2-thiazoline [FL-no: 15.010], the Panel
concluded that 2-methyl-2-thiazoline [FL-no: 15.086] does not give rise to concern with respect to
genotoxicity and can accordingly be evaluated using the Procedure.
For the remaining substances the genotoxicity data are limited and genotoxicity could not be assessed
adequately for these substances. However, except for the two 3-thiazolines, 2,4-dimethyl-3-thiazoline
[FL-no: 15.060] and 2-isobutyl-3-thiazoline [FL-no: 15.119], the genotoxicity data available do not
preclude the evaluation of the remaining 39 candidate substances using the Procedure.
Data on genotoxicity are summarised in Table 15.
CONCLUSIONS
The present revision of FGE.21, Revision 5 includes the assessment of a 90-day study on 2-
pentylthiophene [FL-no: 15.096] supporting 2-butylthiophene [FL-no: 15.045], 2-hexylthiophene [FL-
no: 15.076] and 2-octylthiophene [FL-no: 15.093]. It also includes a 90-day study on 5-
ethylthiophene-2-carbaldehyde [FL-no: 15.074] supporting 2-acetylthiophene [FL-no: 15.040] and 2-
propionylthiophene [FL-no: 15.097]. Updated information on European production figures has been
provided by EFFA for seven substances [FL-no: 15.040, 15.045, 15.074, 15.076, 15.093, 15.096 and
15.097] and the information has been included in their evaluation.
All candidate substances are five- or six-member sulphur-containing heterocyclic compounds, some of
which also contain nitrogen. They have been divided into two main groups: (A) those with an aromatic
ring (33 candidate substances) and (B) those with a non-aromatic ring structure (8 candidate
substances). All are ring-substituted with one or more of the substituents alkyl, alkenyl, aryl, alcohol,
keto, thio. For assessment purposes, the following further subdivision of groups (A) and (B) has been
made:
• Group (A): Aromatic:
– (Subgroup A-Ia: Thiophene. The substance previously allocated to the group is no longer
supported for use as a flavouring substance in Europe by Industry.)
– Subgroup A-Ib: Thiophene derivatives with non-thiol-containing ring substituents.
– Subgroup A-Ic: Thiophene derivatives with thiol-containing ring substituents.
– Subgroup A-II: Thiazole derivatives.
– (Subgroup A-III: Benzothiazoles. The substance previously allocated to the group is no
longer supported for use as a flavouring substance in Europe by Industry.)
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• Group (B): Non-aromatic:
– (Subgroup B-I: Dihydrothiophenes. The substance previously allocated to the group is no
longer supported for use as a flavouring substance in Europe by Industry.)
– Subgroup B-II: Thiazolines.
– (Subgroup B-III: Thiazolidines. The substances previously allocated to the group are no
longer supported for use as flavouring substances in Europe by Industry.)
– Subgroup B-IV: Dithiazine derivatives.
– (Subgroup B-V: Dihydrothiazines. The substances previously allocated to the group are
no longer supported for use as flavouring substances in Europe by Industry.)
– (Subgroup B-VI: Thiadiazine derivatives. The substance previously allocated to the group
is no longer supported for use as a flavouring substance in Europe by Industry.)
Two of the 41 candidate substances possess one chiral centre [FL-no: 15.060 and 15.119], three
substances possess two chiral centres [FL-no: 15.054, 15.057 and 15.135] and two possess three chiral
centres [FL-no: 15.055 and 15.079]. The stereoisomeric composition has been specified for all
substances.
Thirty-three of the candidate substances belong to SC II and eight belong to SC III.
Thirty-one of the candidate substances have been reported to occur naturally in a wide range of foods.
According to the default MSDI approach, the flavouring substances in this FGE.21Rev5 have intakes,
in Europe, ranging from 0.0012 to 5.7 µg/capita per day, which are below the thresholds of concern
values for SC II (540 µg/person per day) and SC III (90 µg/person per day) substances.
On the basis of the reported annual production volumes of the candidate substances as flavourings in
Europe, the combined estimated daily per capita intakes, per subgroup and SC range from 0.14 to
8.2 µg. For all subgroups, the total combined intakes are below the thresholds of concern of
540 µg/person per day and 90 µg/person per day for SCs II and III, respectively.
The candidate substances are structurally related to 28 supporting substances evaluated by the JECFA
at its 59th and 68th meetings. The total combined daily per capita intakes (in Europe) of candidate and
supporting substances evaluated through the Procedure in each of the five subgroups for which
supporting substances were available are: Subgroup A-Ib (8 substances from SC II) 2.9 µg; subgroup
A-Ic (5 substances from SC III) 0.15 µg; subgroup A-II (37 substances from SC II) 500 µg; subgroup
B-II (2 substances from SC II) 0.52 µg; subgroup B-IV (4 substances from SC II) 3.6 µg.
For all subgroups, the total combined intakes are below the thresholds of concern of 540 µg/person per
day and 90 µg/person per day for SCs II and III, respectively.
It is concluded that genotoxicity data are limited and that genotoxicity could not be assessed
adequately for the flavouring substances in FGE.21Rev5. However, except for the two 3-thiazolines,
2,4-dimethyl-3-thiazoline [FL-no: 15.060] and 2-isobutyl-3-thiazoline [FL-no: 15.119], the available
genotoxicity data do not preclude the evaluation of the remaining 39 candidate substances using the
Procedure.
The available metabolism data were insufficient to allow conclusions about the metabolic fate of the
candidate substances and, accordingly, the 39 candidate substances evaluated through the Procedure
could not be anticipated to be metabolised to innocuous products. However, the Panel concluded that
the evidence of binding to macromolecules from possible formation of electrophilic metabolites, (e.g.
by either ring scission or S-oxidation) was not sufficiently strong to preclude the application of the
Procedure.
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Valid toxicological data were available for candidate substances from subgroup A-Ib (thiophenes with
non-thiol-containing ring substituents), subgroup A-Ic (thiophenes with thiol-containing ring
substituents), subgroup A-II (thiazoles), subgroup B-II (only 2-thiazolines) and subgroup B-IV
(dithiazines). Based on these data, the margin of safety compared with the intakes from use as
flavouring substances was considered adequate.
In order to determine whether the conclusion for the 39 candidate substances, which have been
evaluated using the Procedure, can be applied to the materials of commerce, it is necessary to consider
the available specifications. Adequate specifications including purity and identity for the materials of
commerce have been provided for all 39 flavouring substances evaluated through the Procedure.
For the 39 flavouring substances [FL-no: 15.038, 15.039, 15.040, 15.044, 15.045, 15.050, 15.051,
15.052, 15.054, 15.055, 15.057, 15.058, 15.061, 15.062, 15.063, 15.067, 15.068, 15.069, 15.071,
15.074, 15.076, 15.078, 15.079, 15.080, 15.082, 15.084, 15.085, 15.086, 15.087, 15.089, 15.093,
15.096, 15.097, 15.098, 15.108, 15.115, 15.116, 15.118 and 15.135], evaluated using the Procedure,
the Panel concluded that they would present no safety concern at their estimated levels of intake based
on the MSDI approach.
The estimated intakes, based on the mTAMDI, for the 33 candidate substances assigned to SC II and
evaluated using the Procedure, range from 78 to 220 µg/person per day, which is below the threshold
of concern for SC II of 540 µg/person per day. The estimated intakes based on the mTAMDI of the
eight candidate substances assigned to SC III and evaluated through the Procedure ranged from 78 to
250 µg/person per day. For the candidate substances [FL-no: 15.055 and 15.135] the estimated intakes
are above the threshold of concern for SC III substances of 90 µg/person per day. For two candidate
substances [FL-no: 15.057 and 15.079], assigned to SC III, no use levels were provided.
In conclusion, more reliable exposure data are required for [FL-no: 15.055, 15.057, 15.079 and
15.135]. On the basis of such additional data, these flavouring substances should be re-evaluated using
the Procedure. Following this procedure additional toxicological data might become necessary.
For two substances [FL-no: 15.060 and 15.119] the Panel concluded that additional genotoxicity data
are required.
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SUMMARY OF SAFETY EVALUATION
Table 10: Summary of Safety Evaluation Applying the Procedure
FL-no EU Register name Structural formula MSDI (a)
(µg/capita
per day)
Class (b)
Evaluation
procedure path (c)
Outcome on the
named
compound
[(d) or (e)]
Outcome on the
material of
commerce
[(f), (g) or (h)]
Evaluation remarks
15.037 2-Acetyl-3-
methylthiophene
0.18 Class II
B3: Intake below
threshold, B4: No
adequate NOAEL
Additional data
required
No longer supported by
Industry (DG SANCO, 2012).
15.038 2-Acetyl-4-
methylthiazole
0.0049 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.039 2-Acetyl-5-
methylthiazole
0.0024 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.040 2-Acetylthiophene 0.049 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d
15.043 2-Butyl-5-
ethylthiophene
0.0012 Class II
B3: Intake below
threshold, B4: No
adequate NOAEL
Additional data
required
No longer supported by
Industry (DG SANCO, 2012).
15.044 2-Butylthiazole 0.011 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
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Table 10: Summary of Safety Evaluation Applying the Procedure
FL-no EU Register name Structural formula MSDI (a)
(µg/capita
per day)
Class (b)
Evaluation
procedure path (c)
Outcome on the
named
compound
[(d) or (e)]
Outcome on the
material of
commerce
[(f), (g) or (h)]
Evaluation remarks
15.045 2-Butylthiophene 0.012 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d
15.050 2,5-Diethyl-4-
methylthiazole
0.012 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.051 2,5-Diethyl-4-
propylthiazole
0.0012 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.052 2,5-Diethylthiazole 0.015 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.058 4,5-Dimethyl-2-
ethylthiazole
0.015 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.061 2,5-Dimethyl-4-
ethylthiazole
0.011 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.062 2,4-Dimethylthiazole 0.61 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
S
N
S
N
S
N
S
N
S
N
S
N
S
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Table 10: Summary of Safety Evaluation Applying the Procedure
FL-no EU Register name Structural formula MSDI (a)
(µg/capita
per day)
Class (b)
Evaluation
procedure path (c)
Outcome on the
named
compound
[(d) or (e)]
Outcome on the
material of
commerce
[(f), (g) or (h)]
Evaluation remarks
15.063
1758
2,5-Dimethylthiazole 0.0061 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.064 2,5-Dimethylthiophene 0.23 Class II
B3: Intake below
threshold, B4: No
adequate NOAEL
Additional data
required
No longer supported by
Industry (DG SANCO, 2013).
15.067 4-Ethyl-2-
methylthiazole
0.0037 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.068 5-Ethyl-2-
methylthiazole
0.0061 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.069 4-Ethyl-5-
methylthiazole
0.012 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.070 2-Ethyl-5-
methylthiophene
0.061 Class II
B3: Intake below
threshold, B4: No
adequate NOAEL
Additional data
required
No longer supported by
Industry (DG SANCO, 2012).
15.071 2-Ethylthiazole 0.028 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
N
S
S
N
S
N
S
N
S
S
N
S
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Table 10: Summary of Safety Evaluation Applying the Procedure
FL-no EU Register name Structural formula MSDI (a)
(µg/capita
per day)
Class (b)
Evaluation
procedure path (c)
Outcome on the
named
compound
[(d) or (e)]
Outcome on the
material of
commerce
[(f), (g) or (h)]
Evaluation remarks
15.072 2-Ethylthiophene 0.0012 Class II
B3: Intake below
threshold, B4: No
adequate NOAEL
Additional data
required
No longer supported by
Industry (DG SANCO, 2013).
15.074 5-Ethylthiophene-2-
carbaldehyde
0.037 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d
15.076
1764
2-Hexylthiophene 0.46 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d
15.078 2-Isobutyl-4,5-
dimethylthiazole
0.12 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.080 2-Isopropyl-4,5-
dimethylthiazole
0.012 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.084 5-Methyl-2-
pentylthiazole
0.0037 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.085 4-Methyl-2-
propionylthiazole
0.0037 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
S
S
O
S
N
S
N
S
N
S
N
S
O
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Table 10: Summary of Safety Evaluation Applying the Procedure
FL-no EU Register name Structural formula MSDI (a)
(µg/capita
per day)
Class (b)
Evaluation
procedure path (c)
Outcome on the
named
compound
[(d) or (e)]
Outcome on the
material of
commerce
[(f), (g) or (h)]
Evaluation remarks
15.086 2-Methyl-2-thiazoline 0.012 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.089 2-Methylthiazole 0.018 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.091 2-Methylthiophene 0.019 Class II
B3: Intake below
threshold, B4: No
adequate NOAEL
Additional data
required
No longer supported by
Industry (DG SANCO, 2013).
15.092 3-Methylthiophene 0.12 Class II
B3: Intake below
threshold, B4: No
adequate NOAEL
Additional data
required
No longer supported by
Industry (DG SANCO, 2013).
15.093 2-Octylthiophene 0.012 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d
15.094 2-Pentanoylthiophene 0.0012 Class II
B3: Intake below
threshold, B4: No
adequate NOAEL
Additional data
required
No longer supported by
Industry (DG SANCO, 2012).
15.096
2106
2-Pentylthiophene 1.6 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d
N
S
N
S
S
S
S
S
O
S
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Table 10: Summary of Safety Evaluation Applying the Procedure
FL-no EU Register name Structural formula MSDI (a)
(µg/capita
per day)
Class (b)
Evaluation
procedure path (c)
Outcome on the
named
compound
[(d) or (e)]
Outcome on the
material of
commerce
[(f), (g) or (h)]
Evaluation remarks
15.097 2-Propionylthiophene 0.012 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d
15.098 2-Propylthiazole 0.085 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.107 Thiophene-2-
carbaldehyde
0.21 Class II
B3: Intake below
threshold, B4: No
adequate NOAEL
Additional data
required
No longer supported by
Industry (DG SANCO, 2012).
15.115 2-Isobutyl-4-methyl
thiazole
0.011 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.116 2-Acetyl-4-
ethylthiazole
0.024 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.118 4-Butylthiazole 1.3 Class II
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.129 Tetrahydro-2,4,6-
trimethyl-1,3,5(2H)-
thiadiazine
0.61 Class II
B3: Intake below
threshold, B4: No
adequate NOAEL
Additional data
required
No longer supported by
Industry (DG SANCO, 2012).
S
O
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Table 10: Summary of Safety Evaluation Applying the Procedure
FL-no EU Register name Structural formula MSDI (a)
(µg/capita
per day)
Class (b)
Evaluation
procedure path (c)
Outcome on the
named
compound
[(d) or (e)]
Outcome on the
material of
commerce
[(f), (g) or (h)]
Evaluation remarks
15.060 2,4-Dimethyl-3-
thiazoline
0.012 Class II
No evaluation
Concern for genotoxicity.
15.090 2-Methylthiazolidine 0.024 Class II
No evaluation
No longer supported by
Industry (DG SANCO, 2012).
15.099 2-Propylthiazolidine 0.012 Class II
No evaluation
No longer supported by
Industry (DG SANCO, 2012).
15.119 2-Isobutyl-3-thiazoline 0.011 Class II
No evaluation
Concern for genotoxicity.
15.042 2-Butyl-4-
methyl(4H)pyrrolidino[
1,2d]-1,3,5-dithiazine
0.0012 Class III
B3: Intake below
threshold, B4: No
adequate NOAEL
Additional data
required
No longer supported by
Industry (DG SANCO, 2012).
15.054 Dihydro-2,4,6-triethyl-
1,3,5(4H)-dithiazine
0.85 Class III
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.055
1763
[2S-(2a,4a,8ab)] 2,4-
Dimethyl(4H)pyrrolidin
o[1,2e]-1,3,5-dithiazine
0.012 Class III
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.057 4,6-Dimethyl-2-(1-
methylethyl)dihydro-
1,3,5-dithiazine
1.6 Class III
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
N
S
NH
S
NH
S
N
S
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S
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S
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Table 10: Summary of Safety Evaluation Applying the Procedure
FL-no EU Register name Structural formula MSDI (a)
(µg/capita
per day)
Class (b)
Evaluation
procedure path (c)
Outcome on the
named
compound
[(d) or (e)]
Outcome on the
material of
commerce
[(f), (g) or (h)]
Evaluation remarks
15.077 4-Hydroxy-2,5-
dimethylthiophen-
3(2H)-one
0.12 Class III
B3: Intake below
threshold, B4: No
adequate NOAEL
Additional data
required
No longer supported by
Industry (DG SANCO, 2012).
15.079 2-Isobutyldihydro-4,6-
dimethyl-1,3,5-
dithiazine
5.7 Class III
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.082 3-Mercaptothiophene 0.011 Class III
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.087 2-Methyl-3-
mercaptothiophene
0.12 Class III
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.088 2-Methyl-4,5-
benzothiazole
0.0085 Class III
B3: Intake below
threshold, B4: No
adequate NOAEL
Additional data
required
No longer supported by
Industry (DG SANCO, 2012).
15.106 Thiophene 0.12 Class III
B3: Intake below
threshold, B4: No
adequate NOAEL
Additional data
required
No longer supported by
Industry (DG SANCO, 2012).
15.108 2-
Thiophenemethanethiol
0.0073 Class III
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
S
HO O
S
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H
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Table 10: Summary of Safety Evaluation Applying the Procedure
FL-no EU Register name Structural formula MSDI (a)
(µg/capita
per day)
Class (b)
Evaluation
procedure path (c)
Outcome on the
named
compound
[(d) or (e)]
Outcome on the
material of
commerce
[(f), (g) or (h)]
Evaluation remarks
15.135 Ethyl thialdine 0.012 Class III
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d f
15.114 6-Acetyl-2,3-dihydro-
1,4-thiazine
0.012 Class III
No evaluation
No longer supported by
Industry (DG SANCO, 2012).
Concern for genotoxicity.
15.133
1766
5-Acetyl-2,3-dihydro-
1,4-thiazine
0.61 Class III
No evaluation
No longer supported by
Industry (DG SANCO, 2012).
Concern for genotoxicity.
(a): EU MSDI: Quantity added to food as flavour in (kilograms per year) x 10E9 / (0.1 x population in Europe (= 375 × 10E6) × 0.6 × 365) = µg/capita per day.
(b): Thresholds of concern: Class I = 1800 µg/person per day, Class II = 540 µg/person per day, Class III = 90 µg/person per day.
(c): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot.
(d): No safety concern based on intake calculated by the MSDI approach of the named compound.
(e): Data must be available on the substance or closely related substances to perform a safety evaluation.
(f): No safety concern at the estimated level of intake of the material of commerce meeting the specification requirement (based on intake calculated by the MSDI approach).
(g): Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or
information on stereoisomerism.
(h): No conclusion can be drawn because of a lack of information on the purity of the material of commerce.
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SUPPORTING SUBSTANCES SUMMARY
Table 11: Supporting Substances Summary
FL-no EU Register name Structural formula FEMA no
CoE no
CAS no
JECFA no
Specification
available
MSDI (EU) (a)
(µg/capita per
day)
SCF status (b)
JECFA status (c)
CoE status (d)
Comments
2-Isobutyl-4,6-
dimethyldihydro-1,3,5-
dithiazine and 4-isobutyl-
2,6-dimethyldihydro-1,3,5-
dithiazine (mixture)
S
N
H
S S
N
H
S
(Mixture)
3781
101517-87-7 and
101517-86-6
1046
JECFA
specification
(JECFA, 2002b)
0.1
No safety concern
(JECFA, 2002a)
Not in EU-Register
2-Isopropyl-4,6-dimethyl
2,6-dimethyldihydro-1,3,5-
dithiazine and 4-isopropyl-
2,6-dimethyldihydro-1,3,5-
dithiazine (mixture)
S
N
H
S S
N
H
S
(Mixture)
3782
104691-41-0 and
104691-40-9
1047
JECFA
specification
(JECFA, 2002b)
ND
No safety concern
(JECFA, 2002a)
Not in EU-Register
15.001 2-Mercaptothiophene 3062
478
7774-74-5
1052
JECFA
specification
(JECFA,
2002b).
0.012
No safety concern
(JECFA, 2002a)
Deleted (CoE,
1992)
15.002 2-Methyl-5-
methoxythiazole
3192
736
38205-64-0
1057
JECFA
specification
(JECFA,
2002b).
0.012
No safety concern
(JECFA, 2002a)
Category B (CoE,
1992)
15.004 5-Methyl-2-
thiophenecarbaldehyde
3209
2203
13679-70-4
1050
JECFA
specification
(JECFA,
2002b).
0.73
No safety concern
(JECFA, 2002a)
Deleted (CoE,
1992)
15.005 2,4-Dimethyl-5-
vinylthiazole
3145
2237
65505-18-2
1039
JECFA
specification
(JECFA,
2002b).
0.012
No safety concern
(JECFA, 2002a)
Category B (CoE,
1992)
S SH
N
SO
S
O
N
S
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Table 11: Supporting Substances Summary
FL-no EU Register name Structural formula FEMA no
CoE no
CAS no
JECFA no
Specification
available
MSDI (EU) (a)
(µg/capita per
day)
SCF status (b)
JECFA status (c)
CoE status (d)
Comments
15.008 2-Thienyl disulfide 3323
2333
6911-51-9
1053
JECFA
specification
(JECFA,
2002b).
0.061
No safety concern
(JECFA, 2002a)
Category B (CoE,
1992)
15.010 2-Acetyl-2-thiazoline 3817
2335
29926-41-8
1759 0.51
Category B (CoE,
1992)
15.011 5-Acetyl-2,4-
dimethylthiazole
3267
2336
38205-60-6
1055
JECFA
specification
(JECFA,
2002b).
0.012
No safety concern
(JECFA, 2002a)
Category B (CoE,
1992)
15.013 2-Isobutylthiazole 3134
11618
18640-74-9
1034
JECFA
specification
(JECFA,
2002b).
2.3
No safety concern
(JECFA, 2002a)
15.014 5-(2-Hydroxyethyl)-4-
methylthiazole
3204
11621
137-00-8
1031
JECFA
specification
(JECFA,
2002b).
150
No safety concern
(JECFA, 2002a)
15.015 4-Methyl-5-(2-
acetoxyethyl)thiazole
3205
11620
656-53-1
1054
JECFA
specification
(JECFA,
2002b).
8.6
No safety concern
(JECFA, 2002a)
15.017 4,5-Dimethylthiazole 3274
11606
3581-91-7
1035
JECFA
specification
(JECFA,
2002b).
0.18
No safety concern
(JECFA, 2002a)
S S
S
S
S
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Table 11: Supporting Substances Summary
FL-no EU Register name Structural formula FEMA no
CoE no
CAS no
JECFA no
Specification
available
MSDI (EU) (a)
(µg/capita per
day)
SCF status (b)
JECFA status (c)
CoE status (d)
Comments
15.018 4-Methyl-5-vinylthiazole 3313
11633
1759-28-0
1038
JECFA
specification
(JECFA,
2002b).
2.1
No safety concern
(JECFA, 2002a)
15.019 2,4,5-Trimethylthiazole 3325
11650
13623-11-5
1036
JECFA
specification
(JECFA,
2002b).
0.61
No safety concern
(JECFA, 2002a)
15.020 2-Acetylthiazole 3328
11726
24295-03-2
1041
JECFA
specification
(JECFA,
2002b).
9.7
No safety concern
(JECFA, 2002a)
15.021 2-Ethoxythiazole 3340
11611
15679-19-3
1056
JECFA
specification
(JECFA,
2002b).
0.012
No safety concern
(JECFA, 2002a)
15.022 2-(sec-Butyl)thiazole 3372
11598
18277-27-5
1033
JECFA
specification
(JECFA,
2002b).
0.024
No safety concern
(JECFA, 2002a)
JECFA evaluated 2-(1-
methylpropyl)thiazole
(CASrn as in Register).
(R)- or (S)- enantiomer
not specified by CASrn
in Register.
15.026 2-Isopropyl-4-
methylthiazole
3555
15679-13-7
1037
JECFA
specification
(JECFA,
2002b).
19
No safety concern
(JECFA, 2002a)
15.027 2-Propionylthiazole 3611
43039-98-1
1042
JECFA
specification
(JECFA,
2002b).
0.056
No safety concern
(JECFA, 2002a)
N
S
N
S
N
S
O
N
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N
S
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Table 11: Supporting Substances Summary
FL-no EU Register name Structural formula FEMA no
CoE no
CAS no
JECFA no
Specification
available
MSDI (EU) (a)
(µg/capita per
day)
SCF status (b)
JECFA status (c)
CoE status (d)
Comments
15.029 2-(sec-Butyl)-4,5-
dimethyl-3-thiazoline
3619
65894-82-8
1059
JECFA
specification
(JECFA,
2002b).
0.012
No safety concern
(JECFA, 2002a)
JECFA evaluated 2-(2-
Butyl)-4,5-dimethyl-3-
thiazoline (CASrn as in
Register). (R)- or (S)-
enantiomer not
specified by CASrn in
Register.
15.030 4,5-Dimethyl-2-ethyl-3-
thiazoline
3620
76788-46-0
1058
JECFA
specification
(JECFA,
2002b).
0.012
No safety concern
(JECFA, 2002a)
JECFA evaluated 4,5-
dimethyl-2-ethyl-3-
thiazoline (CASrn as in
Register). (R)- or (S)-
enantiomer not
specified by CASrn in
Register.
15.032 4,5-Dimethyl-2-isobutyl-3-
thiazoline
3621
65894-83-9
1045
JECFA
specification
(JECFA,
2002b).
0.012
No safety concern
(JECFA, 2002a)
JECFA evaluated 4,5-
dimethyl-2-isobutyl-3-
thiazoline (CASrn as in
Register). (R)- or (S)-
enantiomer not
specified by CASrn in
Register.
15.033 2-Ethyl 4-methylthiazole 3680
11612
15679-12-6
1044
JECFA
specification
(JECFA,
2002b).
3.2
No safety concern
(JECFA, 2002a)
15.035 4-Methylthiazole 3716
11627
693-95-8
1043
JECFA
specification
(JECFA,
2002b).
0.097
No safety concern
(JECFA, 2002a)
N
S
N
S
N
S
N
S
N
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Table 11: Supporting Substances Summary
FL-no EU Register name Structural formula FEMA no
CoE no
CAS no
JECFA no
Specification
available
MSDI (EU) (a)
(µg/capita per
day)
SCF status (b)
JECFA status (c)
CoE status (d)
Comments
15.109 2,4,6-Trimethyldihydro-
1,3,5(4H)-dithiazine
4018
11649
638-17-5
1049
JECFA
specification
(JECFA,
2002b).
1.1
No safety concern
(JECFA, 2002a)
JECFA evaluated 2,4,6-
trimethyldihydro-4H-
1,3,5-dithiazine (CASrn
as in Register). (R)- or
(S)- enantiomer not
specified by CASrn in
Register.
15.113 5,6-Dihydro-2,4,6,tris(2-
methylpropyl)-4H-1,3,5-
dithiazine
4017
74595-94-1
1048
JECFA
specification
(JECFA,
2002b).
2.4
No safety concern
(JECFA, 2002a)
JECFA evaluated 2,4,6-
triisobutyl-5,6-dihydro-
4H-1,3,5-dithiazine
(CASrn as in Register).
(R)- or (S)- enantiomer
not specified by CASrn
in Register.
16.027 Thiamine hydrochloride 3322
10493
67-03-8
1030
JECFA
specification
(JECFA,
2002b).
300
No safety concern
(JECFA, 2002a)
(a): EU MSDI: Quantity added to food as flavouring substance in (kilograms per year) × 10E9 / (0.1 × population in Europe (= 375 × 10E6) × 0.6 × 365) = µg/capita/day.
(b): Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable because
of evidence of toxicity.
(c): No safety concern at estimated levels of intake.
(d): Category A: Flavouring substance, which may be used in foodstuffs, Category B: Flavouring substance which can be used provisionally in foodstuffs.
ND: No intake data reported
S NH
S
S NH
S
+NH3
N+
S
N
N
HO
2 Cl-
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TOXICITY DATA
Table 12: Acute Toxicity
Chemical Name [FL-no](a) Species Sex Route LD50 (mg/kg bw) Reference
(2-Thienyl disulfide [15.008]) Mouse M, F Gavage 400 (Moran et al., 1980)
(2-Methyl-5-methoxythiazole [15.002]) Rat NR Oral 1250 (Posternak et al., 1975)
(2,4-Dimethyl-5-vinylthiazole [15.005]) Mouse M, F Oral 400 – 800 (Moran et al., 1980)
(5-Acetyl-2,4-dimethylthiazole [15.011]) Mouse M, F Gavage 975 (Moran et al., 1980)
Mouse M, F Gavage M: 610, F: 620 (Shellenberger, 1971)
(5-(2-Hydroxyethyl)-4-methylthiazole [15.014]) Mouse M, F Oral 4800 (Calvary and Nelson, 1944)
(4-Methyl-5-vinylthiazole [15.018]) Mouse M, F Gavage 400 – 800 (Oser, 1970)
(2-Propionylthiazole [15.027]) Mouse M, F Gavage 2113 (Moran et al., 1980)
(4-Methylthiazole [15.035]) Mouse F Gavage 0.36 ml/kg (360 mg/kg,
based on an assumed
specific gravity of 1.0 g/ml)
(O’Neal et al., 1978)
Rat M, F Gavage 930 (Mondino, 1981)
(4,5-Dimethylthiazole [15.017]) Rat M, F Gavage 964.9 (Piccirillo et al., 1982a)
(2-Ethoxythiazole [15.021]) Rat M, F Gavage 910.9 (Piccirillo et al., 1982b)
(2-Isopropyl-4-methylthiazole [15.026]) Rat M, F Gavage 0.83 ml/kg (832 mg/kg
based on a specific gravity
of 1.003 g/ml)
(Griffiths and Babish, 1977)
(2-Ethyl 4-methylthiazole [15.033]) Rat M, F Oral 540 (Moreno et al., 1981)
(Thiamine hydrochloride [16.027]) Rat M Gavage 3710 (Sprince et al., 1974)
(2-(2-Butyl)-4,5-dimethyl-3-thiazoline [15.029]) Mouse M, F Gavage 2827 (Moran et al., 1980)
(4,5-Dimethyl-2-ethyl-3-thiazoline [15.030]) Mouse M, F Gavage 1265 (Moran et al., 1980)
(4,5-Dimethyl-2-isobutyl-3-thiazoline [15.032]) Mouse M, F Gavage 3067 (Moran et al., 1980)
(a): Supporting substances are listed in brackets.
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Table 13: Subacute / Subchronic / Chronic / Carcinogenicity Studies
Chemical Name [FL-no](a) Species; Sex
No./Group
Route Dose levels Duration
(days)
NOAEL
(mg/kg bw
per day)
Reference Comments
(Thiophene (former [
15.106]))
Rat;
M
5
Gavage 0, 50, 100, 500,
1000 mg/kg bw
per day
Up to 19
days
100 (O’Donoghue,
1979)
Inadequately reported study of short duration.
Rat;
M/F
13
Gavage 0, 25, 100, 400
mg/kg bw per day
42 25 (Nagao, 2006) Only a translated summary report available.
2-Pentylthiophene [15.096] Rat;
M/F
5
Gavage 0, 15, 150, 500
mg/kg bw per day
28 (Dhinsa et al.,
2006)
Signs of haemolytic anaemia were seen in all dosage groups, in
the lowest dosage group statistically significant raised bilirubin.
Rat;
M/F
5
Gavage 0, 3 mg/kg bw per
day
28 3 (Marr and
Watson, 2007)
This study is a follow up of (Dhinsa et al., 2006), since in this
study effects were seen at the lowest dose.
Rat;
M, F
3/20
Diet 0, 1.0, 5.5 and
24.4 mg/kg bw
(M)
0, 1.1, 6.2 and
28.4 mg/kg bw (F)
90 days 5.5 (Bauter,
2013b)
OECD Guideline study (408).
Dose levels recalculated to compensate for low stability of the
test substance in the dietary matrix, see text.
(Thiophene-2-carbaldehyde
(former [15.107]))
Rat;
sex not reported
5
Diet 0, 0.1, and 1.0 %
in diet equal to 0,
95 and 840 mg/kg
bw per day
11 days 95 (Sharp, 1979) Reduced food consumption and reduced absolute kidney
weight. Inadequately reported study of short duration.
(5-Methyl-2-
thiophenecarbaldehyde
[15.004])
Rat;
M, F
5/sex/group
Diet 10 mg/kg bw per
day
14 days 10 (Gill and Van
Miller, 1987)
One dose level, GLP study, comprehensively reported, but no
haematology or clinical chemistry carried out, only a limited
number of organs examined at autopsy and only liver and
kidney examined histopathologically. Short duration, limited
study design.
(2-Thienyl disulfide
[15.008])
Rat;
M, F
15/sex
Diet 0.29 mg/kg bw
per day
90 days 0.29 (Morgareidge
and Oser,
1970)
Study carried out at a one low dose level. Standard
toxicological parameters were monitored (body weight, food
consumption, haematology, urinalysis, histopathology).
Parameters assessed were reasonably comprehensive. Study
considered valid.
(5-Acetyl-2,4-
dimethylthiazole [15.011])
Rat;
M, F
23/sex
Diet approx. 25 mg/kg
bw per day.
90 days M: 25.2
F:24.4
(Shellenberger
, 1971)
Old study carried out at a one dose level. Standard toxicological
parameters were monitored (body weight, food consumption,
haematology, urinalysis, histopathology). Parameters assessed
were reasonably comprehensive. Study considered valid.
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Table 13: Subacute / Subchronic / Chronic / Carcinogenicity Studies
Chemical Name [FL-no](a) Species; Sex
No./Group
Route Dose levels Duration
(days)
NOAEL
(mg/kg bw
per day)
Reference Comments
(2-Acetylthiazole [15.020]) Rat; M
5
Diet 5000 and 10 000
mg/kg in diet
equivalent to 250
and 500 mg/kg bw
per day
28 days < 250 (Wheldon et
al., 1970)
Preliminary dose-range finding study for the 90-day study
described below, very limited experimental details provided.
Rat; M
10
Diet 0, 100, 1000, 10
000 mg/kg in diet
equivalent to 0.5,
50, 500 mg/kg bw
per day
90 days 50 (Wheldon et
al., 1970)
Study considered to be of limited validity, since no clinical
chemistry was undertaken, limited number of organs weighed,
number of organs taken for histopathology was limited, and
histopathological review restricted to 5 animals/sex/group.
(2-Methyl-5-
methoxythiazole [15.002])
Rat;
M, F
10-16/sex
Diet approx. 9 mg/kg
bw per day
90 days M: 8.83
F: 8.63
(Posternak et
al., 1975)
Toxicity data reported as part of a summary publication on a
large number of flavouring substances. Body weight, food
utilisation, haematological and histopathology examination
undertaken, clinical chemistry restricted to blood urea nitrogen,
organ weight changes restricted to liver and kidney. Due to
reporting limitations data quality could not be assessed.
(2,4-Dimethyl-5-
vinylthiazole [15.005])
Rat; M, F
10-16/sex
Diet approx. 1 mg/kg
bw per day
90 days M: 0.92
F: 1.0
(Posternak et
al., 1969)
Toxicity data reported as part of a summary publication on a
large number of flavouring substances,. Body weight, food
utilisation, haematological and histopathology examination
undertaken, clinical chemistry restricted to blood urea nitrogen,
organ weight changes restricted to liver and kidney. Due to
reporting limitations data quality could not be assessed.
(2-Acetyl-2-thiazoline
[15.010])
Rat;
M, F
8/sex
Diet 0, 197, 492, 983,
1966, 2949, 3932
mg/kg in diet
equivalent to 0,
0.09, 0.23, 0.45,
0.90, 1.4, 1.8
mg/kg bw per day
90 days 1.8 (Munday and
Kirkby, 1971)
Flavour coctail consisted of 4-hydroxy-5-methyl-2,3-
dihydrofuran-3one [FL-no:13.085] (74 %), 2,3-dimethyl-4-
hydroxy-2,5-dihydrofuran-5-one [FL-no: 10.030] (23 %), 2-
acetyl-2-thiazole [FL-no: 15.020] (1.8 %) and 2-acetyl-2-
thazoline [FL-no: 15.010] (0.9 %).
2-(sec-butyl)-4,5-dimethyl-
3-thiazoline [15.029])
Rat;
M, F
15/sex
Oral 1.21(M) /1.26 (F)
mg/kg bw per day
90 days M: 1.21
F: 1.26
(Babish and
Re, 1978)
Old study carried out at a one dose level. Standard toxicological
parameters were monitored (body weight, food consumption,
haematology, urinalysis, histopathology). Study considered
valid.
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Table 13: Subacute / Subchronic / Chronic / Carcinogenicity Studies
Chemical Name [FL-no](a) Species; Sex
No./Group
Route Dose levels Duration
(days)
NOAEL
(mg/kg bw
per day)
Reference Comments
(5,6-Dihydro-2,4,6,tris(2-
methylpropyl)-4H-1,3,5-
dithiazine [15.113])
Rat
M, F
3/6
Diet 0, 11, 111, 217
mg/kg bw (M)
0, 11, 107, 206
mg/kg bw (F)
14 days >217 (Bauter,
2012a)
OECD Guideline study (407).
Rat
M, F
3/20
Diet 0, 9, 68, 132
mg/kg bw (M)
0, 11, 77, 154
mg/kg bw (F)
90 days 9.3 (M)
11.0 (F)
(Bauter,
2013a)
OECD Guideline study (408).
5-Ethylthiophene-2-
carbaldehyde [15.074]
Rat
M, F
3/6
Diet 0, 22, 194, 676
mg/kg bw per day
(M)
0, 22, 195, 686
mg/kg bw per day
(F)
14 days M: 21.9
F: 686.2
(Bauter,
2012b)
OECD Guideline study (407).
Rat
M, F
3/20
Gavage 0, 2, 8, 75 mg/kg
bw per day
90 days 75 (Bauter,
2013c)
OECD Guideline study (408).
(2-Isobutyl-4,6-
dimethyldihydro-1,3,5-
dithiazine and 4-isobutyl-
2,6-dimethyldihydro-1,3,5-
dithiazine (mixture))
Rat,
M, F
5/sex
Oral 10 mg/kg bw per
day
14 days M: 11.5
F: 11.1
(Rush, 1989a) One dose level study of short duration, no haematological or
clinical chemistry parametes were examined and
histopathological examinations were restricted to liver and
kidney.
(2-Isopropyl-4, 6-
dimethyldihydro-1,3,5-
dithiazine and 4-isopropyl-
2,6-dimethyldihydro-1,3,5-
dithiazine (mixture))
Rat,
M, F
5/sex
Oral 10 mg/kg bw per
day
14 days M: 11.8
F: 11.1
(Rush, 1989b) One dose level study of short duration, no haematological or
clinical chemistry parametes were examined and
histopathological examinations were restricted to liver and
kidney.
(a): Supporting substances are listed in brackets.
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Table 14: Developmental and reproductive toxicity studies
Chemical Name
[FL-no]
Species/
Sex
No./ group
Route Dose
Levels
Duration NOAEL (mg/kg bw per
day), Including information
of possible maternel toxicity
Reference Comments
Thiophene
(former [FL-no:
15.106])
Rats/M, F
13
Gavage 0, 25, 100, 400
mg/kg bw per
day
42 days M: 400 mg/kg bw
F: 25 mg/kg bw
(Nagao, 2006) Only a translated summary report available.
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Table 15: Genotoxicity (In Vitro)
Chemical Name
[FL-no]*
Test System Test Object Concentration Result Reference Comments
Subgroup A-Ia
Thiophene
(former [FL-no:
15.106])
Ames assay
(plate
incorporation
method)
S. typhimurium
TA98; TA100;
TA1535;
TA1537
3 µmol/plate (all
strains)
(252 µg/plate)
Negative
(±S9)
(Florin et al.,
1980)
Published non-GLP study. Qualitative screening in a spot-
test with three strains, quantitative study (4 doses, 0.03, 0.3,
3, 30 µmol/plate) with TA100 only. Limited report of
experimental details and results. Insufficient quality, study
not considered adequate for the evaluation of mutagenic
activity.
Ames assay
(preincubation
method)
S. typhimurium
TA97;TA98;
TA100;
TA1535;
TA1537
Up to 10,000
µg/plate
Negative
(±S9) (a)
(Zeiger et al.,
1987)
Non-GLP study roughly in accordance with OECD
guideline 471. The study is considered valid.
Ames assay
(preincubation
method)
S. typhimurium
TA98; TA100;
TA102
0.01 - 1.2
mmol/plate
(100,968 µg/plate)
Negative
(±S9)
(Aeschbacher et
al., 1989)
Greatest effects are quantified by “mutation factor,” no
numbers are given for negative results. Limited quality
(only 3 strains used), but otherwise acceptable study.
Ames assay
(plate
incorporation
method)
S. typhimurium
TA98; TA100
Up to 100
µmol/plate
(8414 µg/plate)
Negative
(±S9)
(Lee et al., 1994) Only two strains used but otherwise acceptable study.
Ames assay S. typhimurium
TA98, TA100,
TA1535,
TA1537
0, 78, 156, 313,
625, 1250 µg/plate
Negative
(±S9)
(Shibuya, 2006) Valid study according to OECD Test Guidelines and
Guidelines for screening mutagenicity testing of chemicals
(Japan), provided as a translation of the original report in
Japanese.
E. coli WP2
uvrA
0, 78, 156, 313,
625, 1250, 2500,
5000 µg/plate
Negative
(±S9)
Chromosomal
Abberation
Chinese hamster
lung cells
0, 210, 420, 840
µg/ml
Negative
(±S9)
(Tanaka, 2006) Valid study according to Guidelines for screening
mutagenicity testing of chemicals (Japan), provided as a
translation of the original report in Japanese.
Subgroup A-Ib
2-Methylthiophene
(former [FL-no:
15.091])
Ames assay
(preincubation
method)
S. typhimurium
TA98; TA100;
TA102
0.00001 - 1.0
mmol/plate
(98,170 µg/plate)
Negative
(±S9)
(Aeschbacher et
al., 1989)
Greatest effects are quantified by “mutation factor,” no
numbers are given for negative results. Limited quality
(only 3 strains used), but otherwise acceptable study.
Ames assay
(plate
incorporation
S. typhimurium
TA98; TA100
Up to 100
µmol/plate
(9817 µg/plate)
Negative
(±S9)
(Lee et al., 1994) Only two strains used but otherwise acceptable study.
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Table 15: Genotoxicity (In Vitro)
Chemical Name
[FL-no]*
Test System Test Object Concentration Result Reference Comments
method)
3-Methylthiophene
(former [FL-no:
15.092])
Ames assay
(preincubation
method)
S. typhimurium
TA98; TA100;
TA102
0.01 - 1.0
mmol/plate
(98,170 µg/plate)
Negative
(±S9)
(Aeschbacher et
al., 1989)
Greatest effects are quantified by “mutation factor,” no
numbers are given for negative results. Limited quality
(only 3 strains used), but otherwise acceptable study.
Ames assay
(plate
incorporation
method)
S. typhimurium
TA98; TA100
Up to 100
µmol/plate
(9817 µg/plate)
Negative
(±S9)
(Lee et al., 1994) Only two strains used but otherwise acceptable study.
2,5-Dimethylthiophene
(former [FL-no:
15.064])
Ames assay
(plate
incorporation
method)
S. typhimurium
TA98; TA100
Up to 100
µmol/plate
(11,219 µg/plate)
Negative
(±S9)
(Lee et al., 1994) Only two strains used but otherwise acceptable study.
2-Acetylthiophene
[15.040]
Ames assay
(plate
incorporation
method)
S. typhimurium
TA98; TA100
Up to 100
µmol/plate
(12,618 µg/plate)
Negative
(±S9)
(Lee et al., 1994) Only two strains used but otherwise acceptable study.
SOS
Chromotest
E. coli NR Negative with rat
S9,
positive without
rat S9
(Mosier et al.,
2003)
Study endpoint inappropriate for the estimation of
genotoxic potential.
2-Acetyl-3-
Methylthiophene
(former [FL-no:
15.037])
SOS
Chromotest
E. coli NR Negative with rat
S9,
positive without
rat S9
(Mosier et al.,
2003)
Study endpoint inappropriate for the estimation of
genotoxic potential.
Thiophene-2-
carbaldehyde
(former [FL-no:
15.107])
SOS
Chromotest
E. coli NR Negative with rat
S9,
positive without
rat S9
(Mosier et al.,
2003)
Study endpoint inappropriate for the estimation of
genotoxic potential.
5-Ethylthiophene-2-
carbaldehyde [15.074]
SOS
Chromotest
E. coli NR Negative with rat
S9,
positive without
rat S9
(Mosier et al.,
2003)
Study endpoint inappropriate for the estimation of
genotoxic potential.
(5-Methyl-2-
thiophenecarbaldehyde
[15.004])
Ames assay
(plate
incorporation
method)
S. typhimurium
TA98; TA100
Up to 100
µmol/plate
(12,618 µg/plate)
Negative
(±S9)
(Lee et al., 1994) Only two strains used but otherwise acceptable study.
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Table 15: Genotoxicity (In Vitro)
Chemical Name
[FL-no]*
Test System Test Object Concentration Result Reference Comments
Subgroup A-II
2,4-Dimethylthiazole
[15.062]
Ames assay
(plate
incorporation
method)
S. typhimurium
TA100
9.3 and 94 mmol/l
top agar
(10,639 µg/ml)
Negative
(-S9)
(Voogd et al.,
1983)
Insufficient quality (one test strain as well as without
metabolic activation only).
(4,5-Dimethylthiazole
[15.017])
Ames assay
(plate
incorporation
method)
S. typhimurium
TA98; TA100
Up to 100
µmol/plate
(11,318 µg/plate)
Negative
(±S9)
(Lee et al., 1994) Only two strains used but otherwise acceptable study.
(4-Methylthiazole
[15.035])
Ames assay
(plate
incorporation
method)
S. typhimurium
TA98; TA100
Up to 100
µmol/plate
(9916 µg/plate)
Negative
(±S9)
(Lee et al., 1994) Only two strains used but otherwise acceptable study.
Subgroup B-II
2-Acetyl-2-thiazoline
[15.010]
Reverse
mutation
S. typhimurium
TA98, TA100,
TA1535,
TA1537 and
TA102
5, 16, 50, 158, 500,
1581 and 5000
μg/plate(b)
Negative (Mc Garry, 2012) OECD Guideline study (471).
156, 312, 625,
1250,
2500 and 5000 μg 
/plate(c)
Negative
Micronucleus
induction
Human
peripheralblood
lymphocytes
600, 1000 and
1292 μg /ml(d)
600, 1000 and
1292 μg /ml(e)
Negative (Watters, 2012) OECD Guideline study (487).
100, 200, 400 and
600 μg /ml(f)
Negative
* Supporting substances are listed in brackets. NR: Not Reported.
(a): With and without rat and hamster S9 metabolic activation.
No in vivo mutagenicity/genotoxicity data are available for either the candidate substance of the present flavouring group evaluation nor for the supporting
substances evaluated by the JECFA at the 59th and 68th meetings.
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APPENDICES
Appendix A. Procedure for the safety evaluation
The approach for a safety evaluation of chemically defined flavouring substances, as referred to in
Commission Regulation (EC) No 1565/2000 (EC, 2000), named the “Procedure”, is shown in
schematic form in Figure A.1. The Procedure is based on the opinion of the SCF expressed on
2 December 1999 (SCF, 1999), which is derived from the evaluation Procedure developed by JECFA
at its 44th, 46th and 49th meetings (JECFA, 1995, 1996, 1997, 1999).
The Procedure is a stepwise approach that integrates information on intake from current uses,
structure–activity relationships, metabolism and, when needed, toxicity. One of the key elements in
the Procedure is the subdivision of flavourings into three SCs (I, II, III) for which thresholds of
concern (human exposure thresholds) have been specified. Exposures below these thresholds are not
considered to present a safety concern.
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism,
which would suggest a low order of oral toxicity. Class II contains flavourings that have structural
features that are less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that
have structural features that permit no strong initial presumption of safety, or may even suggest
significant toxicity (Cramer et al., 1978). The thresholds of concern for these structural classes of
1 800, 540 or 90 µg/person per day, respectively, are derived from a large database containing data on
subchronic and chronic animal studies (JECFA, 1996).
In Step 1 of the Procedure, the flavourings are assigned to one of the SCs. The further steps address
the following questions:
• Can the flavourings be predicted to be metabolised to innocuous products13 (Step 2)?
• Do their exposures exceed the threshold of concern for the SC (Step A3 and B3)?
• Are the flavourings or their metabolites endogenous14 (Step A4)?
• Does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and
B4)?
In addition to data provided for the flavouring substances to be evaluated (candidate substances),
toxicological background information available for compounds structurally related to the candidate
substances is considered (supporting substances), in order to assure that these data are consistent with
the results obtained after application of the Procedure.
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity.
Therefore, the right is reserved to use alternative approaches if data on specific flavourings warranted
such actions.
13 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the estimated
intakes of the flavouring agent (JECFA, 1997).
14 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or
conjugated; hormones and other substances with biochemical or physiological regulatory functions are not included
(JECFA, 1997).
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Decision tree structural class
Can the substance be predicted to be metabolised to innocuous products?
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances
Do the conditions of use result in an intake greater than the
threshold of concern for the structural class?
Do the conditions of use result in an intake greater than the
threshold of concern for the structural class?
Data must be available on the
substance or closely related
substances to perform a safety
evaluation
Does a NOAEL exist for the substance which provides an adequate
margin of safety under conditions of intended use, or does a NOAEL
exist for s tructurally related substances which is high enough to
accommodate any perceived difference in toxicity between the
substance and the related substances?
Does a NOAEL exist for the substance which provides an adequate
margin of safety under conditions of intended use, or does a NOAEL
exis t for structurally related substances which is high enough to
accommodate any perceived difference in toxicity between the
substance and the related substances?
Substance would not be
expected to be of safety concern
Is the substance or are its metabolites endogenous?
Additional data required
Step 1.
Step 2.
Step A3.
Step A4.
Step A5.
Step B3.
Step B4.
Yes No
Yes
No
No
No
Yes
No
Yes
Yes
Yes
No
Figure A.1: Procedure for safety evaluation of chemically defined flavouring substances
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Appendix B. Use levels/mTAMDI
B.1 Normal and maximum use levels
For each of the 18 food categories (Table B.1.1) in which the candidate substances are used, Flavour
Industry reports a “normal use level” and a “maximum use level” (EC, 2000). According to the
Industry, “normal use” is defined as the average of reported usages and “maximum use” is defined as
the 95th percentile of reported usages (EFFA, 2002). The normal and maximum use levels in different
food categories have been extrapolated from figures derived from 12 model flavouring substances
(EFFA, 2004a).
Table B.1.1: Food categories according to Commission Regulation (EC) No 1565/2000
Food
category
Description
01.0 Dairy products, excluding products of category 02.0
02.0 Fats and oils, and fat emulsions (type water-in-oil)
03.0 Edible ices, including sherbet and sorbet
04.1 Processed fruit
04.2 Processed vegetables (including mushrooms and fungi, roots and tubers, pulses and legumes),
and nuts and seeds
05.0 Confectionery
06.0 Cereals and cereal products, including flours and starches from roots and tubers, pulses and
legumes, excluding bakery
07.0 Bakery wares
08.0 Meat and meat products, including poultry and game
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms
10.0 Eggs and egg products
11.0 Sweeteners, including honey
12.0 Salts, spices, soups, sauces, salads, protein products, etc.
13.0 Foodstuffs intended for particular nutritional uses
14.1 Non-alcoholic (“soft”) beverages, excluding dairy products
14.2 Alcoholic beverages, including alcohol-free and low-alcoholic counterparts
15.0 Ready-to-eat savouries
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat)—foods that could not be placed in
categories 01.0–15.0
The “normal and maximum use levels” are provided by Industry for 39 of 41 candidate substances, for
which use levels have been provided, in the present flavouring group (Table B.1.2).
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Table B.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances FGE.21Rev5 (EFFA, 2004c; EFFA, 2004d; EFFA, 2007; Flavour Industry,
2004-5; Flavour Industry, 2010b).
FL-no Food Categories
Normal use levels (mg/kg)
Maximum use levels (mg/kg)
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0
15.038 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.039 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
-
-
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.040 0,2
1
0,1
0,5
0,2
1
0,2
1
-
-
0,2
1
0,1
0,5
0,2
1
0,1
0,2
0,1
0,2
-
-
-
-
0,1
0,5
0,2
1
0,1
0,5
0,2
1
0,4
2
0,1
0,5
15.044 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.045 0,2
1
0,1
0,5
0,2
1
0,2
1
-
-
0,2
1
0,1
0,5
0,2
1
0,1
0,2
0,1
0,2
-
-
-
-
0,1
0,5
0,2
1
0,1
0,5
0,2
1
0,4
2
0,1
0,5
15.050 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.051 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.052 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.054 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.055 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
0,4
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.058 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,1
0,5
0,4
2
1
5
0,2
1
15.060 0,4
2
0,2
1
0,2
1
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.061 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.062 0,4
2
0,2
1
0,4
2
0,3
1,5
0,4
2
-
-
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
-
-
1
5
0,2
1
15.063 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.067 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.068 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
1
5
0,2
1
0,4
2
-
-
0,2
1
Flavouring Group Evaluation 21 Revision 5
EFSA Journal 2015;13(4):4066 83
Table B.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances FGE.21Rev5 (EFFA, 2004c; EFFA, 2004d; EFFA, 2007; Flavour Industry,
2004-5; Flavour Industry, 2010b).
FL-no Food Categories
Normal use levels (mg/kg)
Maximum use levels (mg/kg)
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0
15.069 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.071 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.074 0,2
1
0,1
0,5
0,2
1
0,2
1
-
-
0,2
1
0,1
0,5
0,2
1
0,1
0,2
0,1
0,2
-
-
-
-
0,1
0,5
0,2
1
0,1
0,5
0,2
1
0,4
2
0,1
0,5
15.076 0,2
1
0,1
0,5
0,2
1
0,2
1
-
-
0,2
1
0,1
0,5
0,2
1
0,1
0,2
0,1
0,2
-
-
-
-
0,1
0,5
0,2
1
0,1
0,5
0,2
1
0,4
2
0,1
0,5
15.078 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.080 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.082 0,2
1
0,1
0,5
0,2
1
0,2
1
-
-
0,2
1
0,1
0,5
0,2
1
0,1
0,2
0,1
0,2
-
-
-
-
0,1
0,5
0,2
1
0,1
0,5
0,2
1
0,4
2
0,1
0,5
15.084 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.085 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.086 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.087 0,2
1
0,1
0,5
0,2
1
0,2
1
-
-
0,2
1
0,1
0,5
0,2
1
0,1
0,2
0,1
0,2
-
-
-
-
0,1
0,5
0,2
1
0,1
0,5
0,2
1
0,4
2
0,1
0,5
15.089 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
-
-
0,4
2
0,2
1
0,2
1
1
5
0,2
1
15.093 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.096 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.097 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.098 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.108 0,2
1
0,1
0,5
0,2
1
0,2
1
-
-
0,2
1
0,1
0,5
0,2
1
0,1
0,2
0,1
0,2
-
-
-
-
0,1
0,5
0,2
1
0,1
0,5
0,2
1
0,4
2
0,2
1
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Table B.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances FGE.21Rev5 (EFFA, 2004c; EFFA, 2004d; EFFA, 2007; Flavour Industry,
2004-5; Flavour Industry, 2010b).
FL-no Food Categories
Normal use levels (mg/kg)
Maximum use levels (mg/kg)
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0
15.115 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.116 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.118 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.119 0,4
2
0,2
1
0,4
2
0,3
1,5
-
-
0,4
2
0,2
1
0,4
2
0,1
0,4
0,1
0,4
-
-
-
-
0,2
1
0,4
2
0,2
1
0,4
2
1
5
0,2
1
15.135 1,5
3
1
2
-
-
0,5
1
0,5
1
-
-
0,5
1
1,5
3
1,5
3
-
-
-
-
-
-
2
12
-
-
-
-
-
-
0,5
1
-
-
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B.2 mTAMDI calculations
The method for calculation of mTAMDI values is based on the approach used by SCF up to 1995
(SCF, 1995). The assumption is that a person may consume the quantities of flavourable foods and
beverages listed in Table B.2.1. These consumption estimates are then multiplied by the reported use
levels in the different food categories and summed up.
Table B.2.1: Estimated quantities of flavourable foods, beverages and exceptions assumed to be
consumed per person per day (SCF, 1995)
Class of product category Intake estimate (grams per day)
Beverages (non-alcoholic) 324.0
Foods 133.4
Exception a: Candy, confectionery 27.0
Exception b: Condiments, seasonings 20.0
Exception c: Alcoholic beverages 20.0
Exception d: Soups, savouries 20.0
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum)
The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as
outlined in Commission Regulation (EC) No 1565/2000 and reported by the Flavour Industry in the
following way (see Table B.2.2):
• Beverages correspond to food category 14.1.
• Foods correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13 and/or 16.
• Exception a corresponds to food category 5 and 11.
• Exception b corresponds to food category 15.
• Exception c corresponds to food category 14.2.
• Exception d corresponds to food category 12.
• Exception e corresponds to others, e.g. chewing gum.
Table B.2.2: Distribution of the 18 food categories listed in Commission Regulation (EC) No
1565/2000 (EC, 2000) into the seven SCF food categories used for TAMDI calculation (SCF, 1995)
Key Food categories according to Commission Regulation
1565/2000
Distribution of the seven SCF food
categories
Food category Food Beverages Exceptions
01.0 Dairy products, excluding products of category 02.0 Food
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food
03.0 Edible ices, including sherbet and sorbet Food
04.1 Processed fruit Food
04.2 Processed vegetables (including mushrooms and fungi,
roots and tubers, pulses and legumes), and nuts and seeds
Food
05.0 Confectionery Exception a
06.0 Cereals and cereal products, including flours and starches
from roots and tubers, pulses and legumes, excluding
bakery
Food
07.0 Bakery wares Food
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Key Food categories according to Commission Regulation
1565/2000
Distribution of the seven SCF food
categories
Food category Food Beverages Exceptions
08.0 Meat and meat products, including poultry and game Food
09.0 Fish and fish products, including molluscs, crustaceans and
echinoderms
Food
10.0 Eggs and egg products Food
11.0 Sweeteners, including honey Exception a
12.0 Salts, spices, soups, sauces, salads, protein products, etc. Exception d
13.0 Foodstuffs intended for particular nutritional uses Food
14.1 Non-alcoholic (“soft”) beverages, excluding dairy products Beverages
14.2 Alcoholic beverages, including alcohol-free and low-
alcoholic counterparts
Exception c
15.0 Ready-to-eat savouries Exception b
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat)—
foods that could not be placed in categories 01.0–15.0
Food
The mTAMDI values (see Table B.2.3) are presented for 41 candidate substances in the present
flavouring group, for which Industry has provided use and use levels (EFFA, 2004c, d, 2007; Flavour
Industry, 2004–5, 2010b). The mTAMDI values are given for only the highest reported normal use
levels (see Table B.2.3). Table B.2.3 also contains the mTAMDI values for the 18 substances no
longer supported by Industry for use as flavouring substances in Europe: [FL-nos: 15.037, 15.042,
15.043, 15.064, 15.070, 15.072, 15.077, 15.088, 15.090, 15.091, 15.092, 15.094, 15.099, 15.106,
15.107, 15.114, 15.129 and 15.133] (DG SANCO, 2012, 2013).
Table B.2.3: Estimated intakes based on the mTAMDI approach
FL-no EU register name mTAMDI
(µg/person per
day)
Structural
class
Threshold of
concern
(µg/person per
day)
15.037 2-Acetyl-3-methylthiophene 78 Class II 540
15.038 2-Acetyl-4-methylthiazole 160 Class II 540
15.039 2-Acetyl-5-methylthiazole 160 Class II 540
15.040 2-Acetylthiophene 78 Class II 540
15.043 2-Butyl-5-ethylthiophene 78 Class II 540
15.044 2-Butylthiazole 160 Class II 540
15.045 2-Butylthiophene 78 Class II 540
15.050 2,5-Diethyl-4-methylthiazole 160 Class II 540
15.051 2,5-Diethyl-4-propylthiazole 160 Class II 540
15.052 2,5-Diethylthiazole 160 Class II 540
15.058 4,5-Dimethyl-2-ethylthiazole 130 Class II 540
15.061 2,5-Dimethyl-4-ethylthiazole 160 Class II 540
15.062 2,4-Dimethylthiazole 140 Class II 540
15.063 2,5-Dimethylthiazole 160 Class II 540
15.064 2,5-Dimethylthiophene 78 Class II 540
15.067 4-Ethyl-2-methylthiazole 160 Class II 540
15.068 5-Ethyl-2-methylthiazole 220 Class II 540
15.069 4-Ethyl-5-methylthiazole 160 Class II 540
15.070 2-Ethyl-5-methylthiophene 78 Class II 540
15.071 2-Ethylthiazole 160 Class II 540
15.072 2-Ethylthiophene 78 Class II 540
15.074 5-Ethylthiophene-2-carbaldehyde 78 Class II 540
15.076 2-Hexylthiophene 78 Class II 540
15.078 2-Isobutyl-4,5-dimethylthiazole 160 Class II 540
15.080 2-Isopropyl-4,5-dimethylthiazole 160 Class II 540
Flavouring Group Evaluation 21 Revision 5
EFSA Journal 2015;13(4):4066 87
FL-no EU register name mTAMDI
(µg/person per
day)
Structural
class
Threshold of
concern
(µg/person per
day)
15.084 5-Methyl-2-pentylthiazole 160 Class II 540
15.085 4-Methyl-2-propionylthiazole 160 Class II 540
15.086 2-Methyl-2-thiazoline 160 Class II 540
15.089 2-Methylthiazole 150 Class II 540
15.091 2-Methylthiophene 78 Class II 540
15.092 3-Methylthiophene 78 Class II 540
15.093 2-Octylthiophene 160 Class II 540
15.094 2-Pentanoylthiophene 160 Class II 540
15.096 2-Pentylthiophene 160 Class II 540
15.097 2-Propionylthiophene 160 Class II 540
15.098 2-Propylthiazole 160 Class II 540
15.107 Thiophene-2-carbaldehyde 78 Class II 540
15.115 2-Isobutyl-4-methyl thiazole 160 Class II 540
15.116 2-Acetyl-4-ethylthiazole 160 Class II 540
15.118 4-Butylthiazole 160 Class II 540
15.129 Tetrahydro-2,4,6-trimethyl-1,3,5(2H)-
thiadiazine
4 000 Class II 540
15.060 2,4-Dimethyl-3-thiazoline 160 Class II 540
15.090 2-Methylthiazolidine 160 Class II 540
15.099 2-Propylthiazolidine 160 Class II 540
15.119 2-Isobutyl-3-thiazoline 160 Class II 540
15.042 2-Butyl-4-methyl(4H)pyrrolidino[1,2d]–
1,3,5-dithiazine
160 Class III 90
15.054 Dihydro-2,4,6-triethyl-1,3,5(4H)-
dithiazine
160 Class III 90
15.055 [2S-(2a,4a,8ab)] 2,4-
Dimethyl(4H)pyrrolidino[1,2e]-1,3,5-
dithiazine
160 Class III 90
15.057 4,6-Dimethyl-2-(1-methylethyl)dihydro-
1,3,5-dithiazine
Class III 90
15.077 4-Hydroxy-2,5-dimethylthiophen-3(2H)-
one
78 Class III 90
15.079 2-Isobutyldihydro-4,6-dimethyl-1,3,5-
dithiazine
Class III 90
15.082 3-Mercaptothiophene 78 Class III 90
15.087 2-Methyl-3-mercaptothiophene 78 Class III 90
15.088 2-Methyl-4,5-benzothiazole 160 Class III 90
15.106 Thiophene 78 Class III 90
15.108 2-Thiophenemethanethiol 78 Class III 90
15.135 Ethyl thialdine 250 Class III 90
15.114 6-Acetyl-2,3-dihydro-1,4-thiazine 160 Class III 90
15.133 5-Acetyl-2,3-dihydro-1,4-thiazine 4 000 Class III 90
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Appendix C. Metabolism
C.1 Introduction
The candidate substances in this FGE are structurally related to the 28 flavouring substances evaluated
in “Safety Evaluations of Groups of Related Flavouring Agents: Sulfur-Containing Heterocyclic
Compounds” (JECFA, 2002a, 2003, 2007, 2008).
The candidate substances from EU chemical groups 29 and 30 in this FGE include five- and six-
membered sulphur-containing aromatic and non-aromatic heterocycles, which in the previous versions
of FGE.21 have been arranged into nine subgroups in order to facilitate comparisons of the datasets
between the groups. This division was done on the basis of degree of aromaticity and according to the
presence of other heteroatoms (i.e. nitrogen). Subgroup A-I has been further divided into three
subgroups: A-Ia (thiophene), A-Ib (thiophenes with alkyl, acyl or carbaldehyde ring substituents) and
A-Ic (thiophenes with thiol-containing ring substituents). Therefore, a total of 11 subgroups. In this
revision 4, FGE.21Rev5, 18 substances are no longer supported by Industry for the use as flavouring
substances and have accordingly been deleted from the text unless the information is considered
relevant for the remaining substances. This means that the following subgroups are no longer
considered: A-Ia, A-III, B-I, B-III, B-V and B-VI.
The substances and subgroups are presented in Table C.1.
Table C.1 Division of candidate and supporting substances into structurally related subgroups –
supporting substances are listed in brackets
FL-no EU Register name Structural formula
A-Ia Thiophene - The substance previously allocated to the group is no longer supported for use as flavouring
substance in Europe by Industry
A-Ib Thiophenes (with non-thiol-containing ring substituents)
(15.004) (5-Methyl-2-thiophenecarbaldehyde)
15.040 2-Acetylthiophene
15.045 2-Butylthiophene
15.074 5-Ethylthiophene-2-carbaldehyde
15.076 2-Hexylthiophene
15.093 2-Octylthiophene
15.096 2-Pentylthiophene
15.097 2-Propionylthiophene
A-Ic Thiophenes (with thiol-containing ring substituents)
(15.001) (2-Mercaptothiophene)
S
O
S
O
S
S
O
S
S
S
S
O
S SH
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Table C.1 Division of candidate and supporting substances into structurally related subgroups –
supporting substances are listed in brackets
FL-no EU Register name Structural formula
(15.008) (2-Thienyl disulfide)
15.082 3-Mercaptothiophene
15.087 2-Methyl-3-mercaptothiophene
15.108 2-Thiophenemethanethiol
A-II Thiazoles
(15.002) (2-Methyl-5-methoxythiazole)
(15.005) (2,4-Dimethyl-5-vinylthiazole)
(15.011) (5-Acetyl-2,4-dimethylthiazole)
(15.013) (2-Isobutylthiazole)
(15.014) (5-(2-Hydroxyethyl)-4-methylthiazole)
(15.015) (4-Methyl-5-(2-acetoxyethyl)thiazole)
(15.017) (4,5-Dimethylthiazole)
(15.018) (4-Methyl-5-vinylthiazole)
(15.019) (2,4,5-Trimethylthiazole)
(15.020) (2-Acetylthiazole)
(15.021) (2-Ethoxythiazole)
(15.022) (2-(sec-Butyl)thiazole)
S S
S
S
S
SH
S
SH
S
SH
N
SO
N
S
N
S
O
N
S
N
SHO
N
SO
O
N
S
N
S
N
S
N
S
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Table C.1 Division of candidate and supporting substances into structurally related subgroups –
supporting substances are listed in brackets
FL-no EU Register name Structural formula
(15.026) (2-Isopropyl-4-methylthiazole)
(15.027) (2-Propionylthiazole)
(15.033) (2-Ethyl 4-methylthiazole)
(15.035) (4-Methylthiazole)
15.038 2-Acetyl-4-methylthiazole
15.039 2-Acetyl-5-methylthiazole
15.044 2-Butylthiazole
15.050 2,5-Diethyl-4-methylthiazole
15.051 2,5-Diethyl-4-propylthiazole
15.052 2,5-Diethylthiazole
15.058 4,5-Dimethyl-2-ethylthiazole
15.061 2,5-Dimethyl-4-ethylthiazole
15.062 2,4-Dimethylthiazole
15.063 2,5-Dimethylthiazole
15.067 4-Ethyl-2-methylthiazole
15.068 5-Ethyl-2-methylthiazole
N
S
N
S
O
N
S
N
S
N
S
O
N
S
O
N
S
N
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N
S
N
S
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Table C.1 Division of candidate and supporting substances into structurally related subgroups –
supporting substances are listed in brackets
FL-no EU Register name Structural formula
15.069 4-Ethyl-5-methylthiazole
15.071 2-Ethylthiazole
15.078 2-Isobutyl-4,5-dimethylthiazole
15.080 2-Isopropyl-4,5-dimethylthiazole
15.084 5-Methyl-2-pentylthiazole
15.085 4-Methyl-2-propionylthiazole
15.089 2-Methylthiazole
15.098 2-Propylthiazole
15.115 2-Isobutyl-4-methylthiazole
15.116 2-Acetyl-4-ethylthiazole
15.118 4-Butylthiazole
(16.027) (Thiamine hydrochloride)
A-III Benzothiazoles - The substance previously allocated to the group is no longer supported for use as
flavouring substance in Europe by Industry
B-I Dihydrothiophenes - The substance previously allocated to the group is no longer supported for use as
flavouring substance in Europe by Industry
B-II Thiazolines
(15.010) 2-Acetyl-2-thiazoline
N
S
N
S
N
S
N
S
N
S
N
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Table C.1 Division of candidate and supporting substances into structurally related subgroups –
supporting substances are listed in brackets
FL-no EU Register name Structural formula
(15.029) (2-(sec-Butyl)-4,5-dimethyl-3-thiazoline)
(15.030) (4,5-Dimethyl-2-ethyl-3-thiazoline)
(15.032) (4,5-Dimethyl-2-isobutyl-3-thiazoline)
15.060 2,4-Dimethyl-3-thiazoline
15.086 2-Methyl-2-thiazoline
15.119 2-Isobutyl-3-thiazoline
B-III Thiazolidines - The substances previously allocated to the group are no longer supported for use as
flavouring substances in Europe by Industry
B-IV Dithiazines
15.054 Dihydro-2,4,6-triethyl-1,3,5(4H)-dithiazine
15.055 [2S-(2a,4a,8ab)] 2,4-
Dimethyl(4H)pyrrolidino[1,2e]-1,3,5-dithiazine
15.057 4,6-Dimethyl-2-(1-methylethyl)dihydro-1,3,5-
dithiazine
15.079 2-Isobutyldihydro-4,6-dimethyl-1,3,5-dithiazine
(15.109) (2,4,6-Trimethyldihydro-1,3,5(4H)-dithiazine)
(15.113) (5,6-Dihydro-2,4,6,tris(2-methylpropyl)-4H-1,3,5-
dithiazine)
N
S
N
S
N
S
N
S
N
S
N
S
S NH
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S
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Table C.1 Division of candidate and supporting substances into structurally related subgroups –
supporting substances are listed in brackets
FL-no EU Register name Structural formula
15.135 Ethyl thialdine
(Not in EU Register) (2-Isobutyl-4,6-dimethyldihydro-1,3,5-dithiazine
and 4-isobutyl-2,6-dimethyldihydro-1,3,5-
dithiazine (mixture))
(Not in EU Register) (2-Isopropyl-4,6-dimethyl 2,6-dimethyldihydro-
1,3,5-dithiazine and 4-isopropyl-2,6-
dimethyldihydro-1,3,5-dithiazine (mixture))
B-V Dihydrothiazines - The substances previously allocated to the group are no longer supported for use as
flavouring substances in Europe by Industry
B-VI Thiadiazines - The substance previously allocated to the group is no longer supported for use as flavouring
substance in Europe by Industry
S
N
H
S
S NH
S
S NH
S
(Mixture)
S NH
S
S NH
S
(Mixture)
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The following is a description of the characteristic features of the subgroups:
A Aromatic group
Subgroup A-I: Thiophenes (10 candidate substances and three supporting substances). Aromatic
heterocyclic five-membered ring substances with a sulphur atom at ring position 1. This group is
further divided into subgroups: A-Ib with seven ring-substituted thiophenes, which have one or more
alkyl, acyl or carbaldehyde substituents to the ring, and subgroup A-Ic with three ring-substituted
thiophenes, which have a free thiol group in their ring-substituent group (subgroup A-Ia no longer
supported).
Subgroup A-II: Thiazoles (23 candidate substances and 17 supporting substances). Five-membered
aromatic heterocycles containing one sulphur and one nitrogen atom in the 1- and 3-ring positions,
respectively. To this heterocyclic ring one or more alkyl- or acyl- substituents may be attached.
B Non-aromatic group
Subgroup B-II: Thiazolines (three candidate substances and four supporting substances). Five-
membered heterocycles containing a sulphur and a nitrogen atom in the 1- and 3-ring positions,
respectively. In the ring, one double bond is present (in contrast to the thiazoles, which have two
double bonds (aromatic)).
Subgroup B-IV: Dithiazines (five candidate substances and four supporting substances). Six-
membered non-aromatic heterocycles containing two sulphur atoms and one nitrogen atom with
various ring substituents, including a fused second ring in one of these.
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C.2 Absorption, distribution and elimination
Only limited data were submitted for the evaluation of the absorption, distribution and elimination of
the candidate flavouring substances in this group. The absorption and elimination were studied for
thiophene15 [former FL-no: 15.106]. Data were also submitted for a few, more or less, related
substances. Because the information is so fragmentary, it is not useful to present it (sub)group-wise. In
addition, some of the studies are related to oral exposure and some others to parenteral dosing, and the
relevance of the latter may be limited.
Single doses of 33 mg/kg bw [2,5-14C]-thiophene were administered to mice via oral and rectal
intubation. At 48 hours after the oral gavage dose, 78 % of the radioactivity was found in the urine,
while 5 % was found in both faeces and expired air. At 24 hours after the rectal dose, 43 % was found
in the urine, but 40 % was found in the expired air. The difference in the elimination pattern after oral
vs. rectal administration was attributed to an extensive first-pass effect after the oral dose. In addition,
the oral dose resulted in liver radioactivity levels 10 times higher than the rectal dose. With thin-layer
chromatography two urinary metabolites were observed. However, neither these metabolites nor the
radioactivity in tissues or excreta were further identified (Chanal et al., 1974).
Female rats (200–250 g) and rabbits (2–3 kg) were administered thiophene as single oral gavage doses
of 60 mg and 450 mg, respectively. Urine was collected over a 24-hour period following dosing. Table
C.2 provides a summary of the quantitative determinations of metabolites in this study.
Table C.2: Summary of excretion of metabolites of thiophene in rabbits and rats
Metabolites Rabbit (N = 6) Rat (N = 3)
(Pre)-mercapturic acids in urine 38 (32–49) 40 (36–45)
Free thiophene expired Not determined 32 (29–35)
Free thiophene in faeces Not determined 0.48 (0.25–0.68)
Tabulated data are percentage of administered dose (%)
Other urinary metabolites, in particular conjugates of 2-hydroxy- or 3-hydroxythiophene, but no acid-
hydrolysable products of thiophene or free thiophene were found (Bray et al., 1971).
When male Sprague–Dawley rats were injected intraperitoneally with a 200 mg/kg bw dose of tritiated
(at C2 and C5 positions) thiophene in maize oil, approximately 31 % of the radioactivity was excreted
between 0 and 15 hours, while 4 % of the radioactivity was excreted between 15 and 50 hours. More
than 94 % of the urinary radioactivity was accounted for by a single metabolite, the 2-mercapturic acid
derivative of 1,4-dihydrothiophene-S-oxide (Dansette et al., 1992).
In rats, a single subcutaneous dose of 35S-thiophene was rapidly absorbed into the bloodstream.
Thiophene produced a peak blood concentration within 30 minutes and peak levels in the brain within
three hours. Radioactivity was excreted in the urine at 61.1 % of the dose within 34 hours and 74.4 %
of the dose within three days (Bikbulatov and Nigmatullina, 1976; O’Donoghue, 2000).
15 Structural formula:
S
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Non-candidate substances
In two male Sprague–Dawley rats, approximately 20 % of the radioactivity of an intraperitoneal
injection of 30 mg/kg bw of the 3-aroylthiophene (tienilic acid isomer 1)16 (14C at the keto position) is
recovered in the urine within 24 hours. Approximately 15 % of urinary radioactivity could be
accounted for as a mixture of two diastereoisomers of the mercapturic acid conjugate of the 3-aroyl-
4,5-dihydrothiophene. The study was designed to identify these two metabolites. The rest of the
urinary radioactivity was identified as parent substance (ca. 17 % of the dose) and an unidentified
metabolite (ca. 1 % of the dose), presumably a derivative of one or both of the already identified
mercapturates (Valadon et al., 1996).
When the benzothiazole derivative fostedil17 was administered to dogs via intravenous infusion or
orally as a solution, a suspension or as an encapsulated substance, mean relative bioavailabilities for
the parent substance after oral dosing could be calculated as 71, 64 or 42 %, respectively. The
substance was cleared from the plasma with a terminal half-life of 6–9 hours and, based on high
biliary excretion, enterohepatic circulation has been suggested. When the substance was administered
with a radiolabel (no further details) 80 % of the radioactivity was found in the faeces (Thomas, 1984;
Thomas and Bopp, 1984).
In a previous FGE.24Rev1 (EFSA, 2008), data on the absorption and elimination of indole18 have been
discussed. As this substance bears some resemblance to the benzothiazoles in subgroup A-III, these
data are also briefly mentioned here. After oral dosing of 2-14C-indole to rats, 62–82 % of the
administered radioactivity was excreted via urine or expired air within 48–72 hours post dosing.
The substances in subgroup B-IV (the dithiazines with FL-no: 15.054, 15.055, 15.057, 15.079 and
15.135) may be regarded as cyclic thioacetals, which could be subject to acid hydrolysis in the
stomach, similar to oxygen-containing acetals. However, thioacetals are more resistant to hydrolysis
than oxygen acetals. In addition, chances of hydrolysis would be reduced even more by their cyclic
character (Smith and March, 2001; EFSA CEF Panel, 2011c). It is thus anticipated that these
substances may be expected to reach the intestinal lumen intact and may also be absorbed as such.
C.3 Metabolism
In the sections below, the available metabolism data have been presented according to the division
into subgroups of the candidate flavouring substances in this FGE.
16 Structure of 3-aroylthiophene (isomer of tienilic acid (2-aroylthiophene)):
S
O
Cl Cl
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17 Structure of fostedil:
18 Structure of indole:
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Aromatic candidate substances
Subgroup A-Ib: Thiophenes with non-thiol-containing ring substituents
(Candidate substances [FL-no: 15.040, 15.045, 15.074, 15.076, 15.093, 15.096 and 15.097])
Data on the structurally related substance thiophene
Thiophene former [FL-no: 15.106] was administered to female rats (200–250 g) and rabbits (2–3 kg)
as single oral gavage doses of 60 mg and 450 mg, respectively. Urine was collected over a 24-hour
period following dosing. The predominant metabolites excreted in the urine were a mercapturic acid
and a premercapturic acid, which, according to the authors, could result from the conjugation of
glutathione with an intermediate 2,3-thiophene-epoxide. 2-Thienylmercapturic acid was excreted in
relatively small quantities and 3-hydroxy-2,3-dihydro-2-thienyl-mercapturic acid was the major
metabolite excreted in urine. The metabolites were identified by IR spectroscopy, gas–liquid
chromatography (GLC) and MS techniques, and further by characteristic chemical reactions of
thiophene derivatives (desulphuration following treatment of the premercapturic acid with Raney
nickel resulting in the formation of 2-butanol) (Bray et al., 1971).
More recently, male Wistar rats (190–400 g) were injected intraperitoneally with 0.2 mmol (≈ 17 mg) 
thiophene in peanut oil, and mercapturic acids were not found to be important thioethers (i.e.
comprising not more than about 1 % of the dose) excreted in the urine (Hickman et al., 1992), contrary
to the results of Bray et al. (1971). It is noted that 2-thienyl mercapturic acid was also identified as a
less important metabolite by Bray et al. (1971) and that the two studies differ in route of
administration. The oral route of administration (Bray et al., 1971) results in higher metabolic
conversion than the intraperitoneal one (Hickman et al., 1992). In addition, identification of thioethers
by Hickman et al. (1992) was carried out only by reaction with Ellman’s reagent following extraction
and hydrolysis of the urine samples. No attempts were made to identify any other thiophene
metabolite in urine samples.
When male Sprague–Dawley rats were injected (intraperitoneal) with 200 mg/kg bw [2,5-3H]-labelled
thiophene, more than 94 % of the urinary radioactivity was accounted for by the 2-mercapturic acid
derivative of 2,5-dihydrothiophene-S-oxide, as identified by NMR, IR and mass spectroscopical
techniques. A small second peak in the high-performance liquid chromatography (HPLC) diagram of
the urine radioactivity was also observed, but this peak was not further studied. The authors concluded
that its formation occurred by S-oxidation yielding the very reactive thiophene sulphoxide, which
undergoes Michael-type addition of glutathione at the 2-position. In subsequent reactions, the
glutathione moiety of this metabolite is converted into an N-acetyl cysteine group. The final
metabolite is subsequently excreted via urine, and may be converted spontaneously into 2-thienyl-
mercapturic acid (Dansette et al., 1992). The authors considered the formation of the epoxide
intermediate, as suggested by Bray et al. (1971), highly unlikely.
Based on subsequent studies with chemically defined reaction mixtures and with microsomal
incubations, the formation of the 2,5-dihydrothiophene-S-oxide was further substantiated by the
formation of two diastereoisomeric thiophene S-oxide dimers (3a,4,7,7a-tetrahydro-4,7epithio-
benzo[b]thiophene 1,8 dioxide) one of which (the 1-syn,-8-syn,endo-isomer) was suggested having
been observed in the in vivo studies by Dansette et al. (ca. 10 % of urinary radioactivity, comprising
2 % of the oral dose in the above study; the unidentified second peak (see above)). The formation of
the dimers may result from a Diels−Alder reaction. Thus, the metabolic fate for the thiophene S-oxide
in vivo involves, predominantly, reaction with nucleophiles such as glutathione (catalysed by
glutathione S-transferase) leading eventually to mercapturate derivatives that are excreted in the urine,
or to a lesser extent it involves dimerisation and the resulting dimer is also excreted via the urine
(Treiber et al., 1997).
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Non-candidate substances
In two male Sprague–Dawley rats injected intraperitoneally with the 3-aroylthiophene tienilic acid
isomer 1 (see above), 15 % of urinary radioactivity (≈ 2 % of the dose) could be accounted for as a 
mixture of two diastereoisomers of the mercapturic acid conjugate of 3-aroyl-4,5-dihydrothiophene. In
the ultimate urinary metabolite, the N-acetylcysteine residue (mercapturate) is found in the 4-position
of the thiophene ring. This residue may be introduced at that position after initial Michael-type
addition of glutathione to the primary thiophene sulphoxide metabolite (see Figure C.1) at ring
position 2 (i.e. the C next to the S atom) and several rearrangements, including ring opening/closing
and reaction with second glutathione molecules. Results of in vitro experiments with rat liver
microsomes indicate that the thiophene sulphoxide is a reactive intermediate in the conversion of the
3-aroylthiophene to the dihydromercapturic acid metabolite (Valadon et al., 1996).
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Figure C.1: Proposed metabolism of 3-alkylthiophenes
Oxidation of 2-phenylthiophene by rat liver microsomes, in the presence of nicotinamide adenine
dinucleotide phosphate, reduced form, (NADPH) and glutathione involves two initial reactions,
resulting in three subsequent types of metabolites. The first reaction involves S-oxidation to yield 2-
phenylthiopene S-oxide that then dimerises by Diels–Alder-type reaction of the S-oxide. Alternatively,
the S-oxide may form a glutathione adduct via a 1,4-Michaël-type addition of glutathione to the C5
position of 2-phenylthiopene S-oxide. The second metabolic reaction involves formation of a 2-
phenylthiophene-4,5-epoxide, which may be subject to subsequent conjugation with glutathione at C4
of the thiophene ring. Subsequent dehydration of the resulting hydroxyl–glutathione conjugate yields
the corresponding glutathione conjugate of phenylthiophene, which is excreted mainly as the 2-
mercapturic derivative. Oxidation of 2-phenylthiophene by recombinant, human cytochrome P450
1A1, in the presence of NADPH and glutathione, also led to these metabolites. These results provide
the evidence that cytochrome P450 (1A1) may catalyse the oxidation of thiophene compounds with
the simultaneous formation of two reactive intermediates, a thiophene-S-oxide and a thiophene
epoxide (Dansette et al., 2005).
The addition of alkyl substituents can result in a significant change in metabolism. Biotransformation
of a thiophene derivative was studied in six healthy male volunteers after administration of a single
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oral dose of 12.5 mg olanzapine19. Mean radiocarbon recovery was 87 %, with 30 % appearing in the
faeces and 57 % excreted in the urine. In addition to other metabolites, the methyl substituent on the
thiophene ring underwent oxidation to the corresponding 2-hydroxymethyl and 2-carboxylic acid
derivatives. There was no evidence for glutathione conjugation of the thiophene S-oxide or
epoxidation of the thiophene ring double bond for alkyl-substituted thiophenes (Kassahun et al.,
1997). However, the total recovery and identification of metabolites in urine or faeces was far from
complete and some metabolites may have been missed in the analysis. In addition, alternative
reactions to S-oxidation (e.g. N-oxidation or N-glucuronidation) may greatly reduce the relevance of
the S-oxidation in this substance as than more simple alkyl-substituted thiophenes.
Subgroup A-Ic: Thiophenes with a thiol group in the ring substituent
Candidate substances [FL-no: 15.082, 15.087 and 15.108]
There is no specific information on any of the candidate substances in this subgroup, or on structurally
related thiophene derivatives. It may be anticipated that some of the metabolic conversions described
above for subgroups A-Ia and A-Ib may also apply to this subgroup.
In addition, the mercapto-group (thiol) in the ring-substituent chain may undergo S-methylation to
produce the corresponding methyl thioether or sulphide, with further oxidation to the corresponding
sulphoxide and sulphone. They may also react with glutathione or other endogenous thiol substances
to form mixed disulphides, which may undergo reduction to thiols or oxidative desulphuration.
Alternatively, they may undergo enzymatic oxygenation resulting in the formation of the
corresponding sulphinic or sulphonic acid. All these metabolites are expected to be excreted in the
urine. A more detailed discussion on the metabolism of sulphur compounds may be found in another
EFSA CEF opinion on other sulphur-containing flavouring substances (EFSA CEF Panel, 2011b).
Additional considerations for the candidate substances in subgroup A-I
No information was submitted that would indicate whether side chain oxidation of the alkyl-
substituted thiophenes or keto-reduction of the acyl-substituted thiophenes could occur. Such reactions
may be anticipated (e.g. omega or omega-1 oxidations). Similar reactions have been discussed for
alkylated pyrazines and furan in previous opinions (EFSA CEF Panel, 2011a, b). In addition, the
aldehyde candidate substance, 5-ethylthiophene-2-carbaldehyde [FL-no: 15.074] may be expected to
be oxidised to the corresponding carboxylic acid. Where applicable, conjugation with amino acids
(e.g. glycine) or glucuronic acid may also be expected to occur (EFSA, 2009; EFSA CEF Panel,
2011a, b).
Rance (1989) has indicated that unsubstituted thiophene may be subject to S-oxidation and ring
substitution. It was stated that S-oxides of thiophene are highly reactive. In this review several studies
have been quoted with C2 substituted thiophene derivatives (in particular the pharmaceuticals tienilic
acid, morantel and pyrantel) for which it was demonstrated that ring C5 hydroxylation of these
substituted thiophenes may occur to a considerable extent. In contrast C2, C5 bisubstituted thiophenes
are less susceptible to ring hydroxylation (Rance, 1989).
19 Structure of olanzapine; the radioactive carbons are indicated with *.
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Subgroup A-II: Thiazoles
Candidate substances [FL-no: 15.038, 15.039, 15.044, 15.050, 15.051, 15.052, 15.058, 15.061,
15.062, 15.063, 15.067, 15.068, 15.069, 15.071, 15.078, 15.080, 15.084, 15.085, 15.089, 15.098,
15.115, 15.116 and 15.118]
No specific information was available for any of the candidate substances in this subgroup.
Non-candidate substances
Thiamine hydrochloride [FL-no: 16.027] and 5-(2-hydroxyethyl)-4-methylthiazole [FL-no: 15.014]
Thiamine (see Figure C.2) is excreted in the urine as an unchanged substance but also in the form of
25–30 metabolites, some of which still contain the pyrimidine moiety, while other metabolites are
generated as a result of molecular cleavage.
In fish and microorganisms, breakdown of thiamine is catalysed by two enzymes, namely thiaminase I
and thiaminase II (Tanphaichitr, 1976; Tietz, 1986). Based on comparative studies in which rodents
were given thiamine intravenously or orally, it has been demonstrated that, in the gastro-intestinal
tract, thiamine may already be split into a pyrimidine and a thiazole derivative, namely 5-(2-
hydroxyethyl)-4-methylthiazole, which together with its oxidation product (4-methylthiazole-5-acetic
acid) and parent thiamine have been identified in urine. The fate of the pyrimidine derivative will not
be further discussed. The relevance of the intraintestinal cleavage may be different among various
animal species (Informatics Inc., 1974).
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Figure C.2: Metabolism of thiamine and 5-(2-hydroxyethyl)-4-methylthiazole
Chlormethiazole
The therapeutic agent chlormethiazole (5-(2-chloroethyl)-4-methylthiazole; see Figure C.3), is an
alkyl- and chloroalkyl-substituted thiazole derivative that is metabolised by C-oxidation of the alkyl-
and chloroalkyl-substituents and by S- and N-oxidation. In human males, a 1 000 mg oral dose of
chlormethiazole is metabolised via side chain C-oxidation of the ethyl C1-position to yield 5-(1-
hydroxyethyl)-4-methylthiazole, 5-acetyl-4-methylthiazole, 5-(1-hydroxy-2-chloroethyl)-4-methyl-
thiazole, 4,5-dimethylthiazole and 4-methylthiazole-5-acetic acid, which is the major C-oxidation
urinary metabolite (see Figure C.3). Presumably, the 5-methyl derivative is formed via
decarboxylation of the 5-acetic acid metabolite. In addition, oxidation of the methyl group at C4 in 5-
(2-hydroxyethyl)-4-methylthiazole yields 5-(2-hydroxyethyl)-4-thiazolecarboxylic acid lactone.
Separate ring sulphoxide and ring N-oxide products were not identified, but a combined ring S- and N-
oxide of a side chain-oxidised metabolite was also eliminated in the 12-hour urine of volunteers. This
was the first reported example of a sulphoxidation of a thiazole sulphur and simultaneous oxidation of
two different heteroatoms in the same heteroaromatic ring in vivo (Offen et al., 1985).
Moore et al. (1975) reported the excretion of urinary metabolites of chlormethiazole after oral
administration of this anticonvulsant drug (in the form of its unstable chlormethiazole
ethanedisulphonate derivative) to humans. The substance was given in capsules to three volunteers
(sex not reported) at the total dose of 768 mg. Urinary samples were collected for up to 36 hours post-
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dosing and processed for the identification and quantification of metabolites by gas chromatography–
mass spectrometry (GC–MS) techniques. Results of urinalysis were compared with results obtained
using reference substances. After oral administration, about 16 % of the dose could be identified in the
36-hour urine as four substances: parent chlormethiaziole (< 0.01 % of the dose), 5-acetyl-4-
methylthiazole, 5-(1-hydroxyethyl)-4-methylthiazole (free and as unspecified conjugate) and 4-
methylthiazole-5-acetic acid (> 75 % of all metabolites identified). 5-(2-Hydroxyethyl)-4-
methylthiazole was found in only trace amounts. In addition, a metabolite was tentatively identified as
4-methyl-5-thiazole-acetaldehyde. The authors noted that at that time 80 % of the dose was still
unaccounted for, which might indicate extensive metabolism of the substance in humans (Moore et al.,
1975).
It has also been reported that chlormethiazole undergoes nucleophilic attack at C2, which would
ultimately result in ring opening. The exact mechanism for the formation of ring-opening products has
not been well-described/identified, but the products are nonetheless found in human urine. It was
suggested that N-oxidation followed by glutathione conjugation and subsequent glutathione
breakdown would yield the 2-thiomethyl derivative of chlormethiazole, whereas hydroxide ion attack
would yield 2,4-pentanedione-3-thiol and thiodiacetic acid. The authors suggest that the N-oxidation
would make the C2 prone to nucleophilic attack (Grupe and Spiteller, 1982; Pal and Spiteller, 1982).
According to data from Grupe and Spiteller (1982), urinary excretion of thiodiacetic acid may
comprise up to about 5 % of the dose of chlormethiazole in humans. For the other metabolites (see
Figure C.3) no quantitative data were provided.
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Figure C.3: Metabolism of chlormethiazole
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Herbertz et al. (1973) studied the metabolism of (2-14C)-chlormethiazole-ethane disulphonate in
isolated recycling-perfused rat liver. After two hours, 35 % of the system’s radioactivity was found in
the bile, which was associated with a polar metabolite not observed in previous in vivo studies in
urine. This metabolite was identified as a mixture of N,4-dimethyl-thiazole-5-acetic acid, 2-hydroxy-
N,4-dimethyl-thiazole-5-acetic acid and the glycine conjugate of the latter. Other substances in the
perfusate were chlormethiazole, 2-hydroxy-4-methyl-5-(2-chloroethyl)thiazole, 4-methyl-5-(2-
hydroxyethyl)thiazole, 4-methylthiazole-5-acetic acid, 2-hydroxy-4-methyl-thiazole-5-acetic acid and
its glycine conjugate (Herbertz et al., 1973).
In vivo, the urine was identified as the primary route of elimination (70 % of the dose within three
hours in a study by Allgen et al. (1963) (cited by Herbertz et al., 1973)), with no formation of N-
methylated products. Hence, it was speculated that in vivo enterohepatic recycling of chlormethiazole
metabolites would occur, in particular of the N-methylated substances, which would be de-methylated
in the gastro-intestinal tract and subsequently be excreted via the kidneys. It was noted that the
difference between the observations in vivo and the perfused system may have occurred because of the
build-up of (secondary) metabolite levels in the (closed) perfused system (Herbertz et al., 1973).
Mizutani et al. (1993) investigated the relationship between the toxicological profile of several
thiazole derivatives and the toxicity of the ring cleavage products, in particular the thioamide
metabolites (see Figure C.4). The various thiazoles were nephrotoxic in vivo in glutathione-depleted
mice, which toxicity decreased upon substitution at the ring 4 and 5 carbons. The larger the
substituents, the less nephrotoxic the substances appeared to be. In addition to being nephrotoxic,
some of the thiazoles studied were also hepatotoxic. In the ring C4- and C5-substituted derivatives,
ring substitution at the 2 position carbon (the one between the sulphur and the nitrogen atoms)
markedly reduced nephrotoxicity, but hepatotoxicity was maintained, except when the substituted was
a hydroxyl group (e.g. 2-hydroxy-4-methylthiazole). It was also demonstrated that thioformamide was
both nephrotoxic and hepatotoxic, but only in glutathione-depleted animals. Thioamides from ring C2-
substituted thiazoles appeared to be only hepatotoxic, both after glutathione-depletion and in normal
animals, although in the normal animals the hepatotoxicity was less pronounced (Mizutani et al.,
1993). Thus, the toxicity appears to be associated with glutathione-depletion, which is a high-dose
phenomenon.
In additional studies, again with mice, administration of another non-flavouring thiazole derivative
with known hepatotoxic and nephrotoxic properties, 4-t-butyl-2-methylthiazole, at a dose of
312 mg/kg bw by gavage, resulted in limited ring C-oxidation. Only 0.25 % of the administered dose
was recovered as a ring fragmentation product (3,3-dimethyl-2-oxobutanal; an alpha-dicarbonyl
metabolite) in the urine within 24 hours. In addition, a thioamide metabolite (thioacetamide) was
found; but this was not quantified. Other metabolites were not studied. Based on the structure of the
dicarbonyl fragment, it was postulated that the 4,5-double bond of the thiazole ring undergoes
epoxidation followed by hydrolysis to yield 4,5-diol. The diol then undergoes hydrolytic cleavage to
yield the corresponding carbonyl derivatives and thioacetamide. Similar, thiazole ring opening has
also been observed with thiabendazole (= 2-(thiazol-4-yl)benzimidazole) and with 2-(p-
methoxyphenyl)-4-methylthiazole (Mizutani et al., 1994).
Additional information for candidate substances in subgroup A-II
In an extensive review on the metabolism of heterocyclic substances, Rance (1989) indicated that
several alternative metabolic pathways are available to thiazoles. One involves S-oxidation to form the
corresponding sulphoxide and sulphone. Electrophilic attack at the ring N (resulting in quaternisation,
e.g. N-methylation) is stated to be even more preferential than S-oxidation. The C2 carbon atom is
electron deficient and substituents at this position are reactive and subject to nucleophilic
displacement, in particular if the ring nitrogen is quaternised. Another pathway involves electrophilic
attack at ring carbons, preferably C5. The C5 hydroxythiazoles exist as two tautomeric forms. C5-
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hydroxylation, however, is quantitatively unimportant because thiazoles do not readily undergo
electrophilic substitution reactions (Rance, 1989).
Alkyl- and acyl-substituted thiazole derivatives can be metabolised via side chain oxidation and ring
S- and N-oxidation (Dalvie et al., 2002). The major metabolites are readily excreted in the urine either
free or as glutathione conjugates. In addition, it may be expected that the presence of alkyl- and acyl-
substituents at the thiazole ring increases the number of metabolic options. It has also been
demonstrated that, to a very small extent, ring C-oxidation may be followed by ring cleavage to yield
alpha-diketone and thioamide fragments (see Figure C.4). The acyl-substituted thiazoles [FL-nos:
15.038, 15.039, 15.085 and 15.116] may also be expected to undergo keto-reduction, possibly
followed by conjugation, similar to acetyl derivatives of furane (EFSA CEF Panel, 2011b) and
pyrazine (EFSA CEF Panel, 2011a). However, there is very limited information to evaluate the extent
of metabolism of ring substituent groups, and it is also very difficult, based on the information
available, to assess how the presence of ring substituents and their positions at the ring might influence
the metabolism of the ring itself.
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Non-aromatic candidate substances
Subgroups B-II and B-IV: Thiazoline and dithiazine derivatives
Candidate substances [FL-no: 15.060, 15.086 and 15.119] (thiazolines from subgroup B-II) and
candidate substances [FL-no: 15.054, 15.055, 15.057, 15.079 and 15.135] (dithiazines from subgroup
B-IV)
No specific information was available to evaluate the metabolism of any of the candidate substances
mentioned in these two subgroups (B-II and B-IV).
It may be speculated that the substances in these chemical groups, which contain a partially or
completely reduced thiazole or dithiazine, are metabolised primarily by ring S-oxidation or via N-
oxidation, similar to the aromatic thiazole compounds. In addition, metabolism of the ring substituents
is likely to occur.
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C.4 Summary on metabolism
The candidate substances in this FGE are structurally related to 28 flavouring substances evaluated by
the JECFA in “Safety Evaluations of Groups of Related Flavouring Agents: Sulfur-Containing
Heterocyclic Compounds”. The candidate and 28 supporting substances in this group were originally
subdivided into 11 subgroups based on the nature of the ring (aromatic (clustered in subgroups A-I to
A-III) vs. non-aromatic (clustered in subgroups B-I to B-VI)), type and number of ring heteroatoms
(sulphur or sulphur with nitrogen) and the degree of saturation in the non-aromatic rings. In this
revision, FGE.21Rev5, the use of 18 candidate substances as flavourings are no longer supported by
Industry, reducing the number of subgroups to five.
For the evaluation of the metabolism of the candidate substances in this group, only very limited data
were available. These were confined to a few references on thiophene, and some thiophene and
thiazole derivatives (i.e. only directly relevant for the evaluation of A subgroups the aromatic
candidate substances). Other information was found in several review papers. Virtually no data were
found on the possible metabolism of the non-aromatic ring structures in the B subgroups.
A subgroups (substances with aromatic ring structures)
Very few data are available on absorption, distribution and excretion. Some of the studies are related
to oral exposure and some others to parenteral dosing, and the relevance of the latter may be limited.
In mice, a thiazolobenzimidazole derivative was rapidly absorbed after oral dosing, S-oxidised and
eliminated from plasma. The structurally related substance thiophene has been shown to be absorbed
rapidly from the gastro-intestinal tract and eliminated via urine as metabolites, or via the lungs. In
addition, the thiazole derivative fostedil is absorbed from the gastro-intestinal tract (42–71 % of the
dose), metabolised and eliminated with a plasma half-life of about six to nine hours in dogs. Hence,
from data on absorption and elimination that are available for the aromatic candidate substances in this
FGE, it may be speculated that most of them will be fairly well absorbed and eliminated after
biotransformation. Some volatile substances may also be eliminated via the lungs. For the non-
aromatic candidate substances no information is available.
From available metabolism data, it may be anticipated that the sulphur- and nitrogen-containing
heterocyclic and heteroaromatic derivatives participate in metabolic pathways, principally involving
side chain C-oxidation, ring S- and N-oxidation to yield sulphoxide or sulphones and N-oxides,
respectively. Sulphoxide metabolites may conjugate with glutathione or may undergo dimerisation via
a Diels–Adler reaction. For substituted thiophenes, epoxidation of the double bonds has also been
reported, which may also be followed by glutathione conjugation and mercapturic acid formation. As
far as studied, ring C-oxidation may, to a very minor extent, be accompanied by heterocyclic ring
cleavage, which for thiazoles could result in the formation of reactive thioamide intermediates.
Additional alkyl and acyl substituents in the thiazole ring may increase the alternative metabolic
pathways available to thiazole derivatives, as was demonstrated for chlormethiazole. Alkyl- and acyl-
substituted thiazole derivatives are primarily metabolised via side chain oxidation and ring S- and N-
oxidation. The major metabolites are readily excreted in the urine either free or as glutathione
conjugates. Metabolites of the side chain oxidation pathways may be expected to be conjugated, e.g. to
glucuronic acid. To a very small extent, ring C-oxidation may be followed by ring cleavage to yield
alpha-diketone and thioamide fragments. The acyl-substituted thiazoles [FL-no: 15.038, 15.039,
15.085 and 15.116] may also be expected to undergo keto-reduction, possibly followed by
conjugation, similar to acyl derivatives of furanes (EFSA CEF Panel, 2011b) and pyrazines (EFSA
CEF Panel, 2011a).
The structurally related thiophene and the ring-substituted thiophenes (subgroups A-Ib and A-Ic)
undergo S-oxidation and glutathione conjugation. In addition, from some studies with thiazole
derivatives, it can be seen that their metabolites may react spontaneously with glutathione, and it is
likely that they also have reactivity towards protein thiols, which may result in toxicity. For example,
for the thiazole ring cleavage products (thioamide intermediates) a relationship with nephrotoxicity
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and hepatotoxicity has been established, especially after glutathione depletion, even though this is only
a very minor metabolite.
Limited information was submitted that indicates that side chain oxidation of the alkyl- or acyl-
substituted thiophenes (subgroups A-Ib and A-Ic) or thiazoles (subgroup A-II) may also occur. Such
reactions may be anticipated (e.g. omega or omega-1 oxidations). Similar reactions have been
discussed for alkylated pyrazines (EFSA CEF Panel, 2011a). In addition, the candidate substance with
an aldehyde group [FL-no: 15.074] may be expected to be oxidised to the corresponding carboxylic
acid. Where applicable, conjugation with amino acids (e.g. glycine) or glucuronic acid may also be
expected to occur (Scheline, 1968; EFSA, 2005; EFSA CEF Panel, 2011a).
Based on the MSDI exposure estimates (see Table 9, Section 7, of the main text) it seems reasonable
to assume that saturation of the metabolic pathways for the candidate substances in this FGE is
unlikely, given these low levels of exposure to the candidate substances from their use as flavouring
substances.
Overall, there is insufficient quantitative information to evaluate the extent of metabolism of ring
substituent groups, and it is also very difficult, based on available data, to assess how the presence of
ring substituents and their positions at the ring influences metabolism of the rings itself, for any of the
subgroups within this FGE. With respect to sulphydryl reactivity in thiophenes (subgroup A-Ic), this
property was a reason to consider such substances, e.g. FGE.13, as not being metabolised through
pathways leading to innocuous metabolites. In concordance with this and based on the information
presented above, it is concluded that for all candidate flavouring substances in A subgroups of the
present FGE it cannot be anticipated that they are metabolised to innocuous metabolites.
B subgroups (substances with non-aromatic ring structures)
No specific information was available on the metabolism of the thiazoline or dithiazine derivatives or
of related substances for any of the (non-aromatic) substances in the B subgroups. It may be
speculated that the substances in these chemical groups are metabolised primarily by ring S-oxidation
or, if applicable, via N-oxidation, similar to the aromatic thiazole and thiophene compounds. In
addition, metabolism of the ring substituents is likely to occur. Owing to the lack of metabolism data
on the substances in the B subgroups, it cannot be concluded that the candidate flavouring substances
in the respective B subgroups will be metabolised to innocuous products.
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ABBREVIATIONS
bw body weight
CAS Chemical Abstract Service
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
CoE Council of Europe
CRL Charles River Laboratories
DNA Deoxyribonucleic acid
EC European Commission
EFFA European Flavour and Fragrance Association
EU European Union
FAO Food and Agriculture Organization of the United Nations
FEMA Flavor and Extract Manufacturers Association
FGE Flavouring Group Evaluation
GC–MS gas chromatography–mass spectrometry
GLC gas–liquid chromatography
GLP Good Laboratory Practice
FLAVIS (FL) Flavour Information System (database)
HPLC high-performance liquid chromatography
ID identity
IOFI International Organization of the Flavour Industry
IR infrared spectroscopy
JECFA Joint FAO/WHO Expert Committee on Food Additives
LD50 Lethal Dose, 50 %; median lethal dose
MNBN micronucleated binucleate cells
MS mass spectrometry
MSDI Maximised Survey-derived Daily Intake
MTS Minimum Toxicity Screen
mTAMDI modified Theoretical Added Maximum Daily Intake
NADPH Nicotinamide Adenine Dinucleotide Phosphate, reduced form
NMR nuclear magnetic resonance
No number
NOAEL no-observed-adverse-effect level
OECD Organisation for Economic Co-operation and Development
RI Replication Index
SC structural class
SCF Scientific Committee on Food
TAMDI Theoretical Added Maximum Daily Intake
TNO Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek
WHO World Health Organization
